GLOBAL INITIATIVE FOR
CHRONIC OBSTRUCTIVE
LUNG DISEASE

GLOBAL STRATEGY FOR THE DIAGNOSIS,
MANAGEMENT, AND PREVENTION OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
(2017 REPORT)

© 2017 Global Initiative for Chronic Obstructive Lung Disease, Inc.
GOLD BOARD OF DIRECTORS
(2016)

Alvar Agusti, MD, Chair
Respiratory Institute, Hospital Clinic, IDIBAPS
Univ. Barcelona and Ciberes
Barcelona, Spain

Marc Decramer, MD, Chair (to 05/16)
University of Leuven
Leuven, Belgium

Bartolome R. Celli, MD
Brigham and Women’s Hospital Boston, Massachusetts, USA

Rongchang Chen, MD
Guangzhou Institute of Respiratory Disease
Guangzhou, PRC

Gerard Criner, MD
Temple University School of Medicine
Philadelphia, Pennsylvania, USA

Peter Frith, MD
Repatriation General Hospital, Adelaide, South Australia, Australia

David Halpin, MD
Royal Devon and Exeter Hospital
Devon, UK

M. Victorina López Varela, MD
Universidad de la República
Montevideo, Uruguay

Masaharu Nishimura, MD
Hokkaido University School of Medicine
Sapporo, Japan

Roberto Rodriguez-Roisin, MD
Respiratory Institute, Hospital Clinic, IDIBAPS
Univ. Barcelona and Ciberes
Barcelona, Spain

Claus Vogelmeier, MD, Chair
University of Marburg
Marburg, Germany

Alvar Agusti, MD
Respiratory Institute, Hospital Clinic, IDIBAPS
Univ. Barcelona and Ciberes
Barcelona, Spain

Antonio Anzueto, MD
University of Texas Health Science Center
San Antonio, Texas, USA

Peter Barnes, MD
National Heart and Lung Institute
London, United Kingdom

Jean Bourbeau, MD
McGill University Health Centre
Montreal, Canada

Gerard Criner, MD
Temple University School of Medicine
Philadelphia, Pennsylvania, USA

Leonardo M. Fabbri, MD
University of Modena & Reggio Emilia
Modena, Italy

Fernando Martinez, MD, MS
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, NY USA

GOLD SCIENCE COMMITTEE*
(2016)

Nicolas Roche, MD
Hôpital Cochin
Paris, France

Roberto Rodriguez-Roisin, MD
Respiratory Institute, Hospital Clinic, IDIBAPS, Univ. Barcelona and Ciberes
Barcelona, Spain

Donald Sin, MD
St. Paul’s Hospital, University of British Columbia
Vancouver, Canada

Dave Singh, MD
University of Manchester
Manchester, UK

Robert Stockley, MD
University Hospital Birmingham
Birmingham, UK

Jørgen Vestbo, MD
University of Manchester
Manchester, England, UK

Jadwiga A. Wedzicha, MD
Imperial College London
London, UK

GOLD PROGRAM DIRECTOR

Rebecca Decker, MSJ
Fontana, Wisconsin, USA

Suzanne Hurd, PhD (Director to 12/15)

* Disclosure forms for GOLD Committees are posted on the GOLD Website, www.goldcopd.org
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD
(2017 REPORT)

GOLD NATIONAL LEADERS

Perlat Kapisyzi, Albania
Eduardo A. Schiavi, Argentina
Otto Chris Burghuber, Austria
Mostafizur Rahman, Bangladesh
Kazi S. Bennoor, Bangladesh
Wim Janssens, Belgium
Jose Roberto Jardim, Brazil
Aquiles Camelier, Brazil
Fernando Lundgren, Brazil
Yavor Ivanov, Bulgaria
Kosta Kostov, Bulgaria
Dennis E. O’Donnell, Canada
Manuel Barros, Chile
Nan-Shan Zhong, China
Jiangtao Lin, China
Chunxue Bai, China
Fu-Qiang Wen, China
Alejandro Casas, Colombia
Neven Miculinic, Croatia
Stanislaw Kos, Czech Republic
Jaromir Musil, Czech Republic
Vladimir Vondra, Czech Republic
Ejvind Frausing Hansen, Denmark
Eduardo Gautreau de Windt, Dominican Republic
Hisham Tarraf, Egypt
Victor Castro Gómez, El Salvador
Gerard Huchon, France
Maia Gotua, Georgia
Klaus Rabe, Germany
David S.C. Hui, Hong Kong
Thorarinn Gislasson, Iceland
Gunnar Gudmundsson, Iceland
Rohini V. Chowgule, India
R.Narasimhan, India
Faisal Yunus, Indonesia
Masjedi Mohammad Reza, Iran
Mohammad Ashkan Moslehi, Iran
Timothy J. McDonnell, Ireland
Zvi G. Fridlender, Israel
Lorenzo Corbetta, Italy
Takahide Nagase, Japan
Michiaki Mishima, Japan

Bashar Nsour, Jordan
Jawad Hamad, Jordan
Damilya Nugmanova, Kazakhstan
Yeon-Mok Oh, Korea
Mousa Khaddadah, Kuwait
Talent Sooronbaev, Kyrgyz Republic
Joseph M Cacciottolo, Malta
J. Javier Díaz Castañón, Mexico
Alexandru Corlateanu, Moldova
Dr Oyunchimeg, Mongolia
Harold Rea, New Zealand
Jorge Cuadra, Nicaragua
Amund Gulsvik, Norway
Ernst Omenaas, Norway
Javaid Khan, Pakistan
Jamil Ur Rehman Tahir, Pakistan
Mohammad Osman Yusuf, Pakistan
Teresita S. deGuia, Philippines
Ewa Nizankowska-Mogilnicka, Poland
Pawel Kuca, Poland
Florin Mihaltan, Romania
Ruxandra Ulmeanu, Romania
Alexander Chuchalin, Russia
Dmitri R. Rackita, Russia
Professor Alexandre Vizel, Russia
Professor Eugeny Shmelev, Russia
Kian-Chung Ong, Singapore
Wan-Cheng Tan, Singapore
Ruzena Tkacova, Slovak Republic
Stanislav Suskovic, Slovenia
EM Irusen, South Africa
Patricia Sobradillo, Spain
Daiana Stolz, Switzerland
Yousser Mohammad, Syria
Professor Ali Kocabas, Turkey
Hakan Gunen, Turkey
Maria Montes de Oca, Venezuela
Ngo Quy Chau, Vietnam
Le Thi Tuyen Lan, Vietnam
Sy Duong-Quy, Vietnam
Khaled Al-Shair, Yemen
In 2011, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD. It recommended a major revision in the management strategy for COPD that was first presented in the original 2001 document. Reports released in January 2013, January 2014, January 2015, and January 2016 were based on updated scientific literature published since the completion of the 2011 document but maintain the same treatment paradigm. The 2015 update added an Appendix on Asthma COPD Overlap Syndrome, material prepared jointly by the GOLD and GINA Science Committees.

The assessment of COPD proposed by GOLD has been based on the patient’s level of symptoms, future risk of exacerbations, the extent of airflow limitation, the spirometric abnormality, and the identification of comorbidities. The “ABCD” assessment tool of the 2011 GOLD update was a major advance from the simple spirometric grading system of the earlier versions of GOLD because it incorporated multimodality assessment, symptom burden and highlighted the importance of exacerbation prevention in the management of COPD. However, there were some important limitations to this scheme. The ABCD assessment tool performed no better than spirometric grades for mortality prediction or other important health outcomes. To address these and other concerns (while at the same time maintaining consistency and simplicity for the practicing clinician), a refinement of the ABCD assessment tool is proposed in this 2017 GOLD Report that separates spirometric grades from the “ABCD” groups. Thus, ABCD groups and their associated implications for pharmacotherapy recommendations will be derived exclusively from patient symptoms and their history of exacerbations. The separation of airflow limitation from clinical parameters makes it clearer what is being evaluated and ranked. This revised assessment tool acknowledges the limitations of FEV₁ in influencing some therapeutic decisions for individualized patient care and highlights the importance of patient symptoms and exacerbation risks in patients with COPD. Spirometry remains key in the diagnosis, prognostication and treatment with nonpharmacologic therapies.

The GOLD report has been used worldwide as a “strategy document” for healthcare professionals to use as a tool to implement effective management programs based on local healthcare systems. The ABCD assessment tool has been used by many to structure their assessment of COPD symptom burden and create treatment plans. A summary of publications that have examined the ABCD grading system since its first presentation in 2011 is provided in the table on the next page. Additional evidence generated from using the original and the revised system proposed in this 2017 GOLD Report will continue to be evaluated by the GOLD committees and management strategy recommendations will be modified as required as new data become available.

GOLD has been fortunate to have a network of international distinguished health professionals from multiple disciplines. Many of these experts have initiated investigations of the causes and prevalence of COPD in their countries, and have developed innovative approaches for the
dissemination and implementation of the GOLD management strategy. The GOLD initiative will continue to work with National Leaders and other interested healthcare professionals to bring COPD to the attention of governments, public health officials, healthcare workers, and the general public to raise awareness of the burden of COPD and to develop programs for early detection, prevention and approaches to management.

Alvar G. Agustí, MD
Chair, GOLD Board of Directors
Hospital Clínic,
Universitat de Barcelona,
Villarroel 170, 08036
Barcelona, Spain

Claus Vogelmeier, MD
Chair, GOLD Science Committee
Department of Medicine,
Pulmonary and Critical Care Medicine
University Medical Center Gießen and Marburg
Philippus-Universität Marburg,
Baldingerstraße
35043 Marburg, Germany
Summary of publications that have examined the ABCD grading system since its implementation in 2011

| Choice of symptom measure (mMRC vs. CAT) influence category assignment | 2-5; 19 |
| The prevalence of the four GOLD groups depends on the specific population studied, C being consistently the least prevalent | 2;4-10 |
| Groups differed in several clinical, functional, imaging and biological characteristics in addition to those used for their definition, including comorbidities | 4;11;12 |
| Prevalence of comorbidities and persistent systemic inflammation were highest in group B. | 11 |
| The new classification systems correlates with exercise capacity | 5 |
| A and D groups were relatively stable over time, whereas groups B and C showed more temporal variability | 11; 18 |
| Good prediction of exacerbations during follow-up | 13 |
| Conflicting results in relation to its capacity to predict mortality | 5-7;14;15; 17 |
| B patients consistently have a mortality and hospitalization rate similar to C patients | 11;13; 18 |
| Prescription appropriateness by GPs (in Italy) is better using new GOLD classification. | 9 |
| A real world observational study in five European countries and US identifies the frequent and potentially inappropriate use of inhaled steroids and bronchodilators in patients at low risk of exacerbations (A and B) | 10 |
| In an Asian population, GOLD predicts exacerbations and mortality moderately well | 16 |

REFERENCES

68(10):914-21.
2017 INVITED CONTRIBUTORS

Prof. Richard Beasley
Medical Research Institute of New Zealand
Wellington, New Zealand

Peter M A Calverley, MD
University Hospital Aintree
Liverpool, UK

Ciro Casanova, MD
Hospital Universitario
Santa Cruz de Tenerife, Tenerife, Spain

James Donohue, MD
University of North Carolina
Chapel Hill, NC, USA

MeiLan Han, MD, MS
University of Michigan
Ann Arbor, MI, USA

Nicola Hanania, MBBS, MS
Baylor College of Medicine
Houston, TX, USA

Maria Montes de Oca, MD
Hospital Universitario de Caracas,
Universidad Central de Venezuela,
Caracas, Venezuela

Takahide Nagase, MD
The University of Tokyo,
Tokyo, Japan

Alberto Papi, MD
University of Ferrara
Ferrara, Italy

Ian Pavord, MD
University of Oxford
Oxford, UK

David Price, FRCGP
Observational and Pragmatic Research Institute, Singapore
University of Aberdeen, Aberdeen, Scotland, UK
GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD 2017 UPDATE†

METHODOLOGY

When the Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was initiated in 1998, a goal was to produce recommendations for management of COPD based on the best scientific information available. The first report, Global Strategy for Diagnosis, Management and Prevention of COPD was issued in 2001. In 2006 and again in 2011 a complete revision was prepared based on published research. These reports, and their companion documents, have been widely distributed and translated into many languages and can be found on the GOLD website (www.goldcopd.org).

The GOLD Science Committee‡ was established in 2002 to review published research on COPD management and prevention, to evaluate the impact of this research on recommendations in the GOLD documents related to management and prevention, and to post yearly updates on the GOLD website. Its members are recognized leaders in COPD research and clinical practice with the scientific credentials to contribute to the task of the Committee and are invited to serve in a voluntary capacity.

Updates of the 2011-revised report were released in January 2013, 2014, 2015, and 2016. The 2017 GOLD Report, the 4th major revision of GOLD, incorporates an update of recent information that has been reviewed by the science committee from 2015 to 2016 and a comprehensive reassessment and revision of prior recommendations for the diagnosis, assessment and treatment of COPD.

Process: To produce the GOLD report, a PubMed (National Center for Biotechnology Information, U.S. National Library of Medicine, Bethesda MD, USA) search was completed using search fields established by the Committee: 1) COPD, All Fields, Adult: 19+ years, only items with abstracts, Clinical Trial, Meta-analyses, Human.

The literature included in the review for this 2017 update was published from 2015 to 2016. Publications in peer reviewed journals not captured by PubMed may be submitted to the Chair, GOLD Science Committee, providing the full paper, including abstract, is submitted in (or translated into) English.

† The Global Strategy for Diagnosis, Management and Prevention of COPD (updated 2016), the Pocket Guide (updated 2016) and the complete list of references examined by the Committee are available on the GOLD website www.goldcopd.org.

Members of the Committee receive a summary of citations and all abstracts. Each abstract is assigned to two Committee members, although all members are offered the opportunity to provide input on any abstract. Members evaluate the abstract or, subject to her/his judgment, the full publication, by answering four specific written questions from a short questionnaire, to indicate if the scientific data presented impacts on recommendations in the GOLD report. If so, the member is asked to specifically identify modifications that should be made.

The GOLD Science Committee meets twice yearly to discuss each publication that was considered by at least one member of the Committee to potentially have an impact on the management of COPD. The full Committee then reaches a consensus on whether to include it in the report, either as a reference supporting current recommendations, or to change the report. In the absence of consensus, disagreements are decided by an open vote of the full Committee.

Recommendations by the GOLD Committees for use of any medication are based on the best evidence available from the published literature and not on labeling directives from government regulators. The Committee does not make recommendations for therapies that have not been approved by at least one major regulatory agency.
SUMMARY OF NEW RECOMMENDATIONS

Chapter 1
The definition of COPD has been revised to include the impact of respiratory symptoms and the role of lung tissue and airway abnormalities in the development of COPD. The origin of COPD development is discussed relative to interactions of host factors and environmental exposures.

Chapter 2
The ABCD assessment tool has been refined to utilize respiratory symptoms and exacerbations alone to assign ABCD categories. The role of spirometry in overall management of COPD has been updated.

Chapter 3
Assessment and regular evaluation of inhaler technique has been added to attempt to improve therapeutic outcomes. Increased evidence for self-management, pulmonary rehabilitation, integrated care and palliative care is presented. Recommendations for noninvasive ventilation, oxygen therapy and lung volume reduction are provided based on new information.

Chapter 4
Examination of symptoms and future risk of exacerbations should provide the map for pharmacologic management of stable COPD. A shift towards more personalized approach to treatment is introduced, with strategies for escalation and de-escalation of pharmacotherapy.

Chapter 5
Detailed hospital discharge and follow up criteria are presented and include integrated team care.

Chapter 6
The strategies for the management of cardiovascular and other important comorbidities are presented in detail. The complex issues of multimorbidity and polypharmacy are outlined.

References
Throughout the document references have been updated and checked for accuracy.
# TABLE OF CONTENTS

PREFACE ......................................................................................................................................... V
REFERENCES........................................................................................................................................ VII
2017 INVITED CONTRIBUTORS ........................................................................................................ IX

GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD 2017 UPDATE ............... X

METHODOLOGY ................................................................................................................................. X
SUMMARY OF NEW RECOMMENDATIONS .................................................................................. XII
TABLE OF CONTENTS ................................................................................................................... XIII

GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD ...................... 1

INTRODUCTION ................................................................................................................................. 1
BACKGROUND ................................................................................................................................... 1
METHODOLOGY ............................................................................................................................... 2
NEW ISSUES PRESENTED IN THIS REPORT ................................................................................ 3
LEVELS OF EVIDENCE .................................................................................................................. 5
REFERENCES .................................................................................................................................... 5

CHAPTER 1: DEFINITION AND OVERVIEW ......................................................................................... 6

OVERALL KEY POINTS: .................................................................................................................. 6
DEFINITION ......................................................................................................................................... 6
BURDEN OF COPD ........................................................................................................................... 7
Prevalence ......................................................................................................................................... 8
Morbidity .......................................................................................................................................... 9
Mortality ........................................................................................................................................... 9
Economic burden ............................................................................................................................ 9
Social burden ................................................................................................................................... 10

FACTORS THAT INFLUENCE DISEASE DEVELOPMENT AND PROGRESSION ........................................... 10
Genetic factors ............................................................................................................................... 11
Age and gender ............................................................................................................................. 11
Lung growth and development ..................................................................................................... 11
Exposure to particles ....................................................................................................................... 12
Socioeconomic status .................................................................................................................... 13
Asthma and airway hyper-reactivity .............................................................................................. 13
Chronic bronchitis ........................................................................................................................ 14
Infections ......................................................................................................................................... 14

PATHOLOGY, PATHOGENESIS AND PATHOPHYSIOLOGY ........................................................................... 14
Pathology ......................................................................................................................................... 14
Pathogenesis .................................................................................................................................. 15
REFERENCES .................................................................................................................................... 18

CHAPTER 2: DIAGNOSIS AND INITIAL ASSESSMENT ............................................................................. 24

OVERALL KEY POINTS: .................................................................................................................. 24
DIAGNOSIS ......................................................................................................................................... 24
SYMPTOMS ...................................................................................................................................... 25
MEDICAL HISTORY ......................................................................................................................... 27
Physical examination.......................................................................................................................... 27
Spirometry.................................................................................................................................................. 27

ASSESSMENT.............................................................................................................................................. 30
Classification of severity of airflow limitation...................................................................................... 30
Assessment of symptoms .......................................................................................................................... 31
Choice of thresholds .................................................................................................................................. 32
Assessment of exacerbation risk .............................................................................................................. 33
Assessment of concomitant chronic diseases (comorbidities) ............................................................... 34
Revised combined COPD assessment ..................................................................................................... 34
Alpha-1 antitrypsin deficiency (AATD)...................................................................................................... 36
Additional investigations .......................................................................................................................... 37

REFERENCES............................................................................................................................................ 40

CHAPTER 3: EVIDENCE SUPPORTING PREVENTION AND MAINTENANCE THERAPY ................................. 45

OVERALL KEY POINTS: .............................................................................................................................. 45
SMOKING CESSATION ............................................................................................................................... 46
Pharmacotherapies for smoking cessation ............................................................................................... 46

VACCINATIONS........................................................................................................................................ 47
Influenza vaccine ..................................................................................................................................... 47
Pneumococcal vaccine ............................................................................................................................. 47

PHARMACOLOGIC THERAPY FOR STABLE COPD..................................................................................... 48
Overview of the medications ................................................................................................................... 48
Bronchodilators ......................................................................................................................................... 48
Antimuscarinic drugs ............................................................................................................................... 50
Methylxanthines ....................................................................................................................................... 51
Combination bronchodilator therapy ........................................................................................................ 52
Anti-inflammatory agents ......................................................................................................................... 52
Inhaled corticosteroids (ICS)... .................................................................................................................. 53
Triple inhaled therapy ................................................................................................................................ 55
Oral glucocorticoids ................................................................................................................................ 55
Phosphodiesterase-4 (PDE4) inhibitors ..................................................................................................... 55
Antibiotics .................................................................................................................................................. 55
Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (NAC, carbocysteine) .................... 56
Other drugs with anti-inflammatory potential .......................................................................................... 56
Issues related to inhaled delivery .............................................................................................................. 56
Other pharmacologic treatments ............................................................................................................... 58

REHABILITATION, EDUCATION & SELF-MANAGEMENT........................................................................... 59
Pulmonary rehabilitation .......................................................................................................................... 59
Education, self-management and integrative care .................................................................................... 60

SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE ....................................................................... 62
Symptom control and palliative care ........................................................................................................ 62
Therapy relevant to all patients with COPD .............................................................................................. 62
End-of-life and hospice care ...................................................................................................................... 63

OTHER TREATMENTS............................................................................................................................... 64
Oxygen therapy and ventilatory support .................................................................................................... 64
Ventilatory Support .................................................................................................................................. 64

INTERVENTIONAL THERAPY....................................................................................................................... 65
Surgical Interventions ............................................................................................................................... 65
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic heart disease (IHD)</td>
<td>115</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>116</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>116</td>
</tr>
<tr>
<td>Hypertension</td>
<td>116</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>116</td>
</tr>
<tr>
<td>Anxiety and depression</td>
<td>117</td>
</tr>
<tr>
<td>COPD and lung cancer</td>
<td>117</td>
</tr>
<tr>
<td>Metabolic syndrome and diabetes</td>
<td>118</td>
</tr>
<tr>
<td>Gastroesophageal reflux (GERD)</td>
<td>118</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>118</td>
</tr>
<tr>
<td>Obstructive sleep apnea</td>
<td>119</td>
</tr>
<tr>
<td>COPD as part of multimorbidity</td>
<td>119</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>120</td>
</tr>
</tbody>
</table>
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD

INTRODUCTION

Much has changed in the 6 years since the last major update of the GOLD report, Global Strategy for the Diagnosis, Management, and Prevention of COPD. This major revision builds on the strengths from prior published recommendations and incorporates new knowledge.

The aim of the GOLD Report is to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD that can aid the clinician. One of the strengths of GOLD reports is the treatment objectives. These have stood the test of time, but are organized into two groups: objectives that are directed towards immediately relieving and reducing the impact of symptoms, and objectives that reduce the risk of adverse health events that may affect the patient at some point in the future. (Exacerbations are an example of such events). This emphasizes the need for clinicians to focus on both the short-term and long-term impact of COPD on their patients.

A second strength of the original strategy was the simple, intuitive system for classifying COPD severity. This was based on FEV₁ and was called a staging system because it was believed, at the time, that the majority of patients followed a path of disease progression in which the severity of COPD tracked the severity of airflow limitation. Much is now known about the characteristics of patients in the different GOLD stages – for example, their risk of exacerbations, hospitalization, and death. However, at an individual patient level, FEV₁ is an unreliable marker of the severity of breathlessness, exercise limitation, and health status impairment.

At the time of the original report, improvement in both symptoms and health status was a GOLD treatment objective, but symptoms assessment did not have a direct relation to the choice of management, and health status measurement was a complex process largely confined to clinical studies. Now, there are simple and reliable questionnaires designed for use in routine daily clinical practice. These are available in many languages. These developments have enabled a new assessment system to be developed that draws together a measure of the impact of the patient’s symptoms and an assessment of the patient’s risk of having a serious adverse health event to the construction of a new approach to management – one that matches assessment to treatment objectives. The new management approach can be used in any clinical setting anywhere in the world and moves COPD treatment towards individualized medicine – matching the patient’s therapy more closely to his or her needs.

BACKGROUND

Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world but is projected to be the 3rd leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. COPD represents an important public
health challenge that is both preventable and treatable. COPD is a major cause of chronic morbidity and mortality throughout the world; many people suffer from this disease for years, and die prematurely from it or its complications. Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population.²

In 1998, with the cooperation of the National Heart, Lung, and Blood Institute, National Institutes of Health and the World Health Organization the Global Initiative for Chronic Obstructive Lung Disease (GOLD) was implemented. Its goals were to increase awareness of the burden of COPD and to improve prevention and management of COPD through a concerted worldwide effort of people involved in all facets of healthcare and healthcare policy. An important and related goal was to encourage greater research interest in this highly prevalent disease.

In 2001, GOLD released its first report, *Global Strategy for the Diagnosis, Management, and Prevention of COPD*. This report was not intended to be a comprehensive textbook on COPD, but rather to summarize the current state of the field. It was developed by individuals with expertise in COPD research and patient care and was based on the best-validated concepts of COPD pathogenesis at that time, along with available evidence on the most appropriate management and prevention strategies. It provided state-of-the-art information about COPD for pulmonary specialists and other interested physicians and served as a source document for the production of various communications for other audiences, including an Executive Summary, a Pocket Guide for Healthcare Professionals, and a Patient Guide.

Immediately following the release of the first GOLD report in 2001, the GOLD Board of Directors appointed a Science Committee, charged with keeping the GOLD documents up-to-date by reviewing published research, evaluating the impact of this research on the management recommendations in the GOLD documents, and posting yearly updates of these documents on the GOLD Website.

In January 2015, the GOLD Science Committee recognized that considerable new information was available particularly related to the pathophysiology, diagnosis, assessment and approaches to management of COPD that warranted preparation of a significantly revised report. The GOLD Science Committee initiated its work to prepare the current comprehensively updated 2017 version of the GOLD report. The methodology used to create the annual updated documents appears below.

**METHODOLOGY**

In 2015 and 2016 while preparing the annual updated reports (www.goldcopd.org), GOLD Science Committee members began to identify the literature that impacted on major recommendations, especially for COPD diagnosis and management. Committee members were assigned chapters to review for proposed modifications and soon reached consensus that the report required significant modification to reach the target audiences – the general practitioner and the individuals in clinics around the world who first see patients that present with respiratory symptoms which could lead to a diagnosis of COPD. A writing committee was established to produce an outline of proposed
chapters; GOLD Board of Directors and GOLD National Leaders were provided summaries of the major new directions recommended. The names of the individuals who contributed appear at the front of this report. In September 2016 the GOLD Science Committee reviewed each of the chapters. The report was sent to 10 experts outside of GOLD for review. Based on their comments the document was revised. The report was launched during the GOLD COPD Care Continuum Conference, held in Philadelphia, PA, USA on November 16, 2016.

NEW ISSUES PRESENTED IN THIS REPORT

1. This document has been updated and revised to provide comprehensive and current information about the pathophysiology of COPD. The importance that COPD has varied trajectories of development over time and the importance of host factors contributing to COPD development are described.

2. Chapter 2 includes information on diagnosis and assessment of COPD. The definition of COPD has been revised to recognize the importance of host factors. The assessment of COPD has been refined to separate the spirometric assessment from symptoms evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations. The separation of airflow limitation from clinical parameters shows clearly what is being evaluated and assessed. We believe this scheme facilitates more precise treatment recommendations based on individual parameters that are driving the patient’s symptoms at a given time.

3. Chapter 3 is a comprehensive revision and reassessment of the recommendations for the various pharmacologic and non-pharmacologic therapies for COPD. A comprehensive and up to date reassessment of the various pharmacologic therapies and their combinations are provided to treat stable disease and prevent future exacerbations. Expanded sections for emphysema interventions, rehabilitation, long term oxygen therapy, noninvasive ventilation in the chronic stable state and self-management are now provided.

4. Chapter 4 provides guidance for interpretation of the information presented for the diagnosis and assessment of COPD (Chapter 2) with the pharmacologic and non-pharmacologic treatments reviewed in Chapter 3. Examples highlighting the importance of the new assessment scheme are provided.

5. Comprehensive schemes are suggested for applying the pharmacologic and non-pharmacologic therapies reviewed in Chapter 3 to patients in each of the ABCD groups.

6. Management of COPD is presented in three chapters: Management of Stable COPD (Chapter 4); Management of COPD Exacerbations (Chapter 5); and COPD and Comorbidities (Chapter 6), covering both management of comorbidities in patients with COPD and management of COPD in patients with comorbidities.

7. In Chapter 4, Management of Stable COPD, recommended approaches to both pharmacologic and non-pharmacologic treatment of COPD are presented. The chapter begins with the importance of identification and reduction of risk factors. Cigarette smoke continues to be identified as the most commonly encountered risk factor for COPD and elimination of this risk factor is an important step toward prevention and control of COPD. However, more data are emerging to recognize the importance of other risk factors for
COPD that should be taken into account where possible. These include occupational dusts and chemicals, and indoor air pollution from biomass cooking and heating in poorly ventilated dwellings – the latter especially among women in developing countries. Examples for escalation and de-escalation of pharmacologic treatment are provided.

8. COPD exacerbations (Chapter 5) are reviewed in detail (definition, diagnosis and pharmacologic and non-pharmacologic therapies) and recommendations provided for the acute treatment and prevention of exacerbations based on the most recent peer-reviewed published literature.

9. In previous GOLD documents, recommendations for management of COPD were based solely on spirometric category. However, there is considerable evidence that the level of FEV\(_1\) is a poor descriptor of disease status and for this reason the management of stable COPD based on a strategy considering both disease impact (determined mainly by symptom burden and activity limitation) and future risk of disease progression (especially of exacerbations) is recommended.

10. Chapter 6, Comorbidities and COPD, focuses on cardiovascular diseases, osteoporosis, anxiety and depression, lung cancer, infections, and metabolic syndrome and diabetes.

11. Evidence category definitions that were used to grade the levels of evidence provided in the 2017 updated report have been further refined (Table A).

12. New revised figures and tables are provided throughout the document.

<table>
<thead>
<tr>
<th>Evidence category</th>
<th>Sources of evidence</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Randomized controlled trials (RCTs)</td>
<td>Evidence is from endpoints of well-designed RCTs that provide consistent findings in the population for which the recommendation is made without any important limitations. Requires high quality evidence from ≥ 2 clinical trials involving a substantial number of subjects, or a single high quality RCT involving substantial numbers of patients without any bias.</td>
</tr>
<tr>
<td></td>
<td>Rich body of high quality evidence without any significant limitation or bias</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Randomized controlled trials (RCTs) with important limitations</td>
<td>Evidence is from RCTs that include only a limited number of patients, post hoc or subgroup analyses of RCTs or meta analyses of RCTs. Also pertains when few RCTs exist, or important limitations are evident (methodologic flaws, small numbers, short duration, undertaken in a population that differs from the target population of the recommendation, or the results are somewhat inconsistent).</td>
</tr>
<tr>
<td></td>
<td>Limited Body of Evidence</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Non-randomized trials</td>
<td>Evidence is from outcomes of uncontrolled or non-randomized trials or from observational studies.</td>
</tr>
<tr>
<td></td>
<td>Observational studies</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>Panel consensus judgment</td>
<td>Provision of guidance is deemed valuable but clinical literature addressing the subject is insufficient. Panel consensus is based on clinical experience or knowledge that does not meet the above stated criteria.</td>
</tr>
</tbody>
</table>
LEVELS OF EVIDENCE

Levels of evidence have been assigned to evidence-based recommendations where appropriate. Evidence levels are indicated in boldface type enclosed in parentheses after the relevant statement e.g., (Evidence A). The methodological issues concerning the use of evidence from meta-analyses were carefully considered. The evidence level scheme with categories A to D used throughout this document (Table A) has been modified from that used in prior GOLD Reports and the evidence category definitions have been refined and updated.

REFERENCES

CHAPTER 1: DEFINITION AND OVERVIEW

OVERALL KEY POINTS:

- *Chronic Obstructive Pulmonary Disease (COPD)* is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

- The most common respiratory symptoms include dyspnea, cough and/or sputum production. These symptoms may be under-reported by patients.

- The main risk factor for COPD is tobacco smoking but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development and accelerated aging.

- COPD may be punctuated by periods of acute worsening of respiratory symptoms, called exacerbations.

- In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality.

DEFINITION

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

The chronic airflow limitation that is characteristic of COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person (Figure 1.1). These changes do not always occur together, but evolve at different rates over time. Chronic inflammation causes structural changes, narrowing of the small airways and destruction of the lung parenchyma that leads to the loss of alveolar attachments to the small airways and decreases lung elastic recoil. In turn, these changes diminish the ability of the airways to remain open during expiration. A loss of small airways may also contribute to airflow limitation and mucociliary dysfunction is a characteristic feature of the disease. Airflow limitation is usually measured by spirometry as this is the most widely available and reproducible test of lung function. Many previous definitions of COPD have emphasized the terms “emphysema” and “chronic bronchitis”, which are not included in the definition used in this or earlier GOLD reports. Emphysema, or destruction of the gas-exchanging surfaces of the lung (alveoli), is a pathological term that is often (but incorrectly) used clinically and describes only one of several structural abnormalities present in patients with COPD. Chronic bronchitis, or the presence
of cough and sputum production for at least 3 months in each of two consecutive years, remains a clinically and epidemiologically useful term, but is present in only a minority of subjects when this definition is used. However, when alternative definitions are used to define chronic bronchitis, or older populations with greater levels of smoke or occupational inhalant exposure are queried, the prevalence of chronic bronchitis is greater. It is important to recognize that chronic respiratory symptoms may precede the development of airflow limitation and may be associated with the development of acute respiratory events. Chronic respiratory symptoms also exist in individuals with normal spirometry and a significant number of smokers without airflow limitation have structural evidence of lung disease manifested by the varying presence of emphysema, airway wall thickening and gas trapping.

**BURDEN OF COPD**

COPD is a leading cause of morbidity and mortality worldwide that induces an economic and social burden that is both substantial and increasing. COPD prevalence, morbidity and mortality vary across countries and across different groups within countries. COPD is the result of a complex interplay of long-term cumulative exposure to noxious gases and particles, combined with a variety of host factors including genetics, airway hyper-responsiveness and poor lung growth during childhood. Often, the prevalence of COPD is directly related to the prevalence of tobacco smoking, although in many countries outdoor, occupational and indoor air pollution (resulting from the burning of wood and other biomass fuels) are major COPD risk factors. The prevalence and burden of COPD are projected to increase over the coming decades due to continued exposure to COPD risk factors and aging of the world’s population; as longevity increases more people will...
express the long-term effects of exposure to COPD risk factors. Information on the burden of COPD can be found on international websites, for example the:

- **World Health Organization (WHO)**
- **World Bank/WHO Global Burden of Disease Study**

**Prevalence**

Existing COPD prevalence data vary widely due to differences in survey methods, diagnostic criteria, and analytical approaches. Importantly, all of the studies defined COPD by spirometry alone and not by the combination of symptoms and spirometry. The lowest estimates of prevalence are those based on self-reporting of a doctor’s diagnosis of COPD, or equivalent condition. For example, most national data show that < 6% of the adult population have been told that they have COPD. This is likely to be a reflection of the widespread under-recognition and under-diagnosis of COPD.

Despite the complexities, data are emerging that enable more accurate estimates of COPD prevalence. A systematic review and meta-analysis, including studies carried out in 28 countries between 1990 and 2004, provided evidence that the prevalence of COPD is appreciably higher in smokers and ex-smokers compared to non-smokers, in those ≥ 40 years of age compared to those < 40, and in men compared to women. The Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) examined the prevalence of post-bronchodilator airflow limitation among persons > 40 years in one major city from each of five Latin American countries – Brazil, Chile, Mexico, Uruguay, and Venezuela. In each country, the prevalence of COPD increased steeply with age, with the highest prevalence among those > 60 years. Prevalence in the total population ranged from a low of 7.8% in Mexico City, Mexico, to a high of 19.7% in Montevideo, Uruguay. In all five cities, the prevalence was appreciably higher in men than in women, which contrasts with findings from European cities such as Salzburg, Austria.

The Burden of Obstructive Lung Diseases (BOLD) program has also used a standardized methodology comprising questionnaires and pre- and post-bronchodilator spirometry to assess the prevalence and risk factors for COPD in people aged 40 and over around the world. Surveys have been completed in 29 countries and studies are on-going in a further nine. BOLD reported worse lung function than earlier studies, with a prevalence of COPD grade 2 or higher of 10.1% (SE 4.8) overall, 11.8% (SE 7.9) for men, and 8.5% (SE 5.8) for women and a substantial prevalence of COPD of 3-11% among never-smokers. BOLD also examined the prevalence of COPD in north and sub-Saharan Africa and Saudi Arabia and found similar results.

Based on BOLD and other large scale epidemiological studies, it is estimated that the number of COPD cases was 384 million in 2010, with a global prevalence of 11.7% (95% confidence interval (CI) 8.4%–15.0%). Globally, there are around three million deaths annually. With the increasing prevalence of smoking in developing countries, and aging populations in high-income countries, the prevalence of COPD is expected to rise over the next 30 years and by 2030 there may be over 4.5 million deaths annually from COPD and related conditions.
Morbidity

Morbidity measures traditionally include physician visits, emergency department visits, and hospitalizations. Although COPD databases for these outcome parameters are less readily available and usually less reliable than mortality databases, to date studies on the available data indicate that morbidity due to COPD increases with age. Morbidity from COPD may be affected by other concomitant chronic conditions (e.g., cardiovascular disease, musculoskeletal impairment, diabetes mellitus) that are related to smoking, aging and COPD. These chronic conditions may significantly impair patient’s health status, in addition to interfering with COPD management and are major drivers of hospitalizations and costs for patients with COPD.

Mortality

The World Health Organization (WHO) publishes mortality statistics for selected causes of death annually for all WHO regions; additional information is available from the WHO Evidence for Health Policy Department. However, data must be interpreted with caution because of the inconsistent use of COPD terminology. In the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), deaths from COPD or chronic airways obstruction are included in the broad category of “COPD and allied conditions” (ICD-10 codes J42-46).

Under-recognition and under-diagnosis of COPD reduces the accuracy of mortality data. Furthermore, the accuracy of COPD diagnosis codes recorded in administrative health databases is also uncertain. In some jurisdictions, reliance on administrative health data, particularly those that only record hospitalizations, may underestimate the burden of COPD. The reliability of recording of COPD-related deaths in mortality data is also problematic. Although COPD is often a primary cause of death, it is more likely to be listed as a contributory cause of death or omitted from the death certificate entirely. However, it is clear that COPD is one of the most important causes of death in most countries. For instance, in 2011, COPD was the third leading cause of death in the United States. This increase in COPD-related mortality has mainly been driven by the expanding epidemic of smoking; reduced mortality from other common causes of death (e.g., ischemic heart disease, infectious diseases); the aging of the world’s population, particularly in high-income countries; and scarcity of effective disease modifying therapies.

Economic burden

COPD is associated with significant economic burden. In the European Union, the total direct costs of respiratory disease are estimated to be about 6% of the total healthcare budget, with COPD accounting for 56% (38.6 billion Euros) of the cost of respiratory disease. In the United States the estimated direct costs of COPD are $32 billion and the indirect costs $20.4 billion. COPD exacerbations account for the greatest proportion of the total COPD burden on the healthcare system. Not surprisingly, there is a striking direct relationship between the severity of COPD and the cost of care, and the cost distribution changes as the disease progresses. For example, hospitalization and ambulatory oxygen costs soar as COPD severity increases. Any estimate of direct medical expenditure for home-based care under-represents the true cost of home-based care to society, because it ignores the economic value of the care provided by family members to people with COPD.
In developing countries, direct medical costs may be less important than the impact of COPD on workplace and home productivity. Because the healthcare sector might not provide long-term supportive care services for severely disabled individuals, COPD may force at least two individuals to leave the workplace—the affected individual and a family member who must now stay home to care for their disabled relative. Since human capital is often the most important national asset for developing countries, the indirect costs of COPD may represent a serious threat to the economy.

Social burden

Since mortality offers only a limited perspective on the human burden of a disease, it is desirable to find other measures of disease burden that are consistent and measurable within and between nations. The authors of the Global Burden of Disease (GBD) Study designed a method to estimate the fraction of mortality and disability attributable to major diseases and injuries using a composite measure of the burden of each health problem: the Disability-Adjusted Life Year (DALY). The DALYs for a specific condition are the sum of years lost because of premature mortality and years of life lived with disability, adjusted for the severity of disability. The GBD Study found that COPD is an increasing contributor to disability and mortality around the world. In 2005 COPD was the eighth leading cause of DALYs lost across the world but by 2013 COPD was ranked as the fifth leading cause of DALYs lost. In the United States, COPD is the second leading cause of reduced DALYs, trailing only ischemic heart disease.

FACTORS THAT INFLUENCE DISEASE DEVELOPMENT AND PROGRESSION

Although cigarette smoking is the most well studied COPD risk factor, it is not the only risk factor and there is consistent evidence from epidemiologic studies that non-smokers may also develop chronic airflow limitation. Much of the evidence concerning risk factors for COPD comes from cross-sectional epidemiological studies that identify associations rather than causal relationships. Nevertheless, compared to smokers with COPD, never smokers with chronic airflow limitation have fewer symptoms, milder disease and lower burden of systemic inflammation. Interestingly, never smokers with chronic airflow limitation do not appear to have an increased risk of lung cancer, or cardiovascular comorbidities, compared to those without chronic airflow limitation. However, there is evidence that they have an increased risk of pneumonia and mortality from respiratory failure.

Although several longitudinal studies of COPD have followed groups and populations for up to 20 years, to date no studies have monitored the progression of the disease through its entire course, or included the pre and perinatal periods that may be important in shaping an individual’s future COPD risk. Thus, the current understanding of risk factors for COPD is in many respects still incomplete.

COPD results from a complex interaction between genes and the environment. Cigarette smoking is the leading environmental risk factor for COPD, yet even for heavy smokers, fewer than 50% develop COPD during their lifetime. Although genetics may play a role in modifying the risk of COPD in smokers, there may also be other risk factors involved. For example, gender may influence whether...
a person takes up smoking or experiences certain occupational or environmental exposures; socioeconomic status may be linked to a child’s birth weight (as it impacts on lung growth and development, and in turn on susceptibility to developing the disease); and longer life expectancy will allow greater lifetime exposure to risk factors. Understanding the relationships and interactions between risk factors requires further investigation.

**Genetic factors**

The genetic risk factor that is best documented is a severe hereditary deficiency of alpha-1 antitrypsin (AATD), a major circulating inhibitor of serine proteases. Although AATD deficiency is relevant to only a small part of the world’s population, it illustrates the interaction between genes and environmental exposures that predispose an individual to COPD.

A significant familial risk of airflow limitation has been observed in people who smoke and are siblings of patients with severe COPD, suggesting that genetics together with environmental factors could influence this susceptibility. Single genes, such as the gene-encoding matrix metalloproteinase 12 (MMP12), have been related to a decline in lung function. Several genome-wide association studies have linked genetic loci with COPD (or FEV\textsubscript{1} or FEV\textsubscript{1}/FVC as the phenotype) including markers near the alpha-nicotinic acetylcholine receptor, hedgehog interacting protein (HHIP), and several others. Nevertheless, it remains uncertain whether these genes are directly responsible for COPD or are merely markers of causal genes.

**Age and gender**

Age is often listed as a risk factor for COPD. It is unclear if healthy aging as such leads to COPD or if age reflects the sum of cumulative exposures throughout life. Aging of the airways and parenchyma mimic some of the structural changes associated with COPD. In the past, most studies have reported that COPD prevalence and mortality are greater among men than women, but more recent data from developed countries has reported that the prevalence of COPD is now almost equal in men and women, probably reflecting the changing patterns of tobacco smoking. Although controversial, some studies have even suggested that women are more susceptible to the effects of tobacco smoke than men, leading to more severe disease for the equivalent quantity of cigarettes consumed. This notion has been validated in animal studies and human pathology specimens, which have demonstrated a greater burden of small airway disease in females compared with males with COPD despite a similar history of tobacco smoke exposure.

**Lung growth and development**

Processes occurring during gestation, birth, and exposures during childhood and adolescence affect lung growth. Reduced maximal attained lung function (as measured by spirometry) may identify individuals who are at increased risk for the development of COPD. Any factor that affects lung growth during gestation and childhood has the potential for increasing an individual’s risk of developing COPD. For example, a large study and meta-analysis confirmed a positive association between birthweight and FEV\textsubscript{1} in adulthood, and several studies have found an effect of early childhood lung infections. Factors in early life termed “childhood disadvantage factors” seem to be as important as heavy smoking in predicting lung function in adult life. Another recent study evaluated three different longitudinal cohorts and found that approximately 50% of patients
developed COPD due to accelerated decline in FEV$_1$ over time, while the other 50% developed COPD due to abnormal lung growth and development (with normal decline in lung function over time; Figure 1.2).

Figure 1.2. FEV$_1$ progression over time

Note: This is a simplified diagram of FEV$_1$ progression over time. In reality, there is tremendous heterogeneity in the rate of decline in FEV$_1$ owing to the complex interactions of genes with environmental exposures and risk factors over an individual’s lifetime [adapted from Lange et al NEJM 2015;373:111-22].

**Exposure to particles**

Across the world, cigarette smoking is the most commonly encountered risk factor for COPD. Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate of decline in FEV$_1$, and a greater COPD mortality rate than non-smokers.\textsuperscript{65} Other types of tobacco (e.g., pipe, cigar, water pipe)\textsuperscript{66,68} and marijuana\textsuperscript{69} are also risk factors for COPD. Passive exposure to cigarette smoke, also known as environmental tobacco smoke (ETS), may also contribute to respiratory symptoms and COPD\textsuperscript{70} by increasing the lung’s total burden of inhaled particles and gases. Smoking during pregnancy may pose a risk for the fetus, by affecting lung growth and development \textit{in utero}, and possibly the priming of the immune system.\textsuperscript{71}

Occupational exposures, including organic and inorganic dusts, chemical agents and fumes, are an under-appreciated risk factor for COPD.\textsuperscript{10,72} A cross-sectional observational study demonstrated that self-reported exposure to workplace dust and fumes is not only associated with increased airflow limitation and respiratory symptoms, but also with more emphysema and gas trapping, assessed by computed tomography scan, in both men and women.\textsuperscript{73} An analysis of the large U.S. population-
based National Health and Nutrition Examination Survey III survey of almost 10,000 adults aged 30-75 years estimated the fraction of COPD attributable to workplace exposures was 19.2% overall, and 31.1% among never-smokers. These estimates are consistent with a statement published by the American Thoracic Society that concluded that occupational exposures account for 10-20% of either symptoms or functional impairment consistent with COPD. The risk from occupational exposures in less regulated areas of the world is likely to be much higher than reported in studies from Europe and North America.

Wood, animal dung, crop residues, and coal, typically burned in open fires or poorly functioning stoves, may lead to very high levels of indoor air pollution. There is growing evidence that indoor pollution from biomass cooking and heating in poorly ventilated dwellings is an important risk factor for COPD. Almost three billion people worldwide use biomass and coal as their main source of energy for cooking, heating, and other household needs, so the population at risk worldwide is very large.

High levels of urban air pollution are harmful to individuals with existing heart or lung disease. The role of outdoor air pollution as a risk factor for COPD is unclear, but its role appears to be relatively small in adults compared to the role of cigarette smoking. However, there is evidence that air pollution has a significant impact on lung maturation and development. For instance, the Children's Health Study found that children from communities with the highest levels of outdoor nitrogen dioxide ($\text{NO}_2$) and particulate matter < 2.5 μm in aerodynamic diameter (PM2.5) were nearly 5 times more likely to have reduced lung function (defined as $\text{FEV}_1 < 80\%$ of predicted) compared to children from communities with the lowest levels of $\text{NO}_2$ and PM2.5. Importantly, reduction in ambient $\text{NO}_2$ and PM2.5 levels significantly mitigated the risk of experiencing impaired lung growth. However, the relative effects of short-term, high-peak exposures and long-term, low-level exposures are yet to be resolved.

**Socioeconomic status**

Lower socioeconomic status is associated with an increased risk for developing COPD but the components of poverty that contribute are unclear. There is strong evidence that the risk of developing COPD is inversely related to socioeconomic status. It is not clear, however, whether this pattern reflects exposures to indoor and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.

**Asthma and airway hyper-reactivity**

Asthma may be a risk factor for the development of chronic airflow limitation and COPD. In a report from a longitudinal cohort of the Tucson Epidemiological Study of Airway Obstructive Disease, adults with asthma were found to have a 12-fold higher risk of acquiring COPD over time compared to those without asthma, after adjusting for smoking. Another longitudinal study of people with asthma found that around 20% of subjects developed irreversible airflow limitation and reduced transfer coefficient. A third longitudinal study observed that self-reported asthma was associated with excess loss of $\text{FEV}_1$ in the general population. A study examining the pattern of lung-growth decline in children with asthma found that 11% met lung function impairment consistent with the spirometric classification of COPD in early adulthood. In the European Community Respiratory
Health Survey, airway hyper-responsiveness was second only to cigarette smoking as the leading risk factor for COPD, responsible for 15% of the population attributable risk (smoking had a population attributable risk of 39%). The pathology of chronic airflow limitation in asthmatic non-smokers and non-asthmatic smokers is markedly different, suggesting that the two disease entities may remain different even when presenting with similarly reduced lung function. However, separating asthma from COPD in adults may be clinically difficult at times.

Airway hyper-responsiveness can exist without a clinical diagnosis of asthma and has been shown to be an independent predictor of COPD and respiratory mortality in population studies as well as an indicator of risk of excess decline in lung function in patients with mild COPD.

**Chronic bronchitis**

In the seminal study by Fletcher and colleagues, chronic bronchitis was not associated with an accelerated decline in lung function. However, subsequent studies have observed an association between mucus hypersecretion and increased FEV\(_1\) decline, and in younger adults who smoke, the presence of chronic bronchitis has been associated with an increased likelihood of developing COPD. Chronic bronchitis has also been associated with an increased risk in the total number as well as severity of exacerbations.

**Infections**

A history of severe childhood respiratory infection has been associated with reduced lung function and increased respiratory symptoms in adulthood. Susceptibility to infections plays a role in exacerbations of COPD but the effect on disease development is less clear. There is evidence that HIV infection accelerates the onset of smoking-related emphysema and COPD; tuberculosis has also been identified as a risk factor for COPD. In addition, tuberculosis is both a differential diagnosis for COPD and a potential comorbidity.

**PATHOLOGY, PATHOGENESIS AND PATHOPHYSIOLOGY**

Inhalation of cigarette smoke or other noxious particles, such as smoke from biomass fuels, causes lung inflammation. Lung inflammation is a normal response that appears to be modified in patients who develop COPD. This chronic inflammatory response may induce parenchymal tissue destruction (resulting in emphysema), and disruption of normal repair and defense mechanisms (resulting in small airway fibrosis). These pathological changes lead to gas trapping and progressive airflow limitation. A brief overview follows that describes and summarizes the pathologic changes in COPD, their cellular and molecular mechanisms, and how these underlie the physiological abnormalities and symptoms characteristic of this disease.

**Pathology**

Pathological changes characteristic of COPD are found in the airways, lung parenchyma, and pulmonary vasculature. The pathological changes observed in COPD include chronic inflammation, with increased numbers of specific inflammatory cell types in different parts of the lung, and structural changes resulting from repeated injury and repair. In general, the inflammatory and
structural changes in the airways increase with disease severity and persist on smoking cessation. Most pathology data comes from studies in smokers and the same balance of airway and parenchymal disease cannot necessarily be assumed when other factors are operative. Systemic inflammation may be present and could play a role in the multiple comorbid conditions found in patients with COPD. 105

Pathogenesis

The inflammation observed in the respiratory tract of COPD patients appears to be a modification of the normal inflammatory response of the respiratory tract to chronic irritants such as cigarette smoke. The mechanisms for this amplified inflammation are not yet understood but may, at least in part, be genetically determined. Although some patients develop COPD without smoking, the nature of the inflammatory response in these patients is as yet unknown. Oxidative stress and an excess of proteinases in the lung are likely to further modify lung inflammation. Together, these mechanisms may lead to the characteristic pathological changes in COPD. Lung inflammation persists after smoking cessation through unknown mechanisms, although autoantigens and perturbations in the lung microbiome may play a role. 106,107 Similar mechanisms may occur for concomitant chronic diseases.

Oxidative stress. Oxidative stress may be an important amplifying mechanism in COPD. 105,108 Biomarkers of oxidative stress (e.g., hydrogen peroxide, 8-isoprostane) are increased in the exhaled breath condensate, sputum, and systemic circulation of COPD patients. Oxidative stress is further increased during exacerbations. Oxidants are both generated by cigarette smoke and other inhaled particulates, and released from activated inflammatory cells such as macrophages and neutrophils. There may also be a reduction in endogenous antioxidants in COPD patients as a result of reduction in levels of the transcription factor \( \textit{Nrf2} \) that regulates many antioxidant genes. 102,109

Protease-antiprotease imbalance. There is compelling evidence for an imbalance in the lungs of COPD patients between proteases that break down connective tissue components and antiproteases that counterbalance this action. 110 Increased levels of several proteases, derived from inflammatory cells and epithelial cells, have been observed in COPD patients. There is increasing evidence that these proteases may interact with each other. Protease-mediated destruction of elastin, a major connective tissue component in lung parenchyma, is believed to be an important feature of emphysema but may be more difficult to establish in airway changes. 111

Inflammatory cells. COPD is characterized by increased numbers of macrophages in peripheral airways, lung parenchyma and pulmonary vessels, together with increased activated neutrophils and increased lymphocytes that include Tc1, Th1, Th17 and ILC3 cells. In some patients there may also be increases in eosinophils, Th2 or ILC2 cells, especially where there is clinical overlap with asthma. All of these inflammatory cells, together with epithelial cells and other structural cells release multiple inflammatory mediators. 105

Inflammatory mediators. The wide variety of inflammatory mediators that have been shown to be increased in COPD patients attract inflammatory cells from the circulation (chemotactic factors), amplify the inflammatory process (proinflammatory cytokines), and induce structural changes (growth factors). 112
**Peribronchiolar and interstitial fibrosis.** Peribronchiolar fibrosis and interstitial opacities have been reported in patients with COPD or those who are asymptomatic smokers. An excessive production of growth factors may be found in smokers or those with preceding airway inflammation who have COPD. Inflammation may precede the development of fibrosis or repeated injury of the airway wall itself may lead to excessive production of muscle and fibrous tissue. This may be a contributing factor to the development of small airways limitation and eventually the obliteration that may precede the development of emphysema.

**Differences in inflammation between COPD and asthma.** Although both COPD and asthma are associated with chronic inflammation of the respiratory tract, there are differences in the inflammatory cells and mediators involved in the two diseases. Some patients with COPD have features consistent with asthma and may have a mixed inflammatory pattern with increased eosinophils.

**Pathophysiology**

There is now a good understanding of how the underlying disease process in COPD leads to the characteristic physiological abnormalities and symptoms. For example, inflammation and narrowing of peripheral airways leads to decreased FEV₁. Parenchymal destruction due to emphysema also contributes to airflow limitation and leads to decreased gas transfer. There is also emerging evidence to suggest that in addition to airway narrowing, there is a loss of small airways, which may contribute to airflow limitation.

**Airflow limitation and gas trapping.** The extent of inflammation, fibrosis, and luminal exudates in the small airways correlates with the reduction in the FEV₁ and FEV₁/FVC ratio, and probably with the accelerated decline in FEV₁ that is characteristic of COPD. This peripheral airway limitation progressively traps gas during expiration, resulting in hyperinflation. Static hyperinflation reduces inspiratory capacity and is commonly associated with dynamic hyperinflation during exercise leading to increased dyspnea and limitation of exercise capacity. These factors contribute to impairment of the intrinsic contractile properties of respiratory muscles. It is thought that hyperinflation develops early in the disease and is the main mechanism for exertional dyspnea. Bronchodilators acting on peripheral airways reduce gas trapping, thereby reducing lung volumes and improving symptoms and exercise capacity.

**Gas exchange abnormalities.** Gas exchange abnormalities result in hypoxemia and hypercapnia, and have several mechanisms in COPD. In general, gas transfer for oxygen and carbon dioxide worsens as the disease progresses. Reduced ventilation may also be due to reduced ventilatory drive or increased dead space ventilation. This may lead to carbon dioxide retention when it is combined with reduced ventilation, due to increased effort to breathe because of severe limitation and hyperinflation coupled with ventilatory muscle impairment. The abnormalities in alveolar ventilation and a reduced pulmonary vascular bed further worsen the Vₐ/Q (ventilation perfusion ratio) abnormalities.

**Mucus hypersecretion.** Mucus hypersecretion, resulting in a chronic productive cough, is a feature of chronic bronchitis and is not necessarily associated with airflow limitation. Conversely, not all
patients with COPD have symptomatic mucus hypersecretion. When present, mucus hypersecretion is due to an increased number of goblet cells and enlarged submucosal glands, both because of chronic airway irritation by cigarette smoke and other noxious agents. Several mediators and proteases stimulate mucus hypersecretion and many of them exert their effects through the activation of epidermal growth factor receptor (EGFR).\textsuperscript{127}

**Pulmonary hypertension.** Pulmonary hypertension may develop late in the course of COPD and is due mainly to hypoxic vasoconstriction of the small pulmonary arteries, eventually resulting in structural changes that include intimal hyperplasia and later smooth muscle hypertrophy/hyperplasia.\textsuperscript{128} However, even in mild COPD, there are significant abnormalities in the pulmonary microvascular blood flow, which worsen with disease progression.\textsuperscript{129}

An inflammatory response in vessels, similar to that seen in the airways, is also observed in COPD, along with evidence of endothelial cell dysfunction. The loss of the pulmonary capillary bed in emphysema may further contribute to increased pressure in the pulmonary circulation. Progressive pulmonary hypertension may lead to right ventricular hypertrophy and eventually to right-side cardiac failure. Interestingly, the diameter of pulmonary artery as measured on computed tomography (CT) scans has been shown to relate to the risk of exacerbation, independent of previous history of exacerbations.\textsuperscript{130} This suggests that perturbations in pulmonary vasculature are major, but under-recognized, drivers of symptoms and exacerbations in COPD.

**Exacerbations.** Exacerbations of respiratory symptoms triggered by respiratory infections with bacteria or viruses (which may coexist), environmental pollutants, or unknown factors often occur in patients with COPD; a characteristic response with increased inflammation occurs during episodes of bacterial or viral infection. During exacerbations there is increased hyperinflation and gas trapping, with reduced expiratory flow, thus accounting for increased dyspnea.\textsuperscript{131} There is also worsening of \( V_a/Q \) abnormalities that can result in hypoxemia.\textsuperscript{132} During exacerbations there is evidence of increased airway inflammation. Other conditions (pneumonia, thromboembolism, and acute cardiac failure) may mimic or aggravate an exacerbation of COPD.

**Systemic features.** Most patients with COPD have concomitant chronic diseases linked to the same risk factors i.e., smoking, aging, and inactivity, which may have a major impact on health status and survival.\textsuperscript{133} Airflow limitation and particularly hyperinflation affect cardiac function and gas exchange.\textsuperscript{134} Inflammatory mediators in the circulation may contribute to skeletal muscle wasting and cachexia, and may initiate or worsen comorbidities such as ischemic heart disease, heart failure, osteoporosis, normocytic anemia, diabetes, and metabolic syndrome.
REFERENCES


CHAPTER 2: DIAGNOSIS AND INITIAL ASSESSMENT

OVERALL KEY POINTS:

- **COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease.**

- **Spirometry is required to make the diagnosis; the presence of a post-bronchodilator \( FEV_1/FVC < 0.70 \) confirms the presence of persistent airflow limitation.**

- **The goals of COPD assessment are to determine the level of airflow limitation, the impact of disease on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.**

- **Concomitant chronic diseases occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety, and lung cancer. These comorbidities should be actively sought and treated appropriately when present as they can influence mortality and hospitalizations independently.**

DIAGNOSIS

COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease (Figure 2.1 and Table 2.1). Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator \( FEV_1/FVC < 0.70 \) confirms the presence of persistent airflow limitation and thus of COPD in patients with appropriate symptoms and significant exposures to noxious stimuli.

Figure 2.1. Pathways to the diagnosis of COPD

![Pathways to the diagnosis of COPD](image-url)
Chronic and progressive dyspnea is the most characteristic symptom of COPD. Cough with sputum production is present in up to 30% of patients. These symptoms may vary from day-to-day and may precede the development of airflow limitation by many years. Individuals, particularly those with COPD risk factors, presenting with these symptoms should be examined to search for the underlying cause(s). These patient symptoms should be used to help develop appropriate interventions.

Significant airflow limitation may also be present without chronic dyspnea and/or cough and sputum production and vice versa. Although COPD is defined on the basis of airflow limitation, in practice the decision to seek medical help is usually determined by the impact of symptoms on a patient’s functional status. A person may seek medical attention either because of chronic respiratory symptoms or because of an acute, transient episode of exacerbated respiratory symptoms.

**Dyspnea.** Dyspnea, a cardinal symptom of COPD, is a major cause of the disability and anxiety that is associated with the disease. Typical COPD patients describe their dyspnea as a sense of increased effort to breathe, chest heaviness, air hunger, or gasping. However, the terms used to describe dyspnea may vary both individually and culturally.

**Cough.** Chronic cough is often the first symptom of COPD and is frequently discounted by the patient as an expected consequence of smoking and/or environmental exposures. Initially, the cough may be intermittent, but subsequently may be present every day, often throughout the day. Chronic cough in COPD may be productive or unproductive. In some cases, significant airflow limitation may develop without the presence of a cough. Other causes of chronic cough are listed in Table 2.2.
**Table 2.2. Other causes of chronic cough**

<table>
<thead>
<tr>
<th>Intrathoracic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
</tr>
<tr>
<td>Lung cancer</td>
</tr>
<tr>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Bronchiectasis</td>
</tr>
<tr>
<td>Left heart failure</td>
</tr>
<tr>
<td>Interstitial lung disease</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Idiopathic cough</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Extrathoracic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic allergic rhinitis</td>
</tr>
<tr>
<td>Post nasal drip syndrome (PNDS)</td>
</tr>
<tr>
<td>Upper Airway Cough Syndrome (UACS)</td>
</tr>
<tr>
<td>Gastroesophageal reflux</td>
</tr>
<tr>
<td>Medication (e.g. ACE inhibitors)</td>
</tr>
</tbody>
</table>

**Sputum production.** COPD patients commonly raise small quantities of tenacious sputum with coughing. Regular production of sputum for three or more months in two consecutive years (in the absence of any other conditions that may explain it) is the classical definition of chronic bronchitis, but this is a somewhat arbitrary definition that does not reflect the entire range of sputum production that occurs in COPD. Sputum production is often difficult to evaluate because patients may swallow sputum rather than expectorate it, a habit that is subject to significant cultural and gender variation. Furthermore, sputum production can be intermittent with periods of flare-up interspersed with periods of remission. Patients producing large volumes of sputum may have underlying bronchiectasis. The presence of purulent sputum reflects an increase in inflammatory mediators, and its development may identify the onset of a bacterial exacerbation, though the association is relatively weak.

**Wheezing and chest tightness.** Wheezing and chest tightness are symptoms that may vary between days, and over the course of a single day. Audible wheeze may arise at the laryngeal level and need not be accompanied by abnormalities heard on auscultation. Alternatively, widespread inspiratory or expiratory wheezes can be present on auscultation. Chest tightness often follows exertion, is poorly localized, is muscular in character, and may arise from isometric contraction of the intercostal muscles. An absence of wheezing or chest tightness does not exclude a diagnosis of COPD, nor does the presence of these symptoms confirm a diagnosis of asthma.

**Additional features in severe disease.** Fatigue, weight loss and anorexia are common problems in patients with severe and very severe COPD. They have prognostic importance and can also be a sign of other diseases, such as tuberculosis or lung cancer, and therefore should always be investigated. Syncope during cough occurs due to rapid increases in intrathoracic pressure during prolonged attacks of coughing. Coughing spells may also cause rib fractures, which are sometimes asymptomatic. Ankle swelling may be the only indicator of the presence of cor pulmonale. Symptoms of depression and/or anxiety merit specific enquiry when obtaining the medical history because they are common in COPD and are associated with an increased risk of exacerbations and poorer health status.
MEDICAL HISTORY

A detailed medical history of a new patient who is known, or suspected, to have COPD should include:

- **Patient’s exposure to risk factors**, such as smoking and occupational or environmental exposures.
- **Past medical history**, including asthma, allergy, sinusitis, or nasal polyps; respiratory infections in childhood; other chronic respiratory and nonrespiratory diseases.
- **Family history of COPD or other chronic respiratory disease**.
- **Pattern of symptom development**: COPD typically develops in adult life and most patients are conscious of increased breathlessness, more frequent or prolonged “winter colds,” and some social restriction for a number of years before seeking medical help.
- **History of exacerbations or previous hospitalizations for respiratory disorder**. Patients may be aware of periodic worsening of symptoms even if these episodes have not been identified as exacerbations of COPD.
- **Presence of comorbidities**, such as heart disease, osteoporosis, musculoskeletal disorders, and malignancies that may also contribute to restriction of activity.
- **Impact of disease on patient’s life**, including limitation of activity, missed work and economic impact, effect on family routines, feelings of depression or anxiety, well-being and sexual activity.
- **Social and family support available to the patient**.
- **Possibilities for reducing risk factors, especially smoking cessation**.

**Physical examination**

Although an important part of patient care, a physical examination is rarely diagnostic in COPD. Physical signs of airflow limitation are usually not present until significant impairment of lung function has occurred, and detection based on physical examination has relatively low sensitivity and specificity. A number of physical signs may be present in COPD, but absence does not exclude the diagnosis.

**Spirometry**

Spirometry is the most reproducible and objective measurement of airflow limitation. It is a noninvasive and readily available test. Despite its good sensitivity, peak expiratory flow measurement alone cannot be reliably used as the only diagnostic test because of its weak specificity. Good quality spirometric measurement is possible in any healthcare setting and all healthcare workers who care for COPD patients should have access to spirometry. Some of the factors needed to achieve accurate test results are summarized in Table 2.3.
Spirometry should measure the volume of air forcibly exhaled from the point of maximal inspiration (forced vital capacity, FVC) and the volume of air exhaled during the first second of this maneuver (forced expiratory volume in one second, FEV₁), and the ratio of these two measurements (FEV₁/FVC) should be calculated. The ratio between FEV₁ and slow vital capacity (VC), FEV₁/VC, is sometimes measured instead of the FEV₁/FVC ratio. This will often lead to lower values of the ratio, especially in pronounced airflow limitation. Spirometry measurements are evaluated by comparison with reference values based on age, height, sex, and race.

### Table 2.3. Considerations in performing spirometry

**Preparation**
- Spirometers need calibration on a regular basis.
- Spirometers should produce hard copy or have a digital display of the expiratory curve to permit detection of technical errors or have an automatic prompt to identify an unsatisfactory test and the reason for it.
- The supervisor of the test needs training in optimal technique and quality performance.
- Maximal patient effort in performing the test is required to avoid underestimation of values and hence errors in diagnosis and management.

**Bronchodilatation**
- Possible dosage protocols are 400 mcg short-acting beta₂-agonist, 160 mcg short-acting anticholinergic, or the two combined. FEV₁ should be measured 10-15 minutes after a short-acting beta₂-agonist is given, or 30-45 minutes after a short-acting anticholinergic or a combination of both classes of drugs.

**Performance**
- Spirometry should be performed using techniques that meet published standards.
- The expiratory volume/time traces should be smooth and free from irregularities. The pause between inspiration and expiration should be < 1 second.
- The recording should go on long enough for a volume plateau to be reached, which may take more than 15 seconds in severe disease.
- Both FVC and FEV₁ should be the largest value obtained from any of three technically satisfactory curves and the FVC and FEV₁ values in these three curves should vary by no more than 5% or 150 ml, whichever is greater.
- The FEV₁/FVC ratio should be taken from the technically acceptable curve with the largest sum of FVC and FEV₁.

**Evaluation**
- Spirometry measurements are evaluated by comparison of the results with appropriate reference values based on age, height, sex, and race.
- The presence of a postbronchodilator FEV₁/FVC < 0.70 confirms the presence of airflow limitation.

---

![Figure 2.2A. Spirometry - Normal Trace](image1)

**FEV₁ = 4L**

**FVC = 5L**

**FEV₁/FVC = 0.8**

![Figure 2.2B. Spirometry - Obstructive Disease](image2)

**FEV₁ = 1.8L**

**FVC = 3.2L**

**FEV₁/FVC = 0.56**

Obstructive
A normal spirometry tracing is shown in Figure 2.2A. A spirometry tracing typical of a patient with obstructive disease is shown in Figure 2.2B. Patients with COPD typically show a decrease in both FEV\textsubscript{1} and FVC.

The spirometric criterion for airflow limitation remains a post-bronchodilator fixed ratio of FEV\textsubscript{1}/FVC < 0.70. This criterion is simple and independent of reference values, and has been used in numerous clinical trials that form the evidence base from which most of our treatment recommendations are drawn. It should be noted that the use of the fixed FEV\textsubscript{1}/FVC ratio to define airflow limitation may result in more frequent diagnosis of COPD in the elderly\textsuperscript{22,23} and less frequent diagnosis in adults < 45 years\textsuperscript{23} especially in mild disease, compared to using a cut-off based on the lower limit of normal (LLN) values for FEV\textsubscript{1}/FVC.

The LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal. From a scientific or clinical perspective, it is difficult to determine which of these criteria will result in optimal COPD diagnostic accuracy. However, LLN values are highly dependent on the choice of valid reference equations using post-bronchodilator FEV\textsubscript{1}, and there are no longitudinal studies available validating the use of the LLN, or studies using reference equations in populations where smoking is not the major cause of COPD.

Normal spirometry may be defined by a new approach from the Global Lung Initiative (GLI)\textsuperscript{24,25}. Using GLI equations, z scores were calculated for FEV\textsubscript{1}, FVC, and FEV\textsubscript{1}/FVC. The diagnostic algorithm was initially based on a single threshold, namely a z score of -1.64 (defining the LLN at the fifth percentile of the normal distribution). The results were compared to fixed ratio data. The findings suggest that among adults with GLI-defined normal spirometry, the use of a fixed ratio may misclassify individuals as having respiratory impairment. It is important that these findings are reproduced in other cohorts.

The risk of misdiagnosis and over-treatment of individual patients using the fixed ratio as a diagnostic criterion is limited, as spirometry is only one parameter for establishing the clinical diagnosis of COPD; the additional parameters being symptoms and other risk factors. Diagnostic simplicity and consistency are crucial for the busy clinician. Thus, GOLD favors the use of the fixed ratio over LLN.

While post-bronchodilator spirometry is required for the diagnosis and assessment of COPD, assessing the degree of reversibility of airflow limitation (e.g., measuring FEV\textsubscript{1} before and after bronchodilator or corticosteroids) to inform therapeutic decisions is no longer recommended.\textsuperscript{26} The degree of reversibility has not been shown to augment the diagnosis of COPD, differentiate the diagnosis from asthma, or to predict the response to long-term treatment with bronchodilators or corticosteroids.\textsuperscript{22}

The role of screening spirometry in the general population is controversial.\textsuperscript{28,29} In asymptomatic individuals without any significant exposures to tobacco or other noxious stimuli, screening spirometry is probably not indicated; whereas in those with symptoms or risk factors (e.g., > 20 pack-years of smoking or recurrent chest infections), the diagnostic yield for COPD is relatively high.
and spirometry should be considered as a method for early case finding. Both FEV₁ and FVC predict all-cause mortality independent of tobacco smoking, and abnormal lung function identifies a subgroup of smokers at increased risk for lung cancer. This has been the basis of an argument that screening spirometry should be employed as a global health assessment tool. However, there are no data to indicate that screening spirometry is effective in directing management decisions or in improving COPD outcomes in patients who are identified before the development of significant symptoms. This may reflect the design and application of current case finding instruments that have not been utilized to identify patients with undiagnosed COPD who are most likely to benefit from existing therapies. Thus, GOLD advocates active case finding i.e., performing spirometry in patients with symptoms and/or risk factors, but not screening spirometry.

Interpretation of the severity of lung function impairment is dependent on having appropriate reference values. The Prospective Urban and Rural Epidemiological (PURE) study analyzed pre-bronchodilator spirometry data from 153,996 healthy people with less than 5-pack-year smoking histories in 17 countries and observed wide variation in lung function. For instance, compared with individuals living in North America or Europe, people living in Southeast Asia had FEV₁ values that were on average 31% lower, adjusted for age, height and sex. Similarly, those living in sub-Saharan Africa, East Asia, Middle East and South America had FEV₁ values that were on average 21%, 13%, 11%, and 6% lower than individuals living in North America or Europe, respectively, independent of age, height, sex, and smoking status. Unless relevant predicted values are used the severity of airflow limitation will be overestimated.

**ASSESSMENT**

The goals of COPD assessment are to determine the level of airflow limitation, its impact on the patient’s health status and the risk of future events (such as exacerbations, hospital admissions or death), in order to, eventually, guide therapy.

To achieve these goals, COPD assessment must consider the following aspects of the disease separately:

- The presence and severity of the spirometric abnormality
- Current nature and magnitude of the patient’s symptoms
- Exacerbation history and future risk
- Presence of comorbidities

**Classification of severity of airflow limitation**

The classification of airflow limitation severity in COPD is shown in Table 2.4. Specific spirometric cut-points are used for purposes of simplicity. Spirometry should be performed after the administration of an adequate dose of at least one short-acting inhaled bronchodilator in order to minimize variability.
It should be noted that there is only a weak correlation between FEV\textsubscript{1}, symptoms and impairment of a patient’s health status.\textsuperscript{39-40} For this reason, formal symptomatic assessment is required.

### Assessment of symptoms

Here we present the two measures of symptoms that are most widely used.

In the past, COPD was viewed as a disease largely characterized by breathlessness. A simple measure of breathlessness such as the Modified British Medical Research Council (mMRC) Questionnaire\textsuperscript{41} (Table 2.5) was considered adequate for assessment of symptoms, as the mMRC relates well to other measures of health status\textsuperscript{42} and predicts future mortality risk.\textsuperscript{43,44}

However, it is now recognized that COPD impacts patients beyond just dyspnea.\textsuperscript{45} For this reason, a comprehensive assessment of symptoms is recommended rather than just a measure of breathlessness. The most comprehensive disease-specific health status questionnaires such as the Chronic Respiratory Questionnaire (CRQ)\textsuperscript{46} and St. George’s Respiratory Questionnaire (SGRQ)\textsuperscript{47} are too complex to use in routine practice, but shorter comprehensive measures e.g., COPD Assessment Test (CAT\textsuperscript{TM}) and The COPD Control Questionnaire (The CCQ\textsuperscript{®}) have been developed and are suitable.

#### COPD Assessment Test (CAT\textsuperscript{TM}).\textsuperscript{§} The COPD Assessment Test is an 8-item uni-dimensional measure of health status impairment in COPD (Figure 2.3).\textsuperscript{48} It was developed to be applicable worldwide and

---

\textsuperscript{§} The COPD Assessment Test was developed by a multi-disciplinary group of international experts in COPD supported by GSK. COPD Assessment Test and the CAT logo is a trademark of the GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline. All rights reserved. GSK activities with respect to the COPD Assessment Test are overseen by a governance board that includes independent external experts, one of whom chairs the board.
validated translations are available in a wide range of languages. The score ranges from 0-40, correlates very closely with the SGRQ, and has been extensively documented in numerous publications.49

Choice of thresholds

The CAT™ and the CCQ© provide measures of the symptomatic impact of COPD but do not categorize patients into symptom severity groups for the purpose of treatment. The SGRQ is the most widely documented comprehensive measure; scores < 25 are uncommon in diagnosed COPD patients50 and scores ≥ 25 are very uncommon in healthy persons.51,52 Therefore, it is recommended that a symptom score equivalent to SGRQ score ≥ 25 should be used as the threshold for considering regular treatment for symptoms including breathlessness, particularly since this corresponds to the range of severity seen in patients recruited to the trials that have provided the evidence base for treatment recommendations. The equivalent cut-point for the CAT™ is 10.53

Figure 2.3. CAT Assessment

For each item below, place a mark (x) in the box that best describes you currently. Be sure to only select one response for each question.

Example: I am very happy 0 1 2 3 4 5 I am very sad

<table>
<thead>
<tr>
<th>Item</th>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I never cough</td>
<td></td>
<td>I cough all the time</td>
</tr>
<tr>
<td>I have no phlegm (mucus) in my chest at all</td>
<td></td>
<td>My chest is completely full of phlegm (mucus)</td>
</tr>
<tr>
<td>My chest does not feel tight at all</td>
<td></td>
<td>My chest feels very tight</td>
</tr>
<tr>
<td>When I walk up a hill or one flight of stairs I am not breathless</td>
<td></td>
<td>When I walk up a hill or one flight of stairs I am very breathless</td>
</tr>
<tr>
<td>I am not limited doing any activities at home</td>
<td></td>
<td>I am very limited doing activities at home</td>
</tr>
<tr>
<td>I am confident leaving my home despite my lung condition</td>
<td></td>
<td>I am not at all confident leaving my home because of my lung condition</td>
</tr>
<tr>
<td>I don’t sleep soundly because of my lung condition</td>
<td></td>
<td>I have no energy at all</td>
</tr>
</tbody>
</table>

An equivalent mMRC score cannot be calculated because a simple breathlessness cut-point cannot equate to a comprehensive symptom score cut-point. The great majority of patients with an SGRQ of ≥ 25 will have an mMRC of ≥ 1; however patients with mMRC < 1 may also have a number of other COPD symptoms.56 For this reason, the use of a comprehensive symptom assessment is recommended. However, because use of the mMRC is widespread, an mMRC of ≥ 2 is still included...
as a threshold for separating “less breathlessness” from “more breathlessness.” Nevertheless, users are cautioned that assessment of other symptoms is required.  

There are other scales available such as the COPD Control Questionnaire (CCQ) and the Chronic Respiratory Disease Questionnaire (CRQ) that will not be discussed in detail.

**Assessment of exacerbation risk**

COPD exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy. These events are classified as mild (treated with short acting bronchodilators (SABDs) only), moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or severe (patient requires hospitalization or visits the emergency room). Severe exacerbations may also be associated with acute respiratory failure. A number of large studies including patients classified using GOLD spirometric grading systems have been conducted and showed that the rate at which exacerbations occur varies greatly between patients. The best predictor of having frequent exacerbations (defined as two or more exacerbations per year) is a history of earlier treated events.

In addition, deteriorating airflow limitation is associated with an increasing prevalence of exacerbations, hospitalization and risk of death. Hospitalization for a COPD exacerbation is associated with poor prognosis and increased risk of death. There is also a significant relationship between spirometric severity and the risk of exacerbation and death. At the population level, approximately 20% of GOLD 2 (moderate airflow limitation) patients may experience frequent exacerbations requiring treatment with antibiotics and/or systemic corticosteroids. The risk of exacerbations is significantly higher for patients with GOLD 3 (severe) and GOLD 4 (very severe). However, FEV1 by itself lacks sufficient precision (i.e., wide variation) to be used clinically as a predictor of exacerbation or mortality in patients with COPD.

**Blood eosinophil count.** Post-hoc analysis of two clinical trials in COPD patients with an exacerbation history showed that higher blood eosinophil counts may predict increased exacerbation rates in patients treated with LABA (without ICS). Furthermore, the treatment effect of ICS/LABA versus LABA on exacerbations was greater in patients with higher blood eosinophil counts. These findings suggest that blood eosinophil counts are 1) a biomarker of exacerbation risk in patients with a history of exacerbations and 2) can predict the effects of ICS on exacerbation prevention. Post-hoc analysis of other clinical trials have reported that the effects of ICS on exacerbation prevention are associated with blood eosinophil counts. One large COPD cohort study showed an association between higher blood eosinophil counts and increased exacerbation frequency, although this was not observed in a different cohort. Differences between studies may be related to different previous exacerbation histories and ICS use. Prospective clinical trials are required to validate the use of blood eosinophil counts to predict ICS effects, to determine a cut-off threshold for blood eosinophils that predict future exacerbation risk in COPD patients with an exacerbation history and to clarify the blood eosinophil cut-off values that could be used in clinical practice. The mechanism for an apparently increased effect of ICS in COPD patients with higher blood eosinophil counts remains unclear.
Assessment of concomitant chronic diseases (comorbidities)

Patients with COPD often have important concomitant chronic illnesses at the time of diagnosis and COPD represents an important component of multimorbidity development particularly in the elderly in response to common risk factors (e.g., aging, smoking, alcohol, diet and inactivity).\textsuperscript{64,69-71} COPD itself also has significant extrapulmonary (systemic) effects including weight loss, nutritional abnormalities and skeletal muscle dysfunction. Skeletal muscle dysfunction is characterized by both sarcopenia (loss of muscle cells) and abnormal function of the remaining cells.\textsuperscript{72} Its causes are likely multifactorial (e.g., inactivity, poor diet, inflammation and hypoxia) and it can contribute to exercise intolerance and poor health status in patients with COPD. Importantly, skeletal muscle dysfunction is a rectifiable source of exercise intolerance.\textsuperscript{73}

Common comorbidities include cardiovascular disease,\textsuperscript{74} skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety and lung cancer. The existence of COPD may actually increase the risk for other diseases; this is particularly striking for COPD and lung cancer.\textsuperscript{75,76} Whether this association is due to common risk factors (e.g., smoking), involvement of susceptibility genes, or impaired clearance of carcinogens is not clear.

Comorbidities can occur in patients with mild, moderate or severe airflow limitation,\textsuperscript{50} influence mortality and hospitalizations independently,\textsuperscript{77} and deserve specific treatment. Therefore, comorbidities should be looked for routinely, and treated appropriately, in any patient with COPD. Recommendations for the diagnosis, assessment of severity, and management of individual comorbidities in patients with COPD are the same as for all other patients. A more detailed description of the management of COPD and comorbidities is provided in Chapter 6.

Revised combined COPD assessment

An understanding of the impact of COPD on an individual patient combines the symptomatic assessment with the patient's spirometric classification and/or risk of exacerbations. The “ABCD” assessment tool of the 2011 GOLD update was a major step forward from the simple spirometric grading system of the earlier versions of GOLD because it incorporated patient-reported outcomes and highlighted the importance of exacerbation prevention in the management of COPD. However, there were some important limitations. Firstly, the ABCD assessment tool performed no better than the spirometric grades for mortality prediction or other important health outcomes in COPD.\textsuperscript{63,78,79} Moreover, group “D” outcomes were modified by two parameters: lung function and/or exacerbation history, which caused confusion.\textsuperscript{80} To address these and other concerns (while at the same time maintaining consistency and simplicity for the practicing clinician), a refinement of the ABCD assessment tool is proposed that separates spirometric grades from the “ABCD” groups. For some therapeutic recommendations, ABCD groups will be derived exclusively from patient symptoms and their history of exacerbation. Spirometry, in conjunction with patient symptoms and exacerbation history, remains vital for the diagnosis, prognostication and consideration of other important therapeutic approaches. This new approach to assessment is illustrated in Figure 2.4.

In the refined assessment scheme, patients should undergo spirometry to determine the severity of airflow limitation (i.e., spirometric grade). They should also undergo assessment of either dyspnea
using mMRC or symptoms using CAT™. Finally, their history of exacerbations (including prior hospitalizations) should be recorded.

The number provides information regarding severity of airflow limitation (spirometric grade 1 to 4) while the letter (groups A to D) provides information regarding symptom burden and risk of exacerbation which can be used to guide therapy. FEV₁ is a very important parameter at the population-level in the prediction of important clinical outcomes such as mortality and hospitalizations or prompting consideration for non-pharmacologic therapies such as lung volume reduction or lung transplantation. However, it is important to note that at the individual patient level, FEV₁ loses precision and thus cannot be used alone to determine all therapeutic options. Furthermore, in some circumstances, such as during hospitalization or urgent presentation to the clinic or emergency room, the ability to assess patients based on symptoms and exacerbation history, independent of the spirometric value, allows clinicians to initiate a treatment plan based on the revised ABCD scheme alone. This assessment approach acknowledges the limitations of FEV₁ in making treatment decisions for individualized patient care and highlights the importance of patient symptoms and exacerbation risks in guiding therapies in COPD. The separation of airflow limitation from clinical parameters makes it clearer what is being evaluated and ranked. This will facilitate more precise treatment recommendations based on parameters that are driving the patient’s symptoms at any given time.

**Example:** Consider two patients - both patients with FEV₁ < 30% of predicted, CAT scores of 18 and one with no exacerbations in the past year and the other with three exacerbations in the past year. Both would have been labelled GOLD D in the prior classification scheme. However, with the new proposed scheme, the subject with 3 exacerbations in the past year would be labelled GOLD grade 4, group D.
Individual decisions on pharmacotherapeutic approaches would use the recommendations in **Chapter 4** based on the ABCD assessment to treat the patient’s major problem at this time i.e., persistent exacerbations. The other patient, who has had no exacerbations, would be classified as GOLD grade 4, group B. In such patients — besides pharmacotherapy and rehabilitation — lung volume reduction, lung transplant or bullectomy may be important considerations for therapy given their symptom burden and level of spirometric limitation.

**Note:** In cases where there is a marked discordance between the level of airflow limitation and the perceived symptoms, a more detailed evaluation should be carried out to better understand lung mechanics (e.g., full lung function tests), lung structure (e.g., computed tomography) and/or comorbidities (e.g., ischemic heart disease) that might impact patient symptoms. In some cases, patients may endorse minimal symptoms despite demonstrating severe airflow limitation. Adapting to the limitations induced by COPD, these patients may reduce their level of physical activity in a way that may result in an underestimation of the symptom load. In these cases exercise tests like the 6 minute walking distance may reveal that the patients are severely constrained and do need more intense treatment than the initial evaluation would have suggested.

The role of spirometry for the diagnosis, assessment and follow-up of COPD is summarized in **Table 2.6**.

**Table 2.6. Role of spirometry**

- **Diagnosis**
- **Assessment of severity of airflow obstruction** (for prognosis)
  - Follow-up assessment
    - Therapeutic decisions.
      - Pharmacological in selected circumstances (e.g., discrepancy between spirometry and level of symptoms).
      - Consider alternative diagnoses when symptoms are disproportionate to degree of airflow obstruction.
    - Non-pharmacological (e.g., interventional procedures).
    - Identification of rapid decline.

**Alpha-1 antitrypsin deficiency (AATD)**

**Alpha-1 antitrypsin deficiency (AATD) screening.** The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once especially in areas with high AATD prevalence.\(^8^0\) Although the classical patient is young (< 45 years) with panlobular basal emphysema, it has become recognized that delay in diagnosis has led to identification of some AATD patients when they are older and have a more typical distribution of emphysema (centrilobular apical).\(^8^1\) A low concentration (< 20% normal) is highly suggestive of homozygous deficiency. Family members should be screened and, together with the patient, referred to specialist centres for advice and management (see **Chapter 3**).
Additional investigations

The following additional investigations may be considered as part of the diagnosis and assessment of COPD.

**Imaging.** A chest X-ray is not useful to establish a diagnosis in COPD, but it is valuable in excluding alternative diagnoses and establishing the presence of significant comorbidities such as concomitant respiratory (pulmonary fibrosis, bronchiectasis, pleural diseases), skeletal (e.g., kyphoscoliosis), and cardiac diseases (e.g., cardiomegaly). Radiological changes associated with COPD include signs of lung hyperinflation (flattened diaphragm and an increase in the volume of the retrosternal air space), hyperlucency of the lungs, and rapid tapering of the vascular markings. Computed tomography (CT) of the chest is not routinely recommended except for detection of bronchiectasis and COPD patients that meet the criteria for lung cancer risk assessment. The presence of emphysema in particular may increase the risk for development of lung cancer. However, CT scanning may be helpful in the differential diagnosis where concomitant diseases are present. In addition, if a surgical procedure such as lung volume reduction, or increasingly non-surgical based lung volume reduction is contemplated, a chest CT scan is necessary since the distribution of emphysema is one of the most important determinants of surgical suitability. A CT scan is also required for patients being evaluated for lung transplantation.

**Lung volumes and diffusing capacity.** COPD patients exhibit gas trapping (a rise in residual volume) from the early stages of the disease, and as airflow limitation worsens, static hyperinflation (an increase in total lung capacity) occurs. These changes can be documented by body plethysmography, or less accurately by helium dilution lung volume measurement. These measurements help characterize the severity of COPD but are not essential to patient management. Measurement of diffusing capacity (DLCO) provides information on the functional impact of emphysema in COPD and is often helpful in patients with breathlessness that may seem out of proportion to the degree of airflow limitation.

**Oximetry and arterial blood gas measurement.** Pulse oximetry can be used to evaluate a patient’s arterial oxygen saturation and need for supplemental oxygen therapy. Pulse oximetry should be used to assess all patients with clinical signs suggestive of respiratory failure or right heart failure. If peripheral arterial oxygen saturation is < 92% arterial or capillary blood gases should be assessed.

**Exercise testing and assessment of physical activity.** Objectively measured exercise impairment, assessed by a reduction in self-paced walking distance or during incremental exercise testing in a laboratory, is a powerful indicator of health status impairment and predictor of prognosis; exercise capacity may fall in the year before death. Walking tests can be useful for assessing disability and risk of mortality and are used to assess the effectiveness of pulmonary rehabilitation. Both the paced shuttle walk test and the unpaced 6-minute walk test can be used. As the course length has a substantial impact on the distance walked, existing reference equations established for a 30 meter course cannot be applied to predict the distance achieved on shorter courses. Laboratory testing
using cycle or treadmill ergometry can assist in identifying co-existing or alternative conditions e.g., cardiac diagnoses.

Monitoring of physical activity may be more relevant regarding prognosis than evaluating exercise capacity. This can be conducted using accelerometers or multi-sensor instruments.

**Composite scores.** Several variables identify patients at increased risk for mortality including FEV$_1$, exercise tolerance assessed by walking distance or peak oxygen consumption, weight loss, and reduction in arterial oxygen tension. A relatively simple approach to identifying disease severity using a combination of most of the above variables has been proposed. The BODE (Body mass index, Obstruction, Dyspnea, and Exercise) method gives a composite score that is a better predictor of subsequent survival than any single component. Simpler alternatives that do not include an exercise test have been suggested but all these approaches need validation across a wide range of disease severities and clinical settings to confirm that they are suitable for routine clinical use.

<table>
<thead>
<tr>
<th>Table 2.7. Differential diagnosis of COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnosis</strong></td>
</tr>
</tbody>
</table>
| COPD | Onset in mid-life.  
Symptoms slowly progressive.  
History of tobacco smoking or exposure to other types of smoke. |
| Asthma | Onset early in life (often childhood).  
Symptoms vary widely from day to day.  
Symptoms worse at night/early morning.  
Allergy, rhinitis, and/or eczema also present.  
Family history of asthma.  
Obesity coexistence. |
| Congestive Heart Failure | Chest X-ray shows dilated heart, pulmonary edema.  
Pulmonary function tests indicate volume restriction, not airflow limitation. |
| Bronchiectasis | Large volumes of purulent sputum.  
Commonly associated with bacterial infection.  
Chest X-ray/CT shows bronchial dilation, bronchial wall thickening. |
| Tuberculosis | Onset all ages.  
Chest X-ray shows lung infiltrate.  
Microbiological confirmation.  
High local prevalence of tuberculosis. |
| Obliterative Bronchiolitis | Onset at younger age, nonsmokers.  
May have history of rheumatoid arthritis or acute fume exposure.  
Seen after lung or bone marrow transplantation.  
CT on expiration shows hypodense areas. |
| Diffuse Panbronchiolitis | Predominantly seen in patients of Asian descent.  
Most patients are male and nonsmokers.  
Almost all have chronic sinusitis.  
Chest X-ray and HRCT show diffuse small centrilobular nodular opacities and hyperinflation. |

*These features tend to be characteristic of the respective diseases, but are not mandatory. For example, a person who has never smoked may develop COPD (especially in the developing world where other risk factors may be more important than cigarette smoking); asthma may develop in adult and even in elderly patients.*

**Differential diagnoses.** In some patients with chronic asthma, a clear distinction from COPD is not possible using current imaging and physiological testing techniques, and for such patients it is assumed that asthma and COPD coexist. The diagnosis Asthma-COPD Overlap Syndrome (ACOS) or Asthma-COPD Overlap (ACO) has been coined to acknowledge that this represents overlap of
common disorders causing chronic airflow limitation rather than a distinct syndrome. For details please refer to the Appendix. Most other potential differential diagnoses are easier to distinguish from COPD (Table 2.7).

**Other considerations.** It is clear that some patients without evidence of airflow limitation have evidence of structural lung disease on chest imaging (emphysema, gas trapping, airway wall thickening) that is consistent with what is found in patients with COPD. Such patients may report exacerbations of respiratory symptoms or even require treatment with respiratory medications on a chronic basis. Whether these patients have acute or chronic bronchitis, a persistent form of asthma or an earlier presentation of what will become COPD as it is currently defined, is unclear at present and will require further study.
REFERENCES


27. Hansen JE, Porszasz J. Counterpoint: Is an increase in FEV1 and/or FVC >/= 12% of control and >/= 200 mL the best way to assess positive bronchodilator response? No. *Chest* 2014; **146**(3): 538-41.
41. Fletcher CM: Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). *BMJ* 1960; **2**: 1662.


CHAPTER 3: EVIDENCE SUPPORTING PREVENTION AND MAINTENANCE THERAPY

OVERALL KEY POINTS:

• Smoking cessation is key. Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates.

• The effectiveness and safety of e-cigarettes as a smoking cessation aid is uncertain at present.

• Pharmacologic therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance.

• Each pharmacologic treatment regimen should be individualized and guided by the severity of symptoms, risk of exacerbations, side-effects, comorbidities, drug availability and cost, and the patient’s response, preference and ability to use various drug delivery devices.

• Inhaler technique needs to be assessed regularly.

• Influenza vaccination decreases the incidence of lower respiratory tract infections.

• Pneumococcal vaccination decreases lower respiratory tract infections.

• Pulmonary rehabilitation improves symptoms, quality of life, and physical and emotional participation in everyday activities.

• In patients with severe resting chronic hypoxemia, long-term oxygen therapy improves survival.

• In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term oxygen treatment should not be prescribed routinely. However, individual patient factors must be considered when evaluating the patient’s need for supplemental oxygen.

• In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long-term non-invasive ventilation may decrease mortality and prevent re-hospitalization.

• In select patients with advanced emphysema refractory to optimized medical care, surgical or bronchoscopic interventional treatments may be beneficial.

• Palliative approaches are effective in controlling symptoms in advanced COPD.
This chapter summarizes the evidence about the effectiveness and safety of maintenance and prevention strategies in COPD. The way in which the evidence is translated into clinical practice is provided in Chapter 4.

### SMOKING CESSATION

Smoking cessation has the greatest capacity to influence the natural history of COPD. If effective resources and time are dedicated to smoking cessation, long-term quit success rates of up to 25% can be achieved.\(^1\)

#### Pharmacotherapies for smoking cessation

**Nicotine replacement products.** Nicotine replacement therapy (nicotine gum, inhaler, nasal spray, transdermal patch, sublingual tablet, or lozenge) reliably increases long-term smoking abstinence rates\(^2-4\) and is significantly more effective than placebo. Medical contraindications to nicotine replacement therapy include recent myocardial infarction or stroke.\(^5,6\) The contraindication to nicotine replacement therapy after acute coronary syndrome remains unclear and the evidence suggests that this treatment should be started > 2 weeks after a cardiovascular event.\(^7\) Continuous chewing of nicotine gum produces secretions that are swallowed rather than absorbed through the buccal mucosa resulting in little absorption and potentially causing nausea. Acidic beverages, particularly coffee, juices, and soft drinks, interfere with the absorption of nicotine.

E-cigarettes are increasingly used as a form of nicotine replacement therapy, although their efficacy in this setting remains controversial.\(^8-12\) Their overall safety profile has not been well defined and some organizations have suggested caution and additional data collection before widespread advocacy.\(^13\)

**Pharmacologic products.** Varenicline,\(^14\) bupropion,\(^15\) and nortriptyline\(^16\) have been shown to increase long-term quit rates,\(^16\) but should always be used as a component of a supportive intervention program rather than a sole intervention for smoking cessation. The effectiveness of the antihypertensive drug clonidine is limited by side effects.\(^16\) Recommendations for treating tobacco use and dependence are summarized in Chapter 4.

<table>
<thead>
<tr>
<th>Table 3.1. Brief strategies to help the patient willing to quit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASK:</strong> Systematically identify all tobacco users at every visit.</td>
</tr>
<tr>
<td>Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.</td>
</tr>
<tr>
<td><strong>ADVISE:</strong> Strongly urge all tobacco users to quit.</td>
</tr>
<tr>
<td>In a clear, strong, and personalized manner, urge every tobacco user to quit.</td>
</tr>
<tr>
<td><strong>ASSESS:</strong> Determine willingness and rationale of patient’s desire to make a quit attempt.</td>
</tr>
<tr>
<td>Ask every tobacco user if he or she is willing to make a quit attempt at this time (e.g., within the next 30 days).</td>
</tr>
<tr>
<td><strong>ASSIST:</strong> Aid the patient in quitting.</td>
</tr>
<tr>
<td>Help the patient with a quit plan; provide practical counseling; provide intra-treatment social support; help the patient obtain extra-treatment social support; recommend use of approved pharmacotherapy except in special circumstances; provide supplementary materials.</td>
</tr>
<tr>
<td><strong>ARRANGE:</strong> Schedule follow-up contact.</td>
</tr>
<tr>
<td>Schedule follow-up contact, either in person or via telephone.</td>
</tr>
</tbody>
</table>
A five-step program for intervention (Table 3.1)\textsuperscript{2-4,17} provides a helpful strategic framework to guide healthcare providers interested in helping their patients stop smoking.\textsuperscript{2,6,18} Because tobacco dependence is a chronic disease,\textsuperscript{2,4} clinicians should recognize that relapse is common and reflects the chronic nature of dependence and addiction, and does not represent failure on the part of the patient or the clinician.

Counseling delivered by physicians and other health professionals significantly increases quit rates over self-initiated strategies.\textsuperscript{19} Even brief (3-minute) periods of counseling urging a smoker to quit improve smoking cessation rates.\textsuperscript{19} There is a relationship between counseling intensity and cessation success.\textsuperscript{20} Ways to intensify treatment include increasing the length of the treatment session, the number of treatment sessions, and the number of weeks over which the treatment is delivered. Sustained quit rates of 10.9% at 6 months have been achieved when clinician tutorials and feedback are linked to counseling sessions.\textsuperscript{21} Financial incentive models for smoking cessation have also been reported to be effective in facilitating smoking cessation. In general, incentive programs were more effective than usual care in increasing smoking cessation rates at 6 months.\textsuperscript{22} The combination of pharmacotherapy and behavioral support increases smoking cessation rates.\textsuperscript{23}

**VACCINATIONS**

**Influenza vaccine**

Influenza vaccination can reduce serious illness (such as lower respiratory tract infections requiring hospitalization)\textsuperscript{24} and death in COPD patients.\textsuperscript{25-28} Only a few studies have evaluated exacerbations and they have shown significant reduction in the total number of exacerbations per vaccinated subject compared with those who received placebo.\textsuperscript{22} Vaccines containing either killed or live inactivated viruses are recommended\textsuperscript{22} as they are more effective in elderly patients with COPD.\textsuperscript{30} Findings from a population-based study suggested that COPD patients, particularly the elderly, had decreased risk of ischemic heart disease when they were vaccinated with influenza vaccine over many years.\textsuperscript{31} Occurrence of adverse reactions is generally mild and transient.

<table>
<thead>
<tr>
<th>Table 3.2. Vaccination for stable COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Influenza vaccination reduces serious illness and death in COPD patients (Evidence B).</td>
</tr>
<tr>
<td>• The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been shown to reduce the incidence of community-acquired pneumonia in COPD patients aged &lt; 65 years with an FEV\textsubscript{1} &lt; 40% predicted and in those with comorbidities (Evidence B).</td>
</tr>
<tr>
<td>• In the general population of adults ≥ 65 years the 13-valent conjugated pneumococcal vaccine (PCV13) has demonstrated significant efficacy in reducing bacteremia and serious invasive pneumococcal disease (Evidence B).</td>
</tr>
</tbody>
</table>

**Pneumococcal vaccine**

Pneumococcal vaccinations, PCV13 and PPSV23, are recommended for all patients ≥ 65 years of age (Table 3.2). The PPSV23 is also recommended for younger COPD patients with significant comorbid conditions including chronic heart or lung disease.\textsuperscript{32} Specific data on the effects of PPSV and PCV in COPD patients are limited and contradictory.\textsuperscript{33} A systematic review of injectable vaccines in COPD patients identified seven studies for inclusion (two trials of a 14-valent vaccine and 5 trials of a 23-valent injectable vaccine) and observed reductions in the incidence of pneumonia and acute
exacerbations that did not reach statistical significance.\textsuperscript{33} PPSV23 has been shown to reduce the incidence of community-acquired pneumonia in COPD patients < 65 years, with an FEV\textsubscript{1} < 40\% predicted, or comorbidities (especially cardiac comorbidities).\textsuperscript{34} The PCV13 has been shown to exhibit at least the same or greater immunogenicity than the PPSV23 up to two years after vaccination in COPD patients.\textsuperscript{35} In a large RCT PCV13 demonstrated significant efficacy for the prevention of vaccine-type community-acquired pneumonia (45.6\%) and vaccine-type invasive pneumococcal disease (75\%) among adults ≥ 65 years and the efficacy persisted for at least 4 years.\textsuperscript{36}

**PHARMACOLOGIC THERAPY FOR STABLE COPD**

**Overview of the medications**

Pharmacologic therapy for COPD is used to reduce symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance and health status. To date, there is no conclusive clinical trial evidence that any existing medications for COPD modify the long-term decline in lung function.\textsuperscript{37-41} \textit{Post-hoc} evidence of such an effect with long-acting bronchodilators and/or inhaled corticosteroids\textsuperscript{42,43} requires confirmation in specifically designed trials.

The classes of medications commonly used to treat COPD are shown in Table 3.3. The choice within each class depends on the availability and cost of medication and favorable clinical response balanced against side effects. Each treatment regimen needs to be individualized as the relationship between severity of symptoms, airflow limitation, and severity of exacerbations can differ between patients.

**Bronchodilators**

Bronchodilators are medications that increase FEV\textsubscript{1} and/or change other spirometric variables. They act by altering airway smooth muscle tone and the improvements in expiratory flow reflect widening of the airways rather than changes in lung elastic recoil. Bronchodilators tend to reduce dynamic hyperinflation at rest and during exercise,\textsuperscript{44,45} and improve exercise performance. The extent of these changes, especially in patients with severe and very severe COPD, is not easy to predict from the improvement in FEV\textsubscript{1} measured at rest.\textsuperscript{46,47}

Bronchodilator dose-response (FEV\textsubscript{1} change) curves are relatively flat with all classes of bronchodilators.\textsuperscript{48,49} Increasing the dose of either a beta\textsubscript{2}-agonist or an anticholinergic by an order of magnitude, especially when given by a nebulizer, appears to provide subjective benefit in acute episodes\textsuperscript{55} but is not necessarily helpful in stable disease.\textsuperscript{56} Bronchodilator medications in COPD are most often given on a regular basis to prevent or reduce symptoms. Toxicity is also dose-related (Table 3.3). Use of short acting bronchodilators on a regular basis is not generally recommended.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Inhaler (mcg)</th>
<th>Solution for nebulizer (mg/ml)</th>
<th>Oral</th>
<th>Vials for injection (mg)</th>
<th>Duration of action (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Beta-agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short-acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol</td>
<td>100–200 (MDI)</td>
<td>1</td>
<td>2.5 mg (pill), 0.05% (syrup)</td>
<td>0.1, 0.25 (extended release)</td>
<td>4-6</td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>45–90 (MDI)</td>
<td>0.1, 0.21, 0.25, 0.42</td>
<td></td>
<td></td>
<td>6-8</td>
</tr>
<tr>
<td>Salbutamol (albuterol)</td>
<td>90, 100, 200 (MDI &amp; DPI)</td>
<td>1, 2, 2.5, 5 mg/ml</td>
<td>2, 4, 5 mg (pill), 8 mg (extended release tablet)</td>
<td>0.1, 0.5 mg (extended release)</td>
<td>4-6, 12 (extended release)</td>
</tr>
<tr>
<td>Terbutaline</td>
<td>500 (DPI)</td>
<td>2.5, 5 mg (pill)</td>
<td>0.2, 0.25, 1 mg</td>
<td></td>
<td>4-6</td>
</tr>
<tr>
<td><strong>Long-acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arformoterol</td>
<td>0.00751</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Formoterol</td>
<td>4.5–9 (DPI)</td>
<td>0.011</td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>75–300 (DPI)</td>
<td>0.01</td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Olodaterol</td>
<td>2.5, 5 (SMI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>25–50 (MDI &amp; DPI)</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td><strong>Anticholinergics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short-acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>20, 40 (MDI)</td>
<td>0.2</td>
<td></td>
<td></td>
<td>6-8</td>
</tr>
<tr>
<td>Oxitropium bromide</td>
<td>100 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td>7-9</td>
</tr>
<tr>
<td>Long-acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albuterol bromide</td>
<td>400 (DPI), 400 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Glycopyrouronium bromide</td>
<td>15.6 &amp; 50 (DPI)</td>
<td>1 mg (solution)</td>
<td>0.2 mg</td>
<td></td>
<td>12-24</td>
</tr>
<tr>
<td>Tiotropium</td>
<td>18 (DPI), 2.5 &amp; 5 (SMI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Umeclidinium</td>
<td>62.5 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td><strong>Combination of short-acting beta-agonist plus anticholinergic in one device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol/ipratropium</td>
<td>50/20 (SMI)</td>
<td>1.25, 0.5 mg in 4 ml</td>
<td></td>
<td></td>
<td>6-8</td>
</tr>
<tr>
<td>Salbutamol/ipratropium</td>
<td>100/20 (SMI), 75/15 (MDI)</td>
<td>0.5, 2.5 mg in 3 ml</td>
<td></td>
<td></td>
<td>6-8</td>
</tr>
<tr>
<td><strong>Combination of long-acting beta-agonist plus anticholinergic in one device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/albuterol</td>
<td>12/400 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Formoterol/glycopyruronium</td>
<td>9.6/14.4 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Indacaterol/glucocorticoid</td>
<td>27.5/15.6 &amp; 110/50 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>12-24</td>
</tr>
<tr>
<td>Vilaat/umeclidinium</td>
<td>25/62.5 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Olodaterol/tiotropium</td>
<td>5/5 (SMI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td><strong>Methylxanthines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminophylline</td>
<td>105 mg/ml (solution)</td>
<td></td>
<td></td>
<td>250, 500 mg</td>
<td>Variable, up to 24</td>
</tr>
<tr>
<td>Theophylline (SR)</td>
<td>100–600 mg (pill)</td>
<td></td>
<td></td>
<td>250, 400, 500 mg</td>
<td>Variable, up to 24</td>
</tr>
<tr>
<td><strong>Combination of long-acting beta-agonist plus corticosteroids in one device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/budesonide</td>
<td>4.5/160 (MDI), 4.5/80 (MDI), 9/320 (DPI), 9/160 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/budesonide</td>
<td>10/200, 10/400 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmetrol/fluticasone</td>
<td>5/100, 50/250, 5/500 (DPI), 21/45, 21/115, 21/230 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vilaat/umeclidinium</td>
<td>25/100 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Phosphodiesterase-4 inhibitors</strong>&lt;br&gt;<strong>Roflumilast</strong></td>
<td>500 mcg (pill)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* MDI = metered dose inhaler; DPI = dry powder inhaler; SMI = soft mist inhaler

* Not all formulations are available in all countries; in some countries other formulations and dosages may be available.

1 Dose availability varies by country.

2 Formoterol nebulized solution is based on the unit doseivial containing 20 mcg in a volume of 2.0 ml.

3 Dose varies by country.
**Beta-agonists.** The principal action of beta₂-agonists is to relax airway smooth muscle by stimulating beta₂-adrenergic receptors, which increases cyclic AMP and produces functional antagonism to bronchoconstriction. There are short-acting (SABA) and long-acting (LABA) beta₂-agonists. The effect of SABAs usually wears off within 4 to 6 hours. Regular and as-needed use of SABAs improve FEV₁ and symptoms. For single-dose, as-needed use in COPD, there appears to be no advantage in routinely using levalbuterol over conventional bronchodilators. LABAs show duration of action of 12 or more hours and do not preclude additional benefit from as-needed SABA therapy.

Formoterol and salmeterol are twice-daily LABAs that significantly improve FEV₁ and lung volumes, dyspnea, health status, exacerbation rate and number of hospitalizations, but have no advantage in routinely using levalbuterol over conventional bronchodilators. LABAs show duration of action of 12 or more hours and do not preclude additional benefit from as-needed SABA therapy.

**Adverse effects.** Stimulation of beta₂-adrenergic receptors can produce resting sinus tachycardia and has the potential to precipitate cardiac rhythm disturbances in susceptible patients. Exaggerated somatic tremor is troublesome in some older patients treated with higher doses of beta₂-agonists, regardless of route of administration. Although hypokalemia can occur, especially when treatment is combined with thiazide diuretics, and oxygen consumption can be increased under resting conditions in patients with chronic heart failure, these metabolic effects decrease over time (i.e., show tachyphylaxis). Mild falls in partial pressure of oxygen (PaO₂) can occur after administration of both SABAs and LABAs but the clinical significance of these changes is uncertain. Despite prior concerns related to the use of beta₂-agonists in the management of asthma, no association between beta₂-agonist use and loss of lung function or increased mortality has been reported in COPD.

**Antimuscarinic drugs**

Antimuscarinic drugs block the bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors expressed in airway smooth muscle. Short-acting antimuscarinics (SAMAs), namely ipratropium and oxtropium, also block the inhibitory neuronal receptor M2, which potentially can cause vagally induced bronchoconstriction. Long-acting antimuscarinic antagonists (LAMAs), such as tiotropium, aclidinium, glycopyrronium bromide and umeclidinium have prolonged binding to M3 muscarinic receptors, with faster dissociation from M2 muscarinic receptors, thus prolonging the duration of bronchodilator effect.

A systematic review of randomized controlled trials concluded that ipratropium, a short acting muscarinic antagonist, alone provided small benefits over short-acting beta₂-agonist in terms of lung function, health status and requirement for oral steroids. Among LAMAs, some are administered once a day (tiotropium and umeclidinium), others twice a day (aclidinium), and some are approved for once daily dosing in some countries and twice daily dosing in others (glycopyrronium). LAMA treatments (tiotropium) improve symptoms and health status and reduce exacerbations and related hospitalizations. Clinical trials have shown a greater effect on exacerbation rates for LAMA
treatment (tiotropium) versus LABA treatment. In a long-term clinical trial of 5,993 patients with COPD, tiotropium added to other standard therapies had no effect on the rate of lung function decline.

Adverse effects. Inhaled anticholinergic drugs are poorly absorbed which limits the troublesome systemic effects observed with atropine. Extensive use of this class of agents in a wide range of doses and clinical settings has shown them to be very safe. The main side effect is dryness of mouth. Although occasional urinary symptoms have been reported, there are no data to prove a true causal relationship. Some patients using ipratropium report a bitter, metallic taste. An unexpected small increase in cardiovascular events in COPD patients regularly treated with ipratropium bromide has been reported. In a large, long-term clinical trial in COPD patients, tiotropium added to other standard therapies had no effect on cardiovascular risk. Although there were some initial concerns regarding the safety of tiotropium delivery via the Respimat® inhaler, the findings of a large trial observed no difference in mortality or exacerbation rates when comparing tiotropium in a dry-powder inhaler and the Respimat® inhaler. There are less safety data available for the other LAMAs, but the rate of anti-cholinergic side effects for drugs in this class appears to be low and generally similar. Use of solutions with a facemask can precipitate acute glaucoma, probably as a direct result of the contact between the solution and the eye.

Methylxanthines

Controversy remains about the exact effects of xanthine derivatives. They may act as non-selective phosphodiesterase inhibitors, but have also been reported to have a range of non-bronchodilator actions, the significance of which is disputed. Data on duration of action for conventional, or even slow-release, xanthine preparations are lacking in COPD.

Theophylline, the most commonly used methylxanthine, is metabolized by cytochrome P450 mixed function oxidases. Clearance of the drug declines with age. Many other physiological variables and drugs modify theophylline metabolism. Enhanced inspiratory muscle function has been reported in patients treated with methylxanthines, but whether this reflects a reduction in gas trapping or a primary effect on the respiratory skeletal muscles is not clear. All studies that have shown efficacy of theophylline in COPD were performed with sustained-release preparations.

There is evidence for a modest bronchodilator effect compared with placebo in stable COPD. Addition of theophylline to salmeterol produces a greater improvement in FEV₁ and breathlessness than salmeterol alone. There is limited and contradictory evidence regarding the effect of low-dose theophylline on exacerbation rates.

Adverse effects. Toxicity is dose-related, which is a particular problem with xanthine derivatives because their therapeutic ratio is small and most of the benefit occurs only when near-toxic doses are given. Methylxanthines are non-specific inhibitors of all phosphodiesterase enzyme subsets, which explains their wide range of toxic effects. Problems include the development of palpitations caused by atrial and ventricular arrhythmias (which can prove fatal) and grand mal convulsions (which can occur irrespective of prior epileptic history). Other side effects include headaches, insomnia, nausea, and heartburn, and these may occur within the therapeutic range of serum levels.
of theophylline. These medications also have significant interactions with commonly used medications such as digitalis and coumadin, among others. Unlike the other bronchodilator classes, xanthine derivatives may predispose patients to an increased risk of overdose (either intentional or accidental).

**Combination bronchodilator therapy**

Combining bronchodilators with different mechanisms and durations of action may increase the degree of bronchodilation with a lower risk of side-effects compared to increasing the dose of a single bronchodilator. Combinations of SABAs and SAMAs are superior compared to either medication alone in improving FEV₁ and symptoms. Treatment with formoterol and tiotropium in separate inhalers has a bigger impact on FEV₁ than either component alone. There are numerous combinations of a LABA and LAMA in a single inhaler available (Table 3.3). These combinations improve lung function compared to placebo; this improvement is consistently greater than long-acting bronchodilator monotherapy effects although the magnitude of improvement is less than the fully additive effect predicted by the individual component responses. In studies where patient reported outcomes (PROs) are the primary endpoint or in pooled analyses, combination bronchodilators have a greater impact on PROs compared to monotherapies. These clinical trials deal with group mean data, but symptom responses to LABA/LAMA combinations are best evaluated on an individual patient basis. A lower dose, twice daily regimen for a LABA/LAMA has also been shown to improve symptoms and health status in COPD patients (Table 3.4).

Most studies with LABA/LAMA combinations have been performed in patients with a low rate of exacerbations. One study in patients with a history of exacerbations indicated that a combination of long-acting bronchodilators is more effective than long-acting bronchodilator monotherapy for preventing exacerbations. Another study in patients with a history of exacerbations confirmed that a LABA/LAMA decreased exacerbations to a greater extent than an ICS/LABA combination.

**Table 3.4. Bronchodilators in stable COPD**

- Inhaled bronchodilators in COPD are central to symptom management and commonly given on a regular basis to prevent or reduce symptoms (Evidence A).
- Regular and as-needed use of SABA or SAMA improves FEV₁ and symptoms (Evidence A).
- Combinations of SABA and SAMA are superior compared to either medication alone in improving FEV₁ and symptoms (Evidence A).
- LABAs and LAMAs significantly improve lung function, dyspnea, health status, and reduce exacerbation rates (Evidence A).
- LAMAs have a greater effect on exacerbation reduction compared with LABAs (Evidence A) and decrease hospitalizations (Evidence B).
- Combination treatment with a LABA and LAMA increases FEV₁ and reduces symptoms compared to monotherapy (Evidence A).
- Combination treatment with a LABA and LAMA reduces exacerbations compared to monotherapy (Evidence B) or ICS/LABA (Evidence B).
- Tiotropium improves the effectiveness of pulmonary rehabilitation in increasing exercise performance (Evidence B).
- Theophylline exerts a small bronchodilator effect in stable COPD (Evidence A) and that is associated with modest symptomatic benefits (Evidence B).

**Anti-inflammatory agents**

To date, exacerbations (e.g., exacerbation rate, patients with at least one exacerbation, time-to-first exacerbation) represent the main clinically relevant end-point used for efficacy assessment of drugs with anti-inflammatory effects (Table 3.5).
Inhaled corticosteroids (ICS)

**Preliminary general considerations.** *In vitro* evidence suggests that COPD-associated inflammation has limited responsiveness to corticosteroids. Moreover, some drugs including beta₂-agonists, theophylline or macrolides may partially facilitate corticosteroid sensitivity in COPD.\(^{108,109}\) The clinical relevance of this effect has not yet been fully established.

*In vivo* data suggest that the dose-response relationships and long-term (> 3 years) safety of inhaled corticosteroids (ICS) in patients with COPD are unclear and require further investigation.\(^{109}\) Because the effects of ICS in COPD can be modulated by the concomitant use of long-acting bronchodilators, these two therapeutic options are discussed separately.

<table>
<thead>
<tr>
<th>Table 3.5. Anti-inflammatory therapy in stable COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inhaled corticosteroids</strong></td>
</tr>
<tr>
<td>- An ICS combined with a LABA is more effective than the individual components in improving lung function and health status and reducing exacerbations in patients with exacerbations and moderate to very severe COPD (Evidence A).</td>
</tr>
<tr>
<td>- Regular treatment with ICS increases the risk of pneumonia especially in those with severe disease (Evidence A).</td>
</tr>
<tr>
<td>- Triple inhaled therapy of ICS/LAMA/LABA improves lung function, symptoms and health status (Evidence A) and reduces exacerbations (Evidence B) compared to ICS/LABA or LAMA monotherapy.</td>
</tr>
<tr>
<td><strong>Oral glucocorticoids</strong></td>
</tr>
<tr>
<td>- Long-term use of oral glucocorticoids has numerous side effects (Evidence A) with no evidence of benefits (Evidence C).</td>
</tr>
<tr>
<td><strong>PDE4 inhibitors</strong></td>
</tr>
<tr>
<td>- In patients with chronic bronchitis, severe to very severe COPD and a history of exacerbations:</td>
</tr>
<tr>
<td>- A PDE4 inhibitor improves lung function and reduces moderate and severe exacerbations (Evidence A).</td>
</tr>
<tr>
<td>- A PDE4 inhibitor improves lung function and decreases exacerbations in patients who are on fixed-dose LABA/ICS combinations (Evidence B).</td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
</tr>
<tr>
<td>- Long-term azithromycin and erythromycin therapy reduces exacerbations over one year (Evidence A).</td>
</tr>
<tr>
<td>- Treatment with azithromycin is associated with an increased incidence of bacterial resistance (Evidence A) and hearing test impairments (Evidence B).</td>
</tr>
<tr>
<td><strong>Mucolytics/antioxidants</strong></td>
</tr>
<tr>
<td>- Regular use of NAC and carbocysteine reduces the risk of exacerbations in select populations (Evidence B).</td>
</tr>
<tr>
<td><strong>Other anti-inflammatory agents</strong></td>
</tr>
<tr>
<td>- Simvastatin does not prevent exacerbations in COPD patients at increased risk of exacerbations and without indications for statin therapy (Evidence A). However, observational studies suggest that statins may have positive effects on some outcomes in patients with COPD who receive them for cardiovascular and metabolic indications (Evidence C).</td>
</tr>
<tr>
<td>- Leukotriene modifiers have not been tested adequately in COPD patients.</td>
</tr>
</tbody>
</table>

**Efficacy of ICS (alone).** Most studies have found that regular treatment with ICS alone does not modify the long-term decline of FEV\(_1\) nor mortality in patients with COPD.\(^ {110}\) Studies and meta-analyses assessing the effect of regular treatment with ICS alone on mortality in patients with COPD have not provided conclusive evidence of benefit.\(^ {110}\) In the TORCH trial, a trend toward higher mortality was observed for patients treated with fluticasone propionate alone compared to those receiving placebo or salmeterol plus fluticasone propionate combination.\(^ {111}\) However, an increase in mortality was not observed in COPD patients treated with fluticasone furoate in the Survival in Chronic Obstructive Pulmonary Disease with Heightened Cardiovascular Risk (SUMMIT) trial.\(^ {111}\)

**ICS in combination with long-acting bronchodilator therapy.** In patients with moderate to very severe COPD and exacerbations, an ICS combined with a LABA is more effective than either component alone in improving lung function, health status and reducing exacerbations.\(^ {113,114}\) Clinical trials powered on all-cause mortality as the primary outcome failed to demonstrate a statistically significant effect of combination therapy on survival.\(^ {111,112}\)
Most studies that found a beneficial effect of LABA/ICS fixed dose combination (FDC) over LABA alone on exacerbation rate, recruited patients with a history of at least one exacerbation in the previous year. A pragmatic RCT conducted in a primary healthcare setting in the United Kingdom compared a LABA/ICS combination with usual care. Findings showed an 8.4% reduction in moderate-to-severe exacerbations (primary outcome) and a significant improvement in CAT score, with no difference in the rate of healthcare contacts or pneumonias. However, basing recommendations on these results is difficult because of the heterogeneity in treatments reported in the usual care group, the higher rate of treatment changes in the group receiving the LABA/ICS combination of interest and the medical practice patterns unique to the UK region where the study was conducted.

Post-hoc analyses from several trials suggest that eosinophil counts in sputum and blood may serve as a biomarker to predict the efficacy of ICS in particular regarding exacerbation prevention, but because of missing key evidence currently this cannot be recommended for daily clinical practice (for details see Chapter 2).

**Adverse effects.** There is high quality evidence from randomized controlled trials (RCTs) that ICS use is associated with higher prevalence of oral candidiasis, hoarse voice, skin bruising and pneumonia. This excess risk has been confirmed in ICS studies using fluticasone furoate, even at low doses. Patients at higher risk of pneumonia include those who currently smoke, are aged ≥ 55 years, have a history of prior exacerbations or pneumonia, a body mass index (BMI) < 25 kg/m², a poor MRC dyspnea grade and/or severe airflow limitation. Independent of ICS use, there is evidence that a blood eosinophil count < 2% increases the risk of developing pneumonia. In a study of patients with moderate COPD, ICS by itself or in combination with a LABA did not increase the risk of pneumonia.

Results from RCTs have yielded varied results regarding the risk of decreased bone density and fractures with ICS treatment, which may be due to differences in study designs and/or differences between ICS compounds. Results of observational studies suggest that ICS treatment could also be associated with increased risk of diabetes/poor control of diabetes, cataracts, and mycobacterial infection including tuberculosis. In the absence of RCT data on these issues, it is not possible to draw firm conclusions. An increased risk of tuberculosis has been found in both observational studies and a meta-analysis of RCTs.

**Withdrawal of ICS.** Results from withdrawal studies provide equivocal results regarding consequences of withdrawal on lung function, symptoms and exacerbations. Some studies, but not all, have shown an increase in exacerbations and/or symptoms following ICS withdrawal, while others have not. There has been evidence for a modest decrease in FEV₁ (approximately 40 mL) with ICS withdrawal, which could be associated with increased baseline circulating eosinophil level. Differences between studies may relate to differences in methodology, including the use of background long-acting bronchodilator medication(s) which may minimize any effect of ICS withdrawal.
**Triple inhaled therapy**

The step up in inhaled treatment to LABA plus LAMA plus ICS (triple therapy) can occur by various approaches. Adding a LAMA to existing LABA/ICS improves lung function and patient reported outcomes, in particular exacerbation risk. A RCT did not demonstrate any benefit of adding ICS to LABA plus LAMA on exacerbations. Altogether, more evidence is needed to draw conclusions on the benefits of triple therapy LABA/LAMA/ICS compared to LABA/LAMA.

**Oral glucocorticoids**

Oral glucocorticoids have numerous side effects, including steroid myopathy which can contribute to muscle weakness, decreased functionality, and respiratory failure in subjects with very severe COPD. Systemic glucocorticoids for treating acute exacerbations in hospitalized patients, or during emergency department visits, have been shown to reduce the rate of treatment failure, the rate of relapse and improve lung function and breathlessness. Conversely, prospective studies on the long-term effects of oral glucocorticoids in stable COPD are limited. Therefore, while oral glucocorticoids play a role in the acute management of exacerbations, they have no role in the chronic daily treatment in COPD because of a lack of benefit balanced against a high rate of systemic complications.

**Phosphodiesterase-4 (PDE4) inhibitors**

**Efficacy.** The principal action of PDE4 inhibitors is to reduce inflammation by inhibiting the breakdown of intracellular cyclic AMP. Roflumilast is a once daily oral medication with no direct bronchodilator activity. Roflumilast reduces moderate and severe exacerbations treated with systemic corticosteroids in patients with chronic bronchitis, severe to very severe COPD, and a history of exacerbations. The effects on lung function are also seen when roflumilast is added to long-acting bronchodilators, and in patients who are not controlled on fixed-dose LABA/ICS combinations. There has been no study directly comparing roflumilast with an inhaled corticosteroid.

**Adverse effects.** PDE4 inhibitors have more adverse effects than inhaled medications for COPD. The most frequent are diarrhea, nausea, reduced appetite, weight loss, abdominal pain, sleep disturbance, and headache. Adverse effects have led to increased withdrawal rates from clinical trials. Adverse effects seem to occur early during treatment, are reversible, and diminish over time with continued treatment. In controlled studies an average unexplained weight loss of 2 kg has been seen and weight monitoring during treatment is advised, in addition to avoiding roflumilast treatment in underweight patients. Roflumilast should also be used with caution in patients with depression.

**Antibiotics**

In older studies prophylactic, continuous use of antibiotics had no effect on the frequency of exacerbations in COPD and a study that examined the efficacy of chemoprophylaxis undertaken
in winter months over a period of 5 years concluded that there was no benefit. More recent studies have shown that regular use of some antibiotics may reduce exacerbation rate. Azithromycin (250 mg/day or 500 mg three times per week) or erythromycin (500 mg two times per day) for one year in patients prone to exacerbations reduced the risk of exacerbations compared to usual care. Azithromycin use was associated with an increased incidence of bacterial resistance and impaired hearing tests. There are no data beyond one-year showing the efficacy or safety of chronic antibiotic use to prevent COPD exacerbations.

Pulse therapy with moxifloxacin (400 mg/day for 5 days every 8 weeks) in patients with chronic bronchitis and frequent exacerbations had no beneficial effect on exacerbation rate overall.

**Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (NAC, carbocysteine)**

In COPD patients not receiving inhaled corticosteroids, regular treatment with mucolytics such as carbocysteine and N-acetylcysteine may reduce exacerbations and modestly improve health status. Due to the heterogeneity of studied populations, treatment dosing and concomitant treatments, currently available data do not allow one to identify precisely the potential target population for antioxidant agents in COPD.

**Other drugs with anti-inflammatory potential**

Two RCTs in COPD patients performed before 2005 that investigated the use of an immunoregulator reported a decrease in the severity and frequency of exacerbations. Additional studies are needed to examine the long-term effects of this therapy in patients receiving currently recommended COPD maintenance therapy.

Nedocromil and leukotriene modifiers have not been tested adequately in COPD patients.

There was no evidence of benefit, and some evidence of harm, including malignancy and pneumonia, following treatment with an anti-TNF-alpha antibody (infliximab) in moderate to severe COPD.

Simvastatin did not prevent exacerbations in patients with COPD who had no metabolic or cardiovascular indication for statin treatment. An association between statin use and improved outcomes (including decreased exacerbations and mortality) has been reported in observational studies of patients with COPD who received them for cardiovascular and metabolic indications.

There is no evidence that supplementation with vitamin D has a positive impact on exacerbations in unselected patients.

**Issues related to inhaled delivery**

When a treatment is given by the inhaled route the importance of education and training in inhaler device technique cannot be over-emphasized. Inhalation devices include nebulizers, metered-dose...
inhalers (MDIs) used without spacers, soft-mist inhalers and breath-actuated devices i.e., breath-actuated MDIs (BAIs) and single-dose and multi-dose dry powder inhalers (DPIs). In multi-dose DPIs, the powder is contained in a reservoir or in individual blisters. All classes of inhaled drugs are not available in all types of device. Particles > 5 microns (µm) are most likely to be deposited in the oropharynx. For drug delivery to the lower respiratory tract and lungs, particle size (mass-median aerodynamic diameter) can be fine (2-5 µm) or extra-fine (< 2 µm), which influences the total respirable fraction (particles < 5 µm) and the amount and site of drug deposition (more peripheral deposition with extra-fine particles). Randomized controlled trials have not identified superiority of one device/formulation. However, patients included in these trials are usually those who master inhalation technique and receive proper education and follow-up regarding this issue, and therefore may not be reflective of normal clinical practice. On average more than two thirds of patients make at least one error in using an inhalational device. A rigorous, prospective observational study of COPD patients discharged from the hospital confirmed appropriate adherence to the use of a DPI in only 23% of patients.

Observational studies have identified a significant relationship between poor inhaler use and symptom control in patients with COPD. Determinants of poor inhaler technique in asthma and COPD patients include: older age, use of multiple devices, and lack of previous education on inhaler technique. In such populations, education improves inhalation technique in some but not all patients, especially when the “teach-back” approach (patients being asked to show how the device has to be used) is implemented. It is important to check that patients continue to use their device correctly. Lack of placebo devices within clinical areas is often a limitation and barrier to providing quality inhaler technique instruction to patients. Encouraging a patient to bring their own devices to clinic is a useful alternative. Those who do not reach mastery may require a change in inhalational delivery device.

The main errors in delivery device use relate to problems with inspiratory flow, inhalation duration, coordination, dose preparation, exhalation maneuver prior to inhalation and breath-holding following dose inhalation (Table 3.6). Specific instructions are available for each type of device. Observational studies in patients with COPD show that, although the type and frequency of inhalation errors vary between devices depending on their characteristics, there is no device obviating the need to explain, demonstrate and regularly check inhalation technique. Strategies for inhaler choice based on patients’ characteristics have been proposed by experts and consensus-based taskforces (Table 3.6), but none have yet been prospectively tested. There is no evidence for superiority of nebulized therapy over hand-held devices in patients who are able to use these devices properly.

<table>
<thead>
<tr>
<th>Table 3.6, The inhaled route</th>
</tr>
</thead>
<tbody>
<tr>
<td>• When a treatment is given by the inhaled route, the importance of education and training in inhaler device technique cannot be over-emphasized.</td>
</tr>
<tr>
<td>• The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient’s ability and preference.</td>
</tr>
<tr>
<td>• It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate and re-check at each visit that patients continue to use their inhaler correctly.</td>
</tr>
<tr>
<td>• Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy is insufficient.</td>
</tr>
</tbody>
</table>
Other pharmacologic treatments

Other pharmacologic treatments for COPD are summarized in Table 3.7.

<table>
<thead>
<tr>
<th>Table 3.7. Other pharmacological treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alpha-1 antitrypsin augmentation therapy</strong></td>
</tr>
<tr>
<td>* Intravenous augmentation therapy may slow down the progression of emphysema (Evidence B).</td>
</tr>
<tr>
<td><strong>Antitussives</strong></td>
</tr>
<tr>
<td>* There is no conclusive evidence of a beneficial role of antitussives in patients with COPD (Evidence C).</td>
</tr>
<tr>
<td><strong>Vasodilators</strong></td>
</tr>
<tr>
<td>* Vasodilators do not improve outcomes and may worsen oxygenation (Evidence B).</td>
</tr>
</tbody>
</table>

**Alpha-1 antitrypsin augmentation therapy.** The logical approach to minimize the development and progression of lung disease in AATD patients is alpha-1-antitrypsin augmentation. Such therapy has been available in many, though not all, countries since the 1980s. Because AATD is rare, formal clinical trials to assess efficacy with conventional spirometric outcome have never been undertaken. However, a wealth of observational studies suggest a reduction in spirometric progression in treated versus non-treated patients and that this reduction is most effective for patients with FEV\(_1\) 35-49% predicted. Never or ex-smokers with an FEV\(_1\) of 35-60% predicted have been suggested as those most suitable for AATD augmentation therapy (Evidence B).

More recently studies using sensitive parameters of emphysema progression determined by CT scans have provided evidence for an effect on preserving lung tissue compared to placebo. Based on the most recent trial the indications for therapy have been extended to include "those patients with evidence of progressive lung disease despite other optimal therapy," However not all patients with AATD develop or persist with rapid spirometric progression especially following smoking cessation. Since the purpose of augmentation therapy is to preserve lung function and structure it seems logical to reserve such expensive therapy for those with evidence of continued and rapid progression following smoking cessation.

The evidence for augmentation therapy efficacy varies according to the outcome studied. Intravenous augmentation therapy has been recommended for individuals with alpha-1 antitrypsin deficiency (AATD) and an FEV\(_1\) ≤ 65% predicted based on previous observational studies. However, the recent study powered on CT scan as an outcome has recommended that all patients with evidence of progressive lung disease should be considered for those with lung disease related to AATD, and an FEV\(_1\) > 65%. Individual discussion is recommended with consideration of the cost of therapy and lack of evidence for much benefit. The main limitation for this therapy is very high cost and lack of availability in many countries.

**Antitussives.** The role of antitussives in patients with COPD is inconclusive.

**Vasodilators.** Vasodilators have not been properly assessed in COPD patients with severe/disproportionate pulmonary hypertension. Inhaled nitric oxide can worsen gas exchange because of altered hypoxic regulation of ventilation-perfusion balance and is contraindicated in
stable COPD. Studies have shown that sildenafil does not improve the results of rehabilitation in patients with COPD and moderately increases pulmonary artery pressure. Tadalafil does not appear to improve exercise capacity or health status in COPD patients with mild pulmonary hypertension.

REHABILITATION, EDUCATION & SELF-MANAGEMENT

Pulmonary rehabilitation

Pulmonary rehabilitation is defined as “a comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, self-management intervention aiming at behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.”

Pulmonary rehabilitation should be considered part of integrated patient management, and usually includes a range of healthcare professionals to ensure optimum coverage of the many aspects involved. Patients should undergo careful assessment prior to enrollment, including identification of the patient’s goals, specific healthcare needs, smoking status, nutritional health, self-management capacity, health literacy, psychological health status and social circumstances, comorbid conditions as well as exercise capabilities and limitations. Optimum benefits are achieved from programs lasting 6 to 8 weeks, and there is no evidence that extending to 12 weeks or longer provides advantages. Supervised exercise training twice weekly is recommended, and this can include any regimen from endurance training, interval training, resistance/strength training; upper and lower limbs ideally should be included as well as walking exercise; flexibility, inspiratory muscle training and neuromuscular electrical stimulation can also be incorporated. In all cases the rehabilitation intervention (scope, intensity) should be individualized to maximize personal functional gains.

The benefits to COPD patients from pulmonary rehabilitation are considerable (Table 3.8), and rehabilitation has been shown to be the most effective therapeutic strategy to improve shortness of breath, health status and exercise tolerance. Pulmonary rehabilitation is appropriate for most patients with COPD; improved functional exercise capacity and health related quality of life have been demonstrated across all grades of COPD severity, although the evidence is especially strong in patients with moderate to severe disease. Even patients with chronic hypercapnic failure show benefit. Limited data exist regarding the effectiveness of pulmonary rehabilitation after an acute exacerbation of COPD, but systematic reviews have shown that among those patients who have had a recent exacerbation (≤ 4 weeks from prior hospitalization), pulmonary rehabilitation can reduce readmissions and mortality. However, initiating pulmonary rehabilitation before the patient’s discharge may compromise survival through unknown mechanisms. Pulmonary rehabilitation also ranks as one of the most cost-effective treatment strategies, with an estimated cost per quality-adjusted life year (QALY) of £2,000-£8,000.
There are many challenges with pulmonary rehabilitation. Uptake and completion of pulmonary rehabilitation are frequently limited, partly through provider ignorance as well as patients’ lack of awareness of availability or benefits. A major barrier to full participation is access, which is particularly limited by geography, culture, finances, transport and other logistics. However, pulmonary rehabilitation can be conducted at a range of sites, including hospital inpatient settings, outpatient settings and/or in the patient’s home. Community-based and home-based programs can be as effective as hospital-based programs as long as the frequency and intensity are equivalent. This may provide a part-solution for many patients who live beyond the practical reach of hospital-based programs.

**Education, self-management and integrative care**

**Education.** Patient “education” often takes the form of providers giving information and advice, and assumes that knowledge will lead to behaviour change. Although enhancing patient knowledge is an important step towards behaviour change, didactic sessions are insufficient for promoting self-management skills. Topics such as smoking cessation, correct use of inhaler devices, early recognition of exacerbation, decision making and taking action, and when to seek help, surgical interventions, considering advance directives, and others will be better dealt with using self-management interventions.

**Self-management.** A recent Delphi process has resulted in a conceptual definition for COPD self-management interventions: “A COPD self-management intervention is structured but personalized and often multi-component, with goals of motivating, engaging and supporting the patients to positively adapt their health behavior(s) and develop skills to better manage their disease.” The process requires iterative interactions between patients and healthcare professionals who are competent in delivering self-management interventions. Behavior change techniques are used to elicit patient motivation, confidence and competence. Literacy sensitive approaches are used to enhance comprehensibility.

Systematic reviews have provided evidence that self-management interventions improve outcomes in COPD. A Cochrane review on COPD self-management reported that self-management interventions that include written negotiated action plans for worsening symptoms led to a lower probability of both respiratory-related hospitalization and all cause hospitalizations. Self-management interventions also improved health status. There have been concerns that health benefits from such self-management programs in COPD could be counterbalanced by increased mortality. A recent meta-analysis, however, reported no impact of self-management interventions on overall mortality. There remain problems with heterogeneity among interventions, consistency of their application, specifics of the intervention, patient populations, follow-up times and outcome measures that make generalization difficult in real life. It is also challenging to formulate clear recommendations regarding the most effective form and content of a self-management intervention in COPD given the range of heterogeneity across studies, and lack of precise definitions of self-management components (e.g., skills taught) and fidelity measures. The recent conceptual definition should help redress these deficiencies.
Integrated care programs. COPD is a complex disease that requires the input of multiple care providers who need to work together closely. In principle, use of a formal structured program that determines how each component is delivered should make care more efficient and effective, but the evidence for this is divided. A meta-analysis of small trials concluded that an integrated care program improved a number of clinical outcomes, although not mortality. In contrast, a large multi-center study in primary care within an existing well-organized system of care did not confirm this. Besides, delivering integrated interventions by telemedicine did not show a significant effect. The pragmatic conclusion is that well organized care is important, but there may be no advantage in structuring it tightly into a formalized program. Furthermore, integrated care needs to be individualized to the stage of the person’s illness and health literacy.

<table>
<thead>
<tr>
<th>Table 3.8. Pulmonary rehabilitation, self-management and integrative care in COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pulmonary rehabilitation</strong></td>
</tr>
<tr>
<td>• Pulmonary rehabilitation improves dyspnea, health status and exercise tolerance in stable patients (Evidence A).</td>
</tr>
<tr>
<td>• Pulmonary rehabilitation reduces hospitalizations among patients who have had a recent exacerbation (≤ 4 weeks from prior hospitalization) (Evidence B).</td>
</tr>
<tr>
<td><strong>Education and self-management</strong></td>
</tr>
<tr>
<td>• Education alone has not been shown to be effective (Evidence C).</td>
</tr>
<tr>
<td>• Self-management intervention with communication with a health care professional improves health status and decreases hospitalizations and emergency department visits (Evidence B).</td>
</tr>
<tr>
<td><strong>Integrated care programs</strong></td>
</tr>
<tr>
<td>• Integrated care and telehealth have no demonstrated benefit at this time (Evidence B).</td>
</tr>
</tbody>
</table>
SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE

Symptom control and palliative care

Palliative care is a broad term that encompasses approaches to symptom control as well as management of terminal patients close to death. The goal of palliative care is to prevent and relieve suffering, and to support the best possible quality of life for patients and their families, regardless of the stage of disease or the need for other therapies. COPD is a highly symptomatic disease and has many elements such as fatigue, dyspnea, depression, anxiety, insomnia that require symptom-based palliative treatments. There is evidence that patients with COPD are less likely to receive such services compared to patients with lung cancer. Palliative care expands traditional disease-model medical treatment to increase the focus on the goals of enhancing quality of life, optimizing function, helping with decision making about end-of-life care, and providing emotional and spiritual support to patients and their families. Palliative approaches are essential in the context of end-of-life care as well as hospice care (a model for delivery of end-of-life care for patients who are terminally ill and predicted to have less than 6 months to live). Increasingly, palliative care teams are available for consultation for hospitalized patients. Availability for outpatient palliative care consultation is less common, but has been shown to improve quality of life, reduce symptoms and even prolong survival for patients with advanced lung cancer.

Therapy relevant to all patients with COPD

Even when receiving optimal medical therapy many patients with COPD continue to experience distressing breathlessness, impaired exercise capacity, fatigue, and suffer panic, anxiety & depression. Some of these symptoms can be improved by wider use of palliative therapies that in the past have often been restricted to end-of-life situations.

**Palliative treatment of dyspnea.** Opiates, neuromuscular electrical stimulation (NMES), chest wall vibration (CWV) and fans blowing air onto the face can relieve breathlessness. Oxygen may offer some benefit even if the patient is not hypoxemic (SpO₂ > 92%). Pulmonary rehabilitation is effective and in severe cases non-invasive ventilation can also reduce daytime breathlessness. Refractory dyspnea may be more effectively managed with a multidisciplinary integrated palliative and respiratory care service.

There is no evidence for a beneficial effect of benzodiazepines and there is not enough data to recommend distractive auditory stimuli (music), relaxation, counseling and support, with or without breathing relaxation training, or psychotherapy.

**Nutritional support.** Low body mass index and particularly low fat free mass is associated with worse outcomes in people with COPD. In malnourished patients with COPD, nutritional supplementation promotes significant weight gain and leads to significant improvements in respiratory muscle strength and overall health-related quality of life.

**Panic, anxiety & depression.** The causes of depression and anxiety symptoms in people with COPD are multifactorial and include behavioral, social and biological factors. Pulmonary rehabilitation
may help reduce anxiety symptoms. The efficacy of antidepressants in patients with COPD has been inconclusive, possibly as a result of methodological issues in the published trials. Cognitive behavioral therapy and mind-body interventions (e.g., mindfulness-based therapy, yoga, and relaxation) can reduce anxiety and depression and mind-body interventions also improve physical outcomes such as lung function, dyspnea, exercise capacity and fatigue in people with COPD and psychological problems. 229

**Fatigue.** Fatigue in people with COPD can be improved by self-management education, pulmonary rehabilitation, nutritional support and mind-body interventions. 230

**End-of-life and hospice care**

In many patients, the disease trajectory in COPD is marked by a gradual decline in health status and increasing symptoms, punctuated by acute exacerbations that are associated with an increased risk of dying. 231 Although mortality rates following hospitalization for an acute exacerbation of COPD are declining, 232 reported rates still vary from 23% 233 to 80%. 234 Progressive respiratory failure, cardiovascular diseases, malignancies and other diseases are the primary cause of death in patients with COPD hospitalized for an exacerbation. 234 In qualitative studies, as well as describing the high symptom burden, patients with COPD and their families describe a need for a better understanding of their condition and the psychological impact of living and dying with COPD. 235 Palliative care is a broad term that includes approaches to symptom control as well as management of terminal patients close to death. Palliative care, end-of-life care, and hospice care are important components of the care of patients with advanced COPD.

End of life care should also include discussions with patients and their families about their views on resuscitation, advance directives and place of death preferences. 236 At an individual level, prediction of 6-month survival in patients with COPD is unreliable and therefore early discussion of these issues is important together with phased introduction of supportive care. 237 Hospitalization may be a trigger to initiate discussion of advance care planning. Patients and their families live with uncertainty about the timing of death and fear death will result from worsening dyspnea and suffocation. 238 Good advance care planning can reduce anxiety for patients and their families by talking about death and dying and offering emotional support. It can also ensure that care is consistent with their wishes and avoids unnecessary, unwanted and costly invasive approaches. 239,240 For patients with very advanced or terminal illness, hospice services may provide additional benefit. Hospice services often focus on patients with severe disability or symptom burden and may provide these services within the patient’s home or in hospice beds in dedicated hospice units or other institutions such as hospitals or nursing homes. Organizations such as the National Hospice and Palliative Care Organization 241 provide guidance for selecting patients with non-cancer diseases like COPD for access to hospice services (for example, disabling dyspnea at rest that is poorly responsive to bronchodilators and progression of advanced disease demonstrated by increasing hospitalizations or emergency department visits). 214,215 These guidelines discuss the difficulties in accurately predicting the prognosis of patients with advanced COPD, but recognize the appropriateness of providing hospice services for some of these patients. 213 Key points for palliative, end-of-life and hospice care in COPD are summarized in Table 3.9.
OTHER TREATMENTS

Oxygen therapy and ventilatory support

Oxygen therapy. The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival in patients with severe resting hypoxemia. Long term oxygen therapy does not lengthen time to death or first hospitalization or provide sustained benefit for any of the measured outcomes in patients with stable COPD and resting or exercise-induced moderate arterial oxygen desaturation (Table 3.10).

Although air travel is safe for most patients with chronic respiratory failure who are on long-term oxygen therapy, patients should ideally maintain an in-flight PaO\textsubscript{2} of at least 6.7 kPa (50 mmHg). Studies indicate that this can be achieved in those with moderate to severe hypoxemia at sea level by supplementary oxygen at 3 liters/min by nasal cannula or 31% by Venturi facemask. Those with a resting oxygen saturation > 95% and 6-minute walk oxygen saturation > 84% may travel without further assessment, although it is important to emphasize that resting oxygenation at sea level does not exclude the development of severe hypoxemia when travelling by air. Careful consideration should be given to any comorbidity that may impair oxygen delivery to tissues (e.g., cardiac impairment, anemia). Also, walking along the aisle may profoundly aggravate hypoxemia.

Ventilatory Support

During exacerbations of COPD. Noninvasive ventilation (NIV) in the form of noninvasive positive pressure ventilation (NPPV) is the standard of care for decreasing morbidity and mortality in patients hospitalized with an exacerbation of COPD and acute respiratory failure (see also Chapter 5).

Stable patient. Whether to use NPPV chronically at home to treat patients with acute on chronic respiratory failure following hospitalization remains undetermined. Two retrospective studies report reductions in re-hospitalization and improved survival with using NPPV post-hospitalization while other studies have demonstrated no improvement. RCTs have yielded conflicting data on the use of home NPPV on survival and re-hospitalization in chronic hypercapnic COPD. Several factors may account for these discrepancies: differences in patient selection and poorly characterized patient populations, underpowered studies, NPPV settings incapable of achieving adequate ventilation, and poor adherence with NPPV therapy. NPPV when indicated should be instituted and monitored under the direction of personnel familiar with the process and the devices utilized. In patients with both COPD and obstructive sleep apnea there are clear benefits
associated with the use of continuous positive airway pressure (CPAP) to improve both survival and the risk of hospital admissions.  

<table>
<thead>
<tr>
<th>Table 3.10. Oxygen therapy and ventilatory support in stable COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oxygen therapy</strong></td>
</tr>
<tr>
<td>• The long-term administration of oxygen increases survival in patients with severe chronic resting arterial hypoxemia (Evidence A).</td>
</tr>
<tr>
<td>• In patients with stable COPD and moderate resting or exercise-induced arterial desaturation, prescription of long-term oxygen does not lengthen time to death or first hospitalization or provide sustained benefit in health status, lung function and 6-minute walk distance (Evidence A).</td>
</tr>
<tr>
<td>• Resting oxygenation at sea level does not exclude the development of severe hypoxemia when traveling by air (Evidence C).</td>
</tr>
<tr>
<td><strong>Ventilatory support</strong></td>
</tr>
<tr>
<td>• NPPV may improve hospitalization-free survival in selected patients after recent hospitalization, particularly in those with pronounced daytime persistent hypercapnia (PaCO₂ ≥ 52 mmHg) (Evidence B).</td>
</tr>
</tbody>
</table>

**INTERVENTIONAL THERAPY**

**Surgical Interventions**

**Lung volume reduction surgery (LVRS).** LVRS is a surgical procedure in which parts of the lungs are resected to reduce hyperinflation, making respiratory muscles more effective pressure generators by improving their mechanical efficiency. LVRS increases the elastic recoil pressure of the lung and thus improves expiratory flow rates and reduces exacerbations. In an RCT that included severe emphysema patients, with an upper-lobe emphysema and low post-rehabilitation exercise capacity, LVRS resulted in improved survival when compared to medical treatment. In similar patients with high post-pulmonary rehabilitation exercise capacity, no difference in survival was noted after LVRS, although health status and exercise capacity improved. LVRS has been demonstrated to result in higher mortality than medical management in severe emphysema patients with an FEV₁ ≤ 20% predicted and either homogeneous emphysema high resolution computed tomography or a DLCO of ≤ 20% of predicted. A prospective economic analysis indicated that LVRS is costly relative to healthcare programs that do not include surgery.

**Bullectomy.** Bullectomy is an older surgical procedure for bullous emphysema. Removal of a large bulla that does not contribute to gas exchange and is, or has been, responsible for complications decompresses the adjacent lung parenchyma. In selected patients with relatively preserved underlying lung, bullectomy is associated with decreased dyspnea, improved lung function and exercise tolerance. Pulmonary hypertension, hypercapnia and severe emphysema are not absolute contraindications for bullectomy.

**Lung transplantation.** In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve health status and functional capacity but not prolong survival. Over 70% of lung transplants conducted in COPD patients are double lung transplants; the remainder are single lung transplants. Bilateral lung transplantation has been reported to provide longer survival than single lung transplantation in COPD patients, especially those < 60 years of age. The median survival for lung transplantation in all COPD patients has increased to 5.5
years; it is 7 years in those receiving a bilateral lung transplant and 5 years in those receiving a single lung transplant.\textsuperscript{272}

Lung transplantation is limited by the shortage of donor organs and cost. The complications most commonly seen in COPD patients after lung transplantation are acute rejection, bronchiolitis obliterans, opportunistic infections and lymphoproliferative disease.\textsuperscript{274}

**Bronchoscopic interventions to reduce hyperinflation in severe emphysema**

Due to the morbidity and mortality associated with LVRS, less invasive bronchoscopic approaches to lung reduction have been examined.\textsuperscript{275} These include a variety of different bronchoscopic procedures.\textsuperscript{275} Although these techniques differ markedly from one another they are similar in their objective to decrease thoracic volume to improve lung, chest wall and respiratory muscle mechanics.

Prospective studies have shown that the use of bronchial stents is not effective.\textsuperscript{276} A multi-center study examining the effects of a lung sealant to create lung reduction was discontinued prematurely; while the study reported significant benefits in some physiologic parameters, the intervention was associated with significant morbidity and mortality.\textsuperscript{277}

A large prospective multicenter RCT of endobronchial valve placement showed statistically significant improvements in FEV\textsubscript{1} and 6-minute walk distance compared to control therapy at 6 months post intervention.\textsuperscript{278} However, the magnitude of the observed improvements was not clinically meaningful. Subsequently, efficacy of the same endobronchial valve has been studied in patients with heterogeneous,\textsuperscript{279} or heterogeneous and homogenous emphysema with mixed outcomes. Non-significant increases in median FEV\textsubscript{1} at three months post valve implantation in one study was attributed to valve placement in some patients with interlobar collateral ventilation.\textsuperscript{279} Another study showed significant increases in FEV\textsubscript{1} and 6-minute walk distance in subjects selected for the absence of interlobar collateral ventilation compared to the control group at 6 months.\textsuperscript{280} Adverse effects in the endobronchial valve treatment group in both studies included pneumothorax, valve removal or valve replacement.\textsuperscript{280} Greater benefit was shown in patients with heterogeneous compared to those with homogenous emphysema.\textsuperscript{280} An RCT of endobronchial valve placement compared with usual care conducted only in homogenous emphysematous patients without interlobar collateral ventilation reported improvements in FEV\textsubscript{1}, 6-minute walk distance and health status at 6 months with targeted lobe reduction in 97% of subjects as measured by volumetric CT (mean reduction 1,195 ml).\textsuperscript{281}

In a prospective RCT, targeted thermal vapour ablation of more diseased segments resulted in clinically meaningful and statistically significant improvements in lung function and health status at 6 months. COPD exacerbation was the most common serious adverse event. Durability of these changes were subsequently reported at 12 months follow-up.\textsuperscript{282,283} This therapy is not currently clinically available.

Two multicenter trials have examined nitinol coils implanted into the lung compared to usual care on changes in 6-minute walk distance, lung function and health status in patients with advanced homogenous and heterogeneous emphysema. Both studies reported an increase in 6 minute walk
distance with coil treatment compared to control and smaller improvements in FEV₁, and quality of life measured by St George’s Respiratory Questionnaire. Major complications included pneumonia, pneumothorax, hemoptysis and COPD exacerbations occurring more frequently in the coil group.

Additional data are needed to define the optimal patient population to receive the specific bronchoscopic lung volume technique and to compare the long-term durability of improvements in functional or physiological performance to lung volume reduction surgery relative to side effects.

Key points for interventional therapy in stable COPD are summarized in Table 3.11.

<table>
<thead>
<tr>
<th>Table 3.11. Interventional therapy in stable COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung volume reduction surgery</strong></td>
</tr>
<tr>
<td>• Lung volume reduction surgery improves survival in severe emphysema patients with an upper-lobe emphysema and low post-rehabilitation exercise capacity (Evidence A)</td>
</tr>
<tr>
<td><strong>Bullectomy</strong></td>
</tr>
<tr>
<td>• In selected patients bullectomy is associated with decreased dyspnea, improved lung function and exercise tolerance (Evidence C).</td>
</tr>
<tr>
<td><strong>Transplantation</strong></td>
</tr>
<tr>
<td>• In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve quality of life and functional capacity (Evidence C).</td>
</tr>
<tr>
<td><strong>Bronchoscopic interventions</strong></td>
</tr>
<tr>
<td>• In select patients with advanced emphysema, bronchoscopic interventions reduces end-expiratory lung volume and improves exercise tolerance, health status and lung function at 6-12 months following treatment. Endobronchial valves (Evidence B); Lung coils (Evidence B)</td>
</tr>
</tbody>
</table>
REFERENCES

7. Lee PN, Fariss MW. A systematic review of possible serious adverse health effects of nicotine replacement therapy. *Arch Toxicol* 2016; *Epub ahead of print*.
17. The tobacco use and dependence clinical practice guideline panel s, and consortium representatives,. A clinical practice guideline for treating tobacco use and dependence. *JAMA* 2000; 283: 3244-54.


71


163. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-


177. van der Palen J, Klein JJ, Schildkamp AM. Comparison of a new multidose powder inhaler (Diskus/Accuhaler) and the Turbuhaler regarding preference and ease of use. *J Asthma* 1998; [35](2): 147-52.


CHAPTER 4: MANAGEMENT OF STABLE COPD

OVERALL KEY POINTS:

- The management strategy for stable COPD should be predominantly based on the individualized assessment of symptoms and future risk of exacerbations.
- All individuals who smoke should be strongly encouraged and supported to quit.
- The main treatment goals are reduction of symptoms and future risk of exacerbations.
- Management strategies are not limited to pharmacologic treatments, and should be complemented by appropriate non-pharmacologic interventions.

INTRODUCTION

Once COPD has been diagnosed, effective management should be based on an individualized assessment to reduce both current symptoms and future risks of exacerbations (Table 4.1).

The individualized assessment is summarized in Chapter 2.

We propose a personalization of initiating and escalating/de-escalating treatment based on the level of symptoms and the individual’s risk of exacerbations. The basis for these recommendations, which propose an organized approach to treatment, is only partially from evidence generated in randomized controlled trials. These recommendations are intended to support clinician decision-making and therefore also incorporate patients’ experiences and preferences.

It is crucial for patients with COPD to understand the nature of the disease, risk factors for its progression, and the role that they and their healthcare workers must play in order to achieve optimal management and health outcomes. In addition, patients should receive general advice on healthy living, including diet, and that physical exercise is safe and encouraged for people with COPD. Ongoing monitoring should include continuous evaluation of exposure to risk factors and monitoring of disease progression, the effect of treatment and possible adverse effects, exacerbation history, and comorbidities.
Identification and reduction of exposure to risk factors is important in the treatment and prevention of COPD. Cigarette smoking is the most commonly encountered and easily identifiable risk factor for COPD, and smoking cessation should be continually encouraged for all individuals who smoke. Reduction of total personal exposure to occupational dusts, fumes, and gases, and to indoor and outdoor air pollutants, should also be addressed.

**Tobacco smoke**

Smoking cessation is a key intervention for all COPD patients who continue to smoke. Healthcare providers are pivotal in delivering smoking cessation messages and interventions to patients. COPD patients who smoke should be encouraged to quit at every opportunity.

Smokers should be provided with counseling when attempting to quit. When possible, the patient should be referred to a comprehensive smoking cessation program, incorporating behavior change techniques that focus on enhancing patient motivation and confidence, patient education, pharmacologic and non-pharmacologic interventions. Recommendations for treating tobacco use and dependence are summarized in Table 4.2.

### Table 4.1. Goals for treatment of stable COPD

- Relieve symptoms
- Improve exercise tolerance
- Improve health status

\[\text{and}\]

- Prevent disease progression
- Prevent and treat exacerbations
- Reduce mortality

\[\text{REDUCE SYMPTOMS}\]

\[\text{REDUCE RISK}\]

### Table 4.2. Treating tobacco use and dependence: A clinical practice guideline — major findings and recommendations

- Tobacco dependence is a chronic condition that warrants repeated treatment until long-term or permanent abstinence is achieved.
- Effective treatments for tobacco dependence exist and all tobacco users should be offered these treatments.
- Clinicians and health care delivery systems must operationalize the consistent identification, documentation, and treatment of every tobacco user at every visit.
- Brief smoking cessation counseling is effective and every tobacco user should be offered such advice at every contact with health care providers.
- There is a strong dose-response relation between the intensity of tobacco dependence counseling and its effectiveness.
- Three types of counseling have been found to be especially effective: practical counseling, social support of family and friends as part of treatment, and social support arranged outside of treatment.
- First-line pharmacotherapies for tobacco dependence—varenicline, bupropion sustained release, nicotine gum, nicotine inhaler, nicotine nasal spray, and nicotine patch—are effective and at least one of these medications should be prescribed in the absence of contraindications.
- Financial incentive programs for smoking cessation may facilitate smoking cessation.
- Tobacco dependence treatments are cost effective interventions.
Indoor and outdoor air pollution

Reducing the risk from indoor and outdoor air pollution is feasible and requires a combination of public policy, local and national resources, cultural changes, and protective steps taken by individual patients. Reduction of exposure to smoke from biomass fuel is a crucial goal to reduce the prevalence of COPD worldwide. Efficient ventilation, non-polluting cooking stoves and similar interventions are feasible and should be recommended.2,3

Occupational exposures

There are no studies that demonstrate whether interventions that reduce occupational exposures also reduce the burden of COPD, but it seems logical to advise patients to avoid ongoing exposures to potential irritants if possible. Measures to reduce risk factor exposure are summarized in Table 4.3.

<table>
<thead>
<tr>
<th>Table 4.3. Identify and reduce risk factor exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Smoking cessation interventions should be actively pursued in all COPD patients (Evidence A).</td>
</tr>
<tr>
<td>• Efficient ventilation, non-polluting cooking stoves and similar interventions should be recommended (Evidence B).</td>
</tr>
<tr>
<td>• Clinicians should advise patients to avoid continued exposures to potential irritants if possible (Evidence D).</td>
</tr>
</tbody>
</table>

TREATMENT OF STABLE COPD

PHARMACOLOGIC TREATMENT

Pharmacologic therapies can reduce symptoms, and the risk and severity of exacerbations, as well as improve health status and exercise tolerance.

The classes of medications commonly used in treating COPD are shown in Table 3.3 and a detailed description of the effects of these medications is given in Chapter 3. The choice within each class depends on the availability of medication and the patient’s response and preference.

Most of the drugs are inhaled so proper inhaler technique is of high relevance. Key points for the inhalation of drugs are given in Table 4.4. Key points for bronchodilator use are given in Table 4.5. Key points for the use of anti-inflammatory agents are summarized in Table 4.6. Key points for the use of pharmacologic treatments are summarized in Table 4.7.

<table>
<thead>
<tr>
<th>Table 4.4. Key points for inhalation of drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient’s ability and preference.</td>
</tr>
<tr>
<td>• It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate and re-check at each visit that patients continue to use their inhaler correctly.</td>
</tr>
<tr>
<td>• Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy requires modification.</td>
</tr>
</tbody>
</table>
Pharmacologic treatment algorithms

A proposed model for the initiation, and then subsequent escalation and/or de-escalation of pharmacologic management of COPD according to the individualized assessment of symptoms and exacerbation risk is shown in Figure 4.1.

In past versions of the GOLD Report, recommendations were only given for initial therapy. However, many COPD patients are already on treatment and return with persistent symptoms after initial therapy, or less commonly with resolution of some symptoms that subsequently may require less therapy. Therefore, we now suggest escalation (and de-escalation) strategies. The recommendations made are based on available efficacy as well as safety data. We are fully aware that treatment escalation has not been systematically tested; trials of de-escalation are also limited and only include ICS.

It should be noted that there is a lack of direct evidence supporting the therapeutic recommendations for patients in groups C and D. These recommendations will be re-evaluated as additional data become available.
Group A
► All Group A patients should be offered bronchodilator treatment based on its effect on breathlessness. This can be either a short- or a long-acting bronchodilator.

► This should be continued if symptomatic benefit is documented.

Group B
► Initial therapy should consist of a long acting bronchodilator. Long-acting inhaled bronchodilators are superior to short-acting bronchodilators taken as needed i.e., pro re nata (prn) and are therefore recommended. 5, 6

► There is no evidence to recommend one class of long-acting bronchodilators over another for initial relief of symptoms in this group of patients. In the individual patient, the choice should depend on the patient's perception of symptom relief.
► For patients with persistent breathlessness on monotherapy the use of two bronchodilators is recommended.

► For patients with severe breathlessness initial therapy with two bronchodilators may be considered.

► If the addition of a second bronchodilator does not improve symptoms, we suggest the treatment could be stepped down again to a single bronchodilator.

► Group B patients are likely to have comorbidities that may add to their symptomatology and impact their prognosis, and these possibilities should be investigated.

**Group C**

► Initial therapy should consist of a single long acting bronchodilator. In two head-to head comparisons the tested LAMA was superior to the LABA regarding exacerbation prevention, therefore we recommend starting therapy with a LAMA in this group.

► Patients with persistent exacerbations may benefit from adding a second long acting bronchodilator (LABA/LAMA) or using a combination of a long acting beta₂-agonist and an inhaled corticosteroid (LABA/ICS). As ICS increases the risk for developing pneumonia in some patients, our primary choice is LABA/LAMA.

**Group D**

► We recommend starting therapy with a LABA/LAMA combination because:
  
  - In studies with patient reported outcomes as the primary endpoint LABA/LAMA combinations showed superior results compared to the single substances. If a single bronchodilator is chosen as initial treatment, a LAMA is preferred for exacerbation prevention based on comparison to LABAs (for details see Chapter 3).
  
  - A LABA/LAMA combination was superior to a LABA/ICS combination in preventing exacerbations and other patient reported outcomes in Group D patients (for details see Chapter 3).
  
  - Group D patients are at higher risk of developing pneumonia when receiving treatment with ICS.

► In some patients initial therapy with LABA/ICS may be the first choice. These patients may have a history and/or findings suggestive of asthma-COPD overlap. High blood eosinophil counts may also be considered as a parameter to support the use of ICS, although this is still under debate (for details see Chapter 2 and Appendix).

► In patients who develop further exacerbations on LABA/LAMA therapy we suggest two alternative pathways:
  
  - Escalation to LABA/LAMA/ICS. Studies are underway comparing the effects of LABA/LAMA vs. LABA/LAMA/ICS for exacerbation prevention.
Switch to LABA/ICS. However, there is no evidence that switching from LABA/LAMA to LABA/ICS results in better exacerbation prevention. If LABA/ICS therapy does not positively impact exacerbations/symptoms, a LAMA can be added.

▶ If patients treated with LABA/LAMA/ICS still have exacerbations the following options may be considered:

- Add roflumilast. This may be considered in patients with an FEV₁ < 50% predicted and chronic bronchitis, particularly if they have experienced at least one hospitalization for an exacerbation in the previous year.
- Add a macrolide. The best available evidence exists for the use of azithromycin. Consideration to the development of resistant organisms should be factored into decision making.
- Stopping ICS. A reported lack of efficacy, an elevated risk of adverse effects (including pneumonia) and evidence showing no significant harm from withdrawal supports this recommendation (see Chapter 3 for further details).

NON-PHARMACOLOGIC TREATMENT

Education and self-management

Self-management education and coaching by healthcare professionals should be a major component of the “Chronic Care Model” within the context of the healthcare delivery system.

The aim of self-management education is to motivate, engage and coach the patients to positively adapt their health behavior(s) and develop skills to better manage their disease.

Physicians and healthcare providers need to go beyond pure education/advice-giving approaches to help patients learn and adopt sustainable self-management skills. In addition to addressing behavioral risk factors (i.e., smoking, diet, exercise), self-management should involve patients in monitoring and managing the signs and symptoms of their disease, being adherent to treatment (including to medications and other medical advice), maintaining regular contact with healthcare providers, and managing the psychosocial consequences of their condition.

The individual patient’s evaluation and risk assessment with respect to exacerbations, patient’s needs, preferences, and personal goals should inform the personalized design of the self-management education plan.

Based on GOLD groups, personalized design could include:

- **Groups A, B, C & D** - addressing behavioral risk factors, including smoking cessation, maintaining or increasing physical activity, and ensuring adequate sleep and a healthy diet.
- **Groups B & D** - learning to self-manage breathlessness, energy conservation techniques, and stress management strategies.
• **Groups C & D** - avoiding aggravating factors, monitoring and managing worsening symptoms, having a written action plan and maintaining regular contact/communication with a healthcare professional.

• **Group D** – discussing with their healthcare providers palliative strategies and advance care directives

Some relevant non-pharmacologic measures for patient groups A to D are summarized in **Table 4.8**.

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Essential</th>
<th>Recommended</th>
<th>Depending on local guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Smoking cessation (can include pharmacologic treatment)</td>
<td>Physical activity</td>
<td>Flu vaccination</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pneumococcal vaccination</td>
</tr>
<tr>
<td>B-D</td>
<td>Smoking cessation (can include pharmacologic treatment)</td>
<td>Physical activity</td>
<td>Flu vaccination</td>
</tr>
<tr>
<td></td>
<td>Pulmonary rehabilitation</td>
<td></td>
<td>Pneumococcal vaccination</td>
</tr>
</tbody>
</table>

**Physical activity**

There is evidence that physical activity is decreased in COPD patients. This leads to a downward spiral of inactivity which predisposes patients to reduced quality of life, increased rates of hospitalization and mortality. As such, there has been tremendous interest in implementing behavior-targeted interventions with the aim of improving physical activity and these should be encouraged. However, most published studies to date provide little guidance, being inconsistent in the techniques, and lacking the necessary details (e.g., type, quantity, timing and method of delivery; tools used; quality-assurance methods) to replicate the study or adapt the interventions for clinical care.

**Pulmonary rehabilitation programs**

Patients with high symptom burden and risk of exacerbations (Groups B, C and D), should be encouraged to take part in a full rehabilitation program that includes setting patient goals, designed and delivered in a structured manner, taking into account the individual's COPD characteristics and comorbidities.

Key time points when it may be appropriate to consider referral are: (a) at diagnosis, (b) at discharge following hospitalization for an exacerbation, and (c) when symptoms are found to be progressively deteriorating. These could relate to each patient at different time points of the disease trajectory.

Because benefits diminish over time if activity and other positively adaptive behaviors are not continued, patients should be offered a maintenance program, or at least supported sufficiently to increase and maintain physical activity in daily living.

The components of pulmonary rehabilitation may vary but evidence-based best practice for program delivery includes: structured and supervised exercise training, smoking cessation, nutrition counseling, and self-management education. Further details and recommendations on the components of pulmonary rehabilitation, the program organization (duration and structure) and evaluation are presented in **Chapter 3**.
**Exercise training**

A combination of constant load or interval training with strength training provides better outcomes than either method alone.\(^26\)

Where possible, endurance exercise training to 60-80% of the symptom-limited maximum work or heart rate is preferred,\(^27\) or to a Borg-rated dyspnea or fatigue score of 4 to 6 (moderate to severe).\(^28\)

Endurance training can be accomplished through either continuous or interval exercise programs. The latter involves the patient doing the same total work but divided into briefer periods of high-intensity exercise, a useful strategy when performance is limited by other comorbidities.\(^29,30\)

Exercise training can be enhanced by optimizing bronchodilators,\(^31\) since both long acting muscarinic antagonists (LAMA) and beta\(_2\)-agonists (LABA) have shown reduced resting and dynamic hyperinflation. These changes contribute to better training effects.\(^32,33\)

Adding strength training to aerobic training is effective in improving strength, but does not improve health status or exercise tolerance.\(^34\)

Upper extremities exercise training improves arm strength and endurance and results in improved functional capacity for upper extremity activities.\(^35\)

Inspiratory muscle training increases strength of inspiratory muscles, but this does not translate to better performance or even reduced dyspnea, unless included in a comprehensive pulmonary rehabilitation program.\(^36,37\)

**Assessment and follow-up.** Baseline and outcome assessments of each participant in a pulmonary rehabilitation program should be made to specify individual maladaptive behaviors (including motivation), physical and mental health impediments to training, goals, barriers and capabilities and to quantify gains and to target areas for improvement.

Assessments should include:

1. Detailed history and physical examination.
3. Assessment of exercise capacity.
5. Assessment of inspiratory and expiratory muscle strength and lower limb strength in patients who suffer from muscle wasting.
6. Discussion about individual patient goals and expectations.

The first two assessments are important for establishing entry suitability and baseline status but are not used in outcome assessment.
Exercise tolerance can be assessed by cycle ergometry or treadmill exercise with the measurement of a number of physiological variables, including maximum oxygen consumption, maximum heart rate, and maximum work performed. Standardized self-paced, timed walking tests (e.g., 6-minute walking distance) are useful in clinical practice as they require minimal facilities and are relevant to routine functioning. Shuttle walking tests provide more complete information than an entirely self-paced test, and are simpler to perform than a treadmill test. Walking tests do require at least one practice session before data can be interpreted.

It is important not to limit assessment only to these outcome measures but gather information on each patient’s ultimate goal (relevant or valued outcomes), such as their desired achievements in work, home and leisure by the end of the program.

Several detailed questionnaires for assessing health status are available, including some specifically designed for patients with respiratory disease. Health status can also be assessed by generic instruments, although these are less sensitive to change than the disease specific questionnaires such as the CAT, CRQ or SGRQ. The Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of Mental Disorders (PRIME-MD) Patient Questionnaire have been used to improve identification and treatment of anxious and depressed patients.

**Self-management education**

The basis of enabling patients to become active partners in their ongoing care is to build knowledge and skills. Topics considered appropriate for an education program include: smoking cessation; basic information about COPD; general approach to therapy and specific aspects of medical treatment (respiratory medications and inhalation devices); strategies to help minimize dyspnea; advice about when to seek help; decision-making during exacerbations; and advance directives and end-of-life issues. The intensity and content of these educational messages will vary depending on the severity of the patient’s disease, although the specific contributions of education to the improvements seen after pulmonary rehabilitation remain unclear. Implicit in this description is the provision of “self-management support/coaching”, which refers to the strategies, techniques and skills used by healthcare providers to arm patients with the knowledge, confidence and skills required to self-manage their disease effectively.

It is important to recognize that patient education alone does not itself change behavior or even motivate patients, and it has had no impact on improving exercise performance or lung function, but it can play a role in improving skills, ability to cope with illness, and health status. Patients may have individual and /or group education sessions. During group sessions, patients engage in active, participatory-based learning of program content. During one-on-one interactions, a motivational communication style should be used, as this approach empowers patients to take greater responsibility for their health and well-being, where physicians and other healthcare professionals only serve as guides in the behavior change process.
**End of life and palliative care**

The goal of palliative care is to relieve the suffering of patients and their families by the comprehensive assessment and treatment of physical, psychosocial, and spiritual symptoms experienced by patients.

Patients with a chronic life-limiting illness like COPD should be informed that, should they become critically ill, they or their family members may be in a position where they would need to decide whether a course of intensive care is likely to achieve their personal goals of care, and they are willing to accept the burdens of such treatment.

Clinicians should develop and implement methods to help patients and their families to make informed choices that are consistent with patients’ values. Simple, structured approaches to facilitate these conversations may help to improve the occurrence and quality of communication from the patients’ perspective.44

**Nutritional support**

For malnourished patients with COPD nutritional supplementation is recommended. This is based on systematic review findings of positive effects on body weight, fat mass and fat-free mass when nutritional supplementation is provided alone to COPD patients (especially if malnourished) and when used as an adjunct to exercise training. The optimal amount and duration of supplementation are not clearly established.45 Patients receiving nutritional supplementation demonstrated significant improvements compared to baseline for 6-minute walk test, respiratory muscle strength and health status (only in malnourished patients).45

**Vaccination**

Influenza vaccination is recommended for all patients with COPD.

Pneumococcal vaccinations, PCV13 and PPSV23, are recommended for all patients > 65 years of age. The PPSV23 is also recommended for younger COPD patients with significant comorbid conditions including chronic heart or lung disease.46

**Oxygen therapy**

Long-term oxygen therapy is indicated for stable patients who have:
- PaO$_2$ at or below 7.3 kPa (55 mmHg) or SaO$_2$ at or below 88%, with or without hypercapnia confirmed twice over a three week period; or
- PaO$_2$ between 7.3 kPa (55 mmHg) and 8.0 kPa (60 mmHg), or SaO$_2$ of 88%, if there is evidence of pulmonary hypertension, peripheral edema suggesting congestive cardiac failure, or polycythemia (hematocrit > 55%).

Once placed on long-term oxygen therapy (LTOT) the patient should be re-evaluated after 60 to 90 days with repeat arterial blood gas (ABG) or oxygen saturation while inspiring the same level of oxygen or room air to determine if oxygen is therapeutic and still indicated, respectively.
An appropriate algorithm for the prescription of oxygen to COPD patients is shown in Figure 4.2.

**Figure 4.2. Prescription of supplemental oxygen to COPD patients**

Ventilatory support

NIV is occasionally used in patients with stable very severe COPD. NIV may be considered of some use in a selected group of patients, particularly in those with pronounced daytime hypercapnia and recent hospitalization, although systematic review is unable to support or refute this. However, in patients with both COPD and obstructive sleep apnea there are clear indications for continuous positive airway pressure (CPAP).

Interventional bronchoscopy and surgery

- In selected patients with heterogeneous or homogenous emphysema and significant hyperinflation refractory to optimized medical care, surgical or bronchoscopic modes of lung volume reduction (e.g., endobronchial one-way valves or lung coils) may be considered.
- In selected patients with a large bulla, surgical bullectomy may be considered.
- In selected patients with very severe COPD and without relevant contraindications, lung transplantation may be considered.

Choosing bronchoscopic lung reduction (coil placement or endobronchial valve) or surgical resection (lung volume reduction surgery, LVRS) to treat hyperinflation in an emphysematous patient depends on a number of factors. These include: the extent and pattern of emphysema identified on HRCT; the presence of interlobar collateral ventilation measured by fissure integrity on HRCT or physiological assessment (endoscopic balloon occlusion and flow assessment); local proficiency in the performance of the procedures; and patient and provider preferences.
In patients with fissure integrity or lack of interlobar collateral ventilation based on physiologic assessment, endobronchial valve, lung coil treatment or LVRS could all be useful. In patients with lack of fissure integrity or interlobar collateral ventilation, lung coil therapy or LVRS may be performed but endobronchial valve therapy is not useful. Patients with heterogeneous upper lobe predominant emphysema may be candidates for either LVRS or bronchoscopic lung reduction approaches. The presence of interlobar collateral ventilation would exclude the use of endobronchial valve therapy but lung coil therapy could be considered along with LVRS. Patients with homogenous emphysema are not routinely considered candidates for LVRS at most centers, however, bronchoscopic lung reduction can be successful using either lung coils or endobronchial valve therapies. Again the presence of interlobar collateral ventilation is important in selecting endobronchial valve or lung coil therapy as the intervention of choice. An algorithm depicting an overview of various interventions is shown in Figure 4.3.

**Figure 4.3. Interventional Bronchoscopic and Surgical Treatments for COPD**

Criteria for referral for lung transplantation include COPD with progressive disease, not a candidate for endoscopic or surgical lung volume reduction, BODE index of 5 to 6, Pco\(_2\) > 50 mmHg or 6.6 kPa and/or PaO\(_2\) < 60 mmHg or 8 kPa, and FEV\(_1\) < 25% predicted. Recommended criteria for listing include one of the following: BODE index > 7, FEV\(_1\) < 15-20% predicted, three or more severe exacerbations during the preceding year, one severe exacerbation with acute hypercapnic respiratory failure, or moderate to severe pulmonary hypertension. Key points for the use of non-pharmacologic treatments are given in Table 4.9.
MONITORING AND FOLLOW-UP

Routine follow-up of COPD patients is essential. Lung function may worsen over time, even with the best available care. Symptoms, exacerbations and objective measures of airflow limitation should be monitored to determine when to modify management and to identify any complications and/or comorbidities that may develop. Based on current literature, comprehensive self-management or routine monitoring has not shown long term benefits in terms of health status over usual care alone for COPD patients in general practice.52

Monitoring disease progression and development of complications and/or comorbidities

Measurements. Decline in FEV$_1$ can be tracked by spirometry performed at least once a year to identify patients who are declining quickly, although other lung function parameters reflecting hyperinflation and gas transfer may also be informative.
Functional capacity as measured by a timed walking test (6-minute walking distance or shuttle-walking test) provides additional information regarding prognosis. Measurement of oxygenation at rest in an arterial blood gas sample may help identify patients who will benefit from supplemental oxygen to improve both symptoms and survival in those with severe resting hypoxemia.

**Symptoms.** At each visit, information on symptoms since the last visit should be collected, including cough and sputum, breathlessness, fatigue, activity limitation, and sleep disturbances. Questionnaires such as the COPD Assessment Test (CAT) can be used; trends and changes are more valuable than single measurements.

**Exacerbations.** The frequency, severity, type and likely causes of all exacerbations should be monitored. Sputum volume and presence or absence of sputum purulence should be noted. Specific inquiry into response to previous treatment, unscheduled visits to providers, telephone calls for assistance, and use of urgent or emergency care facilities is important. Hospitalizations should be documented, including the facility, duration of stay, and any use of critical care or mechanical ventilatory support.

**Imaging.** If there is a clear worsening of symptoms, imaging may be indicated. When exacerbations are repeatedly characterized by purulent sputum, patients should be investigated for bronchiectasis.

**Smoking status.** At each visit, the current smoking status and smoke exposure should be determined followed by appropriate action.

**Pharmacotherapy and other medical treatment**

In order to adjust therapy appropriately as the disease progresses, each follow-up visit should include a discussion of the current therapeutic regimen. Monitoring should focus on:

- Dosages of prescribed medications.
- Adherence to the regimen.
- Inhaler technique.
- Effectiveness of the current regime.
- Side effects.

Treatment modifications should be recommended (Figure 4.1).

**Comorbidities**

Those symptoms that may indicate the worsening or development of another comorbid condition such as obstructive sleep apnea, congestive heart failure, ischemic heart disease, etc. should be recorded and an approach to their evaluation and treatment enacted. Therefore monitoring is recommended for conditions including heart failure, ischemic heart disease, arrhythmias, osteoporosis, depression/anxiety and lung cancer (see also Chapter 6).
**Surgery in the COPD patient**

**General.** Postoperative pulmonary complications are as important and common as postoperative cardiac complications and, consequently, are a key component of the increased risk posed by surgery in COPD patients. The key factors that can contribute to the risk include smoking, poor general health status, age, obesity, and COPD severity. A comprehensive definition of postoperative pulmonary complications should include only major pulmonary respiratory complications, namely lung infections, atelectasis and/or increased airflow limitation, which all potentially result in acute respiratory failure and aggravation of COPD.

Increased risk of postoperative pulmonary complications in COPD patients may vary with the severity of COPD, although the surgical site is the most important predictor and risk increases as the incision approaches the diaphragm. Most reports conclude that epidural or spinal anesthesia have a lower risk than general anesthesia, although the results are not totally uniform. Some studies conducted in patients undergoing sham bronchoscopic procedures have reported acute exacerbation rates as high as 8.4%. These data suggest that intubation and/or simple airway manipulation may increase the risk of exacerbation in select COPD patients.

To prevent postoperative pulmonary complications, stable COPD patients clinically symptomatic and/or with limited exercise capacity should be treated medically intensively before surgery, with all the measures already well established for stable COPD patients who are not about to have surgery. The presence of comorbid conditions, especially cardiac abnormalities, should be systemically assessed and treated before any major surgical intervention.

**Lung resection.** For lung resection, the individual patient’s risk factors should be identified by careful history taking including physical examination, chest radiography, and pulmonary function tests. Although the value of pulmonary function tests remains contentious, there is consensus that all COPD candidates for lung resection should undergo a complete battery of tests, including spirometry with bronchodilator response, static lung volumes, diffusing capacity, and arterial blood gases at rest. COPD patients at high risk for surgical complications due to poor lung function should undergo further assessment, for example, tests of regional distribution of perfusion and exercise capacity.

The risk of postoperative complications from lung resection appears to be increased in patients with decreased predicted postoperative pulmonary function (FEV$_1$ or DLCO < 30-40% predicted) or exercise capacity (peak VO$_2$ < 10 ml/kg/min or 35% predicted). The final decision to pursue surgery should be made after discussion with the surgeon, pulmonary specialist, primary clinician, and the patient. Surgery should be postponed if an exacerbation is present.
REFERENCES


CHAPTER 5: MANAGEMENT OF EXACERBATIONS

OVERALL KEY POINTS:

- An exacerbation of COPD is defined as an acute worsening of respiratory symptoms that results in additional therapy.

- Exacerbations of COPD can be precipitated by several factors. The most common causes are respiratory tract infections.

- The goal for treatment of COPD exacerbations is to minimize the negative impact of the current exacerbation and to prevent subsequent events.

- Short-acting inhaled beta_2-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation.

- Maintenance therapy with long-acting bronchodilators should be initiated as soon as possible before hospital discharge.

- Systemic corticosteroids can improve lung function (FEV$_1$), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days.

- Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days.

- Methylxanthines are not recommended due to increased side effect profiles.

- Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival.

- Following an exacerbation, appropriate measures for exacerbation prevention should be initiated (see Chapter 3 and Chapter 4).
INTRODUCTION

Exacerbations of chronic obstructive pulmonary disease (COPD) are important events in the management of COPD because they negatively impact health status, rates of hospitalization and readmission, and disease progression.\textsuperscript{,1,2} COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucous production and marked gas trapping. These changes contribute to increased dyspnea that is the key symptom of an exacerbation. Other symptoms include increased sputum purulence and volume, together with increased cough and wheeze.\textsuperscript{3} As comorbidities are common in COPD patients, exacerbations must be differentiated clinically from other events such as acute coronary syndrome, worsening congestive heart failure, pulmonary embolism and pneumonia.

**COPD exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy.**\textsuperscript{1,2}

They are classified as:

- Mild (treated with short acting bronchodilators only, SABDs)
- Moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or
- Severe (patient requires hospitalization or visits the emergency room). Severe exacerbations may also be associated with acute respiratory failure.

It is now recognized that many exacerbations are not reported to healthcare professionals for therapy and yet these events, although often shorter in duration, also have a significant impact on health status.\textsuperscript{4,5} Thus COPD patients need to receive education about the importance of understanding exacerbation symptoms and when to seek professional healthcare.

Exacerbations are mainly triggered by respiratory viral infections although bacterial infections and environmental factors such as pollution and ambient temperature may also initiate and/or amplify these events.\textsuperscript{6} The most common virus isolated is human rhinovirus (the cause of the common cold) and can be detected for up to a week after an exacerbation onset.\textsuperscript{6,12} When associated with viral infections, exacerbations are often more severe, last longer and precipitate more hospitalizations, as seen during winter.

Exacerbations can be associated with increased sputum production and, if purulent, there are studies that demonstrated increased bacteria in the sputum\textsuperscript{3,7,8} There is reasonable evidence to support the concept that eosinophils are increased in the airways, lung, and blood in a significant proportion of patients with COPD. Furthermore, eosinophil numbers increase together with neutrophils and other inflammatory cells during exacerbations in a proportion of subjects with COPD exacerbations.\textsuperscript{9,11} The presence of sputum eosinophilia has been related to susceptibility to viral infection.\textsuperscript{8} It has been suggested that exacerbations associated with an increase in sputum or blood eosinophils may be more responsive to systemic steroids\textsuperscript{12} although more prospective trials are needed to test this hypothesis.\textsuperscript{12}
During a COPD exacerbation symptoms usually last between 7 to 10 days, but some events may last longer. At 8 weeks, 20% of patients have not recovered to their pre-exacerbation state. It is well established that COPD exacerbations contribute to disease progression. Disease progression is even more likely if recovery from exacerbations is slow. Exacerbations can also cluster in time and once a COPD patient experiences an exacerbation, they will show increased susceptibility to another event (see Chapter 2).

Some COPD patients are particularly susceptible to frequent exacerbations (defined as two or more exacerbations per year), and these patients have been shown to have worse health status and morbidity than patients with less frequent exacerbations. Patients at high risk of frequent exacerbations can be recognized across all disease severity groups and the strongest predictor of a patient’s future exacerbation frequency is the number of exacerbations they have had in the prior year. It is recognized that these patients form a moderately stable phenotype, although some studies have shown that a significant proportion of patients change their exacerbation frequency especially with worsening FEV₁.

Other factors that have been associated with an increased risk of acute exacerbations and/or severity of exacerbations include an increase in the ratio of the pulmonary artery to aorta cross sectional dimension (i.e., ratio > 1), a greater percentage of emphysema or airway wall thickness measured by chest CT imaging and the presence of chronic bronchitis.

**TREATMENT OPTIONS**

**Treatment Setting**

The goals of treatment for COPD exacerbations are to minimize the negative impact of the current exacerbation and prevent the development of subsequent events. Depending on the severity of an exacerbation and/or the severity of the underlying disease, an exacerbation can be managed in either the outpatient or inpatient setting. More than 80% of exacerbations are managed on an outpatient basis with pharmacologic therapies including bronchodilators, corticosteroids, and antibiotics.

The indications for assessing the need for hospitalization during a COPD exacerbation are shown in Table 5.1. When patients with a COPD exacerbation come to the emergency department, they should be provided with supplemental oxygen and undergo assessment to determine whether the exacerbation is life-threatening and if increased work of breathing or impaired gas exchange requires consideration for non-invasive ventilation. If so, healthcare providers should consider admission to the respiratory or intensive care unit of the hospital. Otherwise, the patient may be managed in the emergency department or hospital ward unit. In addition to pharmacologic therapy, hospital management of exacerbations includes respiratory support (oxygen therapy, ventilation). The management of severe, but not life threatening, exacerbations is outlined in Table 5.2.
The clinical presentation of COPD exacerbation is heterogeneous, thus we recommend that in hospitalized patients the severity of the exacerbation should be based on the patient’s clinical signs and recommend the following classification.\textsuperscript{24}

**No respiratory failure:** Respiratory rate: 20-30 breaths per minute; no use of accessory respiratory muscles; no changes in mental status; hypoxemia improved with supplemental oxygen given via Venturi mask 28-35% inspired oxygen (FiO\textsubscript{2}); no increase in PaCO\textsubscript{2}.

**Acute respiratory failure — non-life-threatening:** Respiratory rate: > 30 breaths per minute; using accessory respiratory muscles; no change in mental status; hypoxemia improved with supplemental oxygen via Venturi mask 35-40% FiO\textsubscript{2}; hypercarbia i.e., PaCO\textsubscript{2} increased compared with baseline or elevated 50-60 mmHg.

**Acute respiratory failure — life-threatening:** Respiratory rate: > 30 breaths per minute; using accessory respiratory muscles; acute changes in mental status; hypoxemia not improved with supplemental oxygen via Venturi mask or requiring FiO\textsubscript{2} > 40%; hypercarbia i.e., PaCO\textsubscript{2} increased compared with baseline or elevated > 60 mmHg or the presence of acidosis (pH < 7.25).

### Table 5.1. Potential indications for hospitalization assessment* 

- Severe symptoms such as sudden worsening of resting dyspnea, high respiratory rate, decreased oxygen saturation, confusion, drowsiness.
- Acute respiratory failure.
- Onset of new physical signs (e.g., cyanosis, peripheral edema).
- Failure of an exacerbation to respond to initial medical management.
- Presence of serious comorbidities (e.g., heart failure, newly occurring arrhythmias, etc.).
- Insufficient home support.

*Local resources need to be considered.

### Table 5.2. Management of severe but not life-threatening exacerbations* 

- Assess severity of symptoms, blood gases, chest radiograph.
- Administer supplemental oxygen therapy, obtain serial arterial blood gas, venous blood gas and pulse oximetry measurements.
- Bronchodilators:
  - Increase doses and/or frequency of short-acting bronchodilators.
  - Combine short-acting beta 2-agonists! and anticholinergics.
  - Consider use of long-acting bronchodilators when patient becomes stable.
  - Use spacers or air-driven nebulizers when appropriate.
- Consider oral corticosteroids.
- Consider antibiotics (oral) when signs of bacterial infection are present.
- Consider noninvasive mechanical ventilation (NIV).
- At all times:
  - Monitor fluid balance.
  - Consider subcutaneous heparin or low molecular weight heparin for thromboembolism prophylaxis.
  - Identify and treat associated conditions (e.g., heart failure, arrhythmias, pulmonary embolism etc.).

*Local resources need to be considered.

Long-term prognosis following hospitalization for COPD exacerbation is poor, with a five-year mortality rate of about 50%.\textsuperscript{24} Factors independently associated with poor outcome include older age, lower body mass index, comorbidities (e.g., cardiovascular disease or lung cancer), previous hospitalizations for COPD exacerbations, clinical severity of the index exacerbation and need for
long-term oxygen therapy at discharge.\textsuperscript{25-28} Patients characterized by a higher prevalence and severity of respiratory symptoms, poorer quality of life, worse lung function, lower exercise capacity, lower lung density and thickened bronchial walls on CT-scan are also at increased risk for a higher mortality following an acute COPD exacerbation.\textsuperscript{27}

Key points for the management of all exacerbations are given in Table 5.3.

<table>
<thead>
<tr>
<th>Table 5.3. Key points for the management of exacerbations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Short-acting inhaled beta\textsubscript{2}-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation (Evidence C).</td>
</tr>
<tr>
<td>• Systemic corticosteroids can improve lung function (FEV\textsubscript{1}), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days (Evidence A).</td>
</tr>
<tr>
<td>• Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days (Evidence B).</td>
</tr>
<tr>
<td>• Methylxanthines are not recommended due to increased side effect profiles (Evidence B).</td>
</tr>
<tr>
<td>• Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure (Evidence A).</td>
</tr>
<tr>
<td>• NIV should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival (Evidence A).</td>
</tr>
</tbody>
</table>

Pharmacologic Treatment

The three classes of medications most commonly used for COPD exacerbations are bronchodilators, corticosteroids, and antibiotics.

**Bronchodilators.** Although there is no high-quality evidence from RCTs, it is recommended that short-acting inhaled beta\textsubscript{2}-agonists, with or without short-acting anticholinergics, are the initial bronchodilators for acute treatment of a COPD exacerbation.\textsuperscript{28,29} A systematic review of the route of delivery of short-acting bronchodilators found no significant differences in FEV\textsubscript{1} between using metered dose inhalers (MDI) (with or without a spacer device) or nebulizers to deliver the agent,\textsuperscript{30} although the latter may be an easier delivery method for sicker patients. It is recommended that patients do not received continuous nebulization, but use the MDI inhaler one puff every one hour for two or three doses and then every 2-4 hours based on the patient’s response. Although, there are no clinical studies that have evaluated the use of inhaled long-acting bronchodilators (either beta\textsubscript{2}-agonists or anticholinergics or combinations) with or without inhaled corticosteroids during an exacerbation, we recommend to continue these treatments during the exacerbation or to start these medications as soon as possible before hospital discharge. Intravenous methylxanthines (theophylline or aminophylline) are not recommended to use in these patients due to significant side effects.\textsuperscript{31,32}

**Glucocorticoids.** Data from studies indicate that systemic glucocorticoids in COPD exacerbations shorten recovery time and improve lung function (FEV\textsubscript{1}). They also improve oxygenation,\textsuperscript{33-36} the risk of early relapse, treatment failure,\textsuperscript{37} and the length of hospitalization.\textsuperscript{33,35,38} A dose of 40 mg prednisone per day for 5 days is recommended.\textsuperscript{39} Therapy with oral prednisolone is equally effective to intravenous administration.\textsuperscript{40} Nebulized budesonide alone, although more expensive, may be an alternative to oral corticosteroids in some patients for treatment of exacerbations.\textsuperscript{36,41,42} Recent
studies suggest that glucocorticoids may be less efficacious to treat acute COPD exacerbations in patients with lower levels of blood eosinophils.\textsuperscript{9,12,15}

**Antibiotics.** Although the infectious agents in COPD exacerbations can be viral or bacterial,\textsuperscript{6,44} the use of antibiotics in exacerbations remains controversial.\textsuperscript{44,46} The uncertainties originate from studies that did not differentiate between bronchitis (acute or chronic) and COPD exacerbations, studies without placebo-control, and/or studies without chest X-rays that do not exclude that patients may have had underlying pneumonia. There is evidence supporting the use of antibiotics in exacerbations when patients have clinical signs of a bacterial infection e.g., increased sputum purulence.\textsuperscript{45,46}

A systematic review of placebo-controlled studies has shown that antibiotics reduce the risk of short-term mortality by 77%, treatment failure by 53% and sputum purulence by 44%.\textsuperscript{47} The review provides evidence to treat moderately or severely ill patients with COPD exacerbations and increased cough and sputum purulence with antibiotics.\textsuperscript{47,48} These data are supported by more recent RCTs in patients with diagnoses of moderate COPD.\textsuperscript{49} In the outpatient setting, sputum cultures are not feasible as they take at least two days and frequently do not give reliable results for technical reasons. Several biomarkers of airway infection are being studied in exacerbations of COPD that have a better diagnostic profile. Studies of C-reactive protein (CRP) have reported contradictory findings; CRP has been reported to be elevated in both bacterial and viral infections, therefore its use in this condition is not recommended.\textsuperscript{50,51} Another biomarker that has been investigated is procalcitonin, a marker that is more specific for bacterial infections and that may be of value in the decision to use antibiotics,\textsuperscript{52} but this test is expensive and not readily available. Several studies have suggested that procalcitonin-guided antibiotic treatment reduces antibiotic exposure and side effects with the same clinical efficacy.\textsuperscript{53,54} A study in COPD patients with exacerbations requiring mechanical ventilation (invasive or noninvasive) indicated that not giving antibiotics was associated with increased mortality and a greater incidence of secondary nosocomial pneumonia.\textsuperscript{55}

In summary, antibiotics should be given to patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).\textsuperscript{4,6} The recommended length of antibiotic therapy is 5-7 days.\textsuperscript{46}

The choice of the antibiotic should be based on the local bacterial resistance pattern. Usually initial empirical treatment is an aminopenicillin with clavulanic acid, macrolide, or tetracycline. In patients with frequent exacerbations, severe airflow limitation,\textsuperscript{57,58} and/or exacerbations requiring mechanical ventilation,\textsuperscript{59} cultures from sputum or other materials from the lung should be performed, as gram-negative bacteria (e.g., *Pseudomonas species*) or resistant pathogens that are not sensitive to the above-mentioned antibiotics may be present. The route of administration (oral or intravenous) depends on the patient’s ability to eat and the pharmacokinetics of the antibiotic, although it is preferable that antibiotics be given orally. Improvements in dyspnea and sputum purulence suggest clinical success.
**Adjunct Therapies.** Depending on the clinical condition of the patient, an appropriate fluid balance, use of diuretics when clinically indicated, anticoagulants, treatment of comorbidities and nutritional aspects should be considered. At all times, healthcare providers should strongly enforce the need for smoking cessation. Given that patients hospitalized with COPD exacerbations are at increased risk of deep vein thrombosis and pulmonary embolism, prophylactic measures for thromboembolism should be instituted.

**Respiratory Support**

**Oxygen therapy.** This is a key component of hospital treatment of an exacerbation. Supplemental oxygen should be titrated to improve the patient’s hypoxemia with a target saturation of 88-92%. Once oxygen is started, blood gases should be checked frequently to ensure satisfactory oxygenation without carbon dioxide retention and/or worsening acidosis. A recent study demonstrated that venous blood gas to assess bicarbonate levels and pH is accurate when compared with arterial blood gas assessment. Additional data are needed to clarify the utility of venous blood gas sampling to make clinical decisions in scenarios of acute respiratory failure; most patients included had a pH > 7.30 on presentation, PCO<sub>2</sub> levels were dissimilar when measured by venous compared to arterial blood samples and the severity of airflow limitation was not reported. Venturi masks (high-flow devices) offer more accurate and controlled delivery of oxygen than do nasal prongs.

**Ventilatory Support.** Some patients need immediate admission to the respiratory care or intensive care unit (ICU) (Table 5.4). Admission of patients with severe exacerbations to intermediate or special respiratory care units may be appropriate if adequate personnel skills and equipment exist to identify and manage acute respiratory failure. Ventilatory support in an exacerbation can be provided by either noninvasive (nasal or facial mask) or invasive (orotracheal tube or tracheostomy) ventilation. Respiratory stimulants are not recommended for acute respiratory failure.

**Table 5.4. Indications for respiratory or medical intensive care unit admission**

- Severe dyspnea that responds inadequately to initial emergency therapy.
- Changes in mental status (confusion, lethargy, coma).
- Persistent or worsening hypoxemia (PaO<sub>2</sub> < 5.3 kPa or 40 mmHg) and/or severe/worsening respiratory acidosis (pH < 7.25) despite supplemental oxygen and noninvasive ventilation.
- Need for invasive mechanical ventilation.
- Hemodynamic instability—need for vasopressors.

*Local resources need to be considered.

**Noninvasive mechanical ventilation.** The use of noninvasive mechanical ventilation (NIV) is preferred over invasive ventilation (intubation and positive pressure ventilation) as the initial mode of ventilation to treat acute respiratory failure in patients hospitalized for acute exacerbations of COPD. NIV has been studied in RCTs showing a success rate of 80-85%. NIV has been shown to improve improve oxygenation and acute respiratory acidosis i.e., NIV increases pH and decreases PaCO<sub>2</sub>. NIV also decreases respiratory rate, work of breathing and the severity of breathlessness but also decreases complications such as ventilator associated pneumonia, and length of hospital stay. More importantly, mortality and intubation rates are reduced by this intervention. The indications for NIV are summarized in Table 5.5.
Invasive mechanical ventilation. The indications for initiating invasive mechanical ventilation during an exacerbation are shown in Table 5.6, and include failure of an initial trial of NIV.\textsuperscript{24} As experience is gained with the generalized clinical use of NIV in COPD, a number of indications for invasive mechanical ventilation are being successfully treated with NIV, thus eliminating invasive mechanical ventilation as first line treatment of acute respiratory failure during hospitalization for COPD exacerbation.\textsuperscript{24} In patients who fail non-invasive ventilation as initial therapy and receive invasive ventilation as subsequent rescue therapy, morbidity, hospital length of stay and mortality are greater.\textsuperscript{69} The use of invasive ventilation in patients with very severe COPD is influenced by the likely reversibility of the precipitating event, the patient’s wishes, and the availability of intensive care facilities.\textsuperscript{69} When possible, a clear statement of the patient’s own treatment wishes, such as an advance directive or “living will”, makes these difficult decisions easier to resolve. Major hazards include the risk of ventilator-acquired pneumonia (especially when multi-resistant organisms are prevalent), barotrauma and volutrauma, and the risk of tracheostomy and consequential prolonged ventilation.

Acute mortality among COPD patients with respiratory failure is lower than mortality among patients ventilated for non-COPD causes.\textsuperscript{24} Despite this, there is evidence that patients who might otherwise survive are frequently denied admission to intensive care for intubation because of unwarranted prognostic pessimism.\textsuperscript{24} A large study of COPD patients with acute respiratory failure reported in-hospital mortality of 17-49%.\textsuperscript{22} Further deaths were reported over the next 12 months, particularly among those patients who had poor lung function before invasive ventilation (FEV\textsubscript{1} < 30% predicted), had a non-respiratory comorbidity, or were housebound. Patients who did not have a previously diagnosed comorbidity, had respiratory failure due to a potentially reversible cause (such as an infection), or were relatively mobile and not using long-term oxygen, did well after ventilator support.
Hospital discharge and follow-up

The cause, severity, impact, treatment and time course of exacerbations varies from patient to patient and facilities in the community, and healthcare systems, differ from country to country. Accordingly, there are no standards that can be applied to the timing and nature of discharge. However, it is recognized that recurrent exacerbations leading to short-term readmission and increased all-cause mortality are associated with the initial hospitalization for an acute episode of deterioration. Consequently, the clinical practice and management of the acute hospitalization have been studied extensively and the introduction of factors thought to be beneficial has been investigated increasingly in recent years. When features related to re-hospitalization and mortality have been studied, defects in perceived optimal management have been identified including spirometric assessment and arterial blood gas analysis. Mortality relates to patient age, the presence of acidotic respiratory failure, the need for ventilatory support and comorbidities including anxiety and depression.

The introduction of care bundles at hospital discharge to include education, optimization of medication, supervision and correction of inhaler technique, assessment and optimal management of comorbidities, early rehabilitation, telemonitoring and continued patient contact have all been investigated to address these issues (Table 5.7). Whereas these measures all seem sensible there is insufficient data that they influence either readmission rates or short-term mortality and there is little evidence of cost-effectiveness. Nevertheless, it remains good clinical practice to cover these issues before discharge with the possible exception of early rehabilitation as there is some evidence that this factor is associated with increased mortality, although the reasons remain unknown. However, other data suggest that early rehabilitation post hospital discharge (i.e., < 4 weeks) may be associated with improved survival.

Early follow-up (within one month) following discharge should be undertaken when possible and has been related to less exacerbation-related readmissions. There are many patient issues that prevent early follow-up; those not attending early follow-up have increased 90-day mortality. This may reflect both patient compliance, limited access to medical care, poor social support, and/or the presence of more severe disease.

Nevertheless, early follow-up permits a careful review of discharge therapy (and especially any remaining need for long-term oxygen treatment by assessment of both oxygen saturation and arterial blood gases) and an opportunity to make any needed changes in therapy (antibiotic and steroid therapy review).

Additional follow-up at three months is recommended to ensure return to a stable clinical state and permit a review of the patient’s symptoms, lung function (by spirometry), and where possible the assessment of prognosis using multiple scoring systems such as BODE. In addition, arterial oxygen saturation and blood gas assessment will determine the need for long-term oxygen therapy more accurately at prolonged follow-up compared to shortly after discharge. CT assessment to determine the presence of bronchiectasis and emphysema should be done in patients with recurrent
A further detailed assessment of the presence and management of comorbidities should also be undertaken (Table 5.7).

**Prevention of exacerbations**

After an acute exacerbation appropriate measures for prevention of further exacerbations should be initiated (Table 5.3 and Table 5.8). For the following treatment modalities significant effects on exacerbation risk/frequency could be shown in clinical trials. For details and references refer to Chapter 3 and Chapter 4.

**Table 5.7. Discharge criteria and recommendations for follow-up**

- Full review of all clinical and laboratory data.
- Check maintenance therapy and understanding.
- Reassess inhaler technique.
- Ensure understanding of withdrawal of acute medications (steroids and/or antibiotics).
- Assess need for continuing any oxygen therapy.
- Provide management plan for comorbidities and follow-up.
- Ensure follow-up arrangements: early follow-up < 4 weeks, and late follow-up < 12 weeks as indicated.
- All clinical or investigational abnormalities have been identified.

1–4 Weeks Follow-Up

- Evaluate ability to cope in his/her usual environment.
- Review understanding treatment regimen.
- Reassess inhaler techniques.
- Reassess need for long-term oxygen.
- Document the capacity to do physical activity and activities of daily living.
- Document symptoms: CAT or mMRC.
- Determine status of comorbidities.

12–16 Weeks Follow-Up

- Evaluate ability to cope in his/her usual environment.
- Review understanding treatment regimen.
- Reassess inhaler techniques.
- Reassess need for long-term oxygen.
- Document the capacity to do physical activity and activities of daily living.
- Measure spirometry: FEV1.
- Document symptoms: CAT or mMRC.
- Determine status of comorbidities.

**Table 5.8. Interventions that reduce the frequency of COPD exacerbations**

<table>
<thead>
<tr>
<th>Intervention class</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilators</td>
<td>LABAs, LAMAs, LABA + LAMA</td>
</tr>
<tr>
<td>Corticosteroid-containing regimens</td>
<td>LABA + ICS, LABA + LAMA + ICS</td>
</tr>
<tr>
<td>Anti-inflammatory (non-steroid)</td>
<td>Roflumilast</td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>Vaccines, Long term macrolides</td>
</tr>
<tr>
<td>Mucoregulators</td>
<td>N-acetylcysteine, Carbocysteine</td>
</tr>
<tr>
<td>Various others</td>
<td>Smoking cessation, Rehabilitation, Lung volume reduction</td>
</tr>
</tbody>
</table>
REFERENCES


CHAPTER 6: COPD AND COMORBIDITIES

OVERALL KEY POINTS:

- COPD often coexists with other diseases (comorbidities) that may have a significant impact on disease course.
- In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD.
- Lung cancer is frequently seen in patients with COPD and is a main cause of death.
- Cardiovascular diseases are common and important comorbidities in COPD.
- Osteoporosis and depression/anxiety are frequent, important comorbidities in COPD, are often under-diagnosed, and are associated with poor health status and prognosis.
- Gastroesophageal reflux (GERD) is associated with an increased risk of exacerbations and poorer health status.
- When COPD is part of a multimorbidity care plan, attention should be directed to ensure simplicity of treatment and to minimize polypharmacy.

INTRODUCTION

COPD often coexists with other diseases (comorbidities) that may have a significant impact on prognosis. Some of these arise independently of COPD whereas others may be causally related, either with shared risk factors or by one disease increasing the risk or compounding the severity of the other. It is possible that features of COPD, are shared with other diseases and as such this mechanism represents a link between COPD and some of its comorbidities. This risk of comorbid disease can be increased by the sequelae of COPD e.g., reduced physical activity or continued smoking. Whether or not COPD and comorbid diseases are related, management of the COPD patient must include identification and treatment of its comorbidities. Importantly, comorbidities with symptoms also associated with COPD may be overlooked e.g., heart failure and lung cancer (breathlessness) or depression (fatigue and reduced physical activity).

Comorbidities are common at any severity of COPD and the differential diagnosis can often be difficult. For example, in a patient with both COPD and heart failure, an exacerbation of COPD may be accompanied by worsening of heart failure or vice versa. Although COPD is negatively impacted by multiple comorbid diseases, COPD itself is one of the most important comorbid conditions that adversely affects outcome of other disorders. For example, patients hospitalized with congestive heart failure or undergoing cardiac procedures such as coronary artery bypass grafting have greater morbidity and mortality when COPD is present compared to when it is absent.
Below is a brief guide to the management of some common comorbidities occurring in patients with COPD with stable disease. The recommendations may be insufficient for the management of all COPD patients and are not a substitute for the use of guidelines for the management of each individual comorbid condition.

**Cardiovascular disease (CVD)**

CVD is a frequent and important comorbidity in COPD. Five separate entities within CVD will be considered: ischemic heart disease, heart failure, arrhythmias, peripheral vascular disease, and hypertension.

**Heart failure**

► The prevalence of systolic or diastolic heart failure in COPD patients ranges from 20 to 70%, and its annual incidence between 3-4%. Incident heart failure is a significant and independent predictor of all-cause mortality.

► Unrecognized heart failure may mimic or accompany acute exacerbations of COPD; 40% of COPD patients that are mechanically ventilated because of hypercapnic respiratory failure have evidence of left ventricular dysfunction.

► There is no evidence that chronic heart failure should be treated differently in the presence of COPD. Treatment with β₁-blockers improves survival in heart failure and is recommended. However, β₁-blockers are often not prescribed in COPD despite available evidence showing that their use in COPD is safe. Selective β₁-blockers should be used.

► Acute heart failure should be treated according to usual heart failure guidelines since there is no evidence to support an alternative management strategy. Noninvasive ventilation added to conventional therapy improves outcomes for patients with either hypercapnic respiratory failure due to an exacerbation of COPD as well as heart failure with acute pulmonary edema.

**Ischaemic heart disease (IHD)**

► Ischaemic heart disease should be considered in all COPD patients depending on their risk factor profile. The cardiovascular risk may be assessed by the global risk calculator, which can be found on the US National Heart Blood Lung Institute website and treatment initiated based on the current recommendations.

► During acute COPD exacerbations, there is an increased risk of myocardial damage in patients with concomitant ischemic heart disease. Patients who demonstrate abnormal cardiac troponins in isolation are at increased risk of adverse outcomes including short-term (30day) and long-term mortality.

► The treatment of ischaemic heart disease should be according to guidelines irrespective of the presence of COPD and vice versa.
Arrhythmias
► Cardiac arrhythmias are common in COPD and *vice versa*. Atrial fibrillation is frequent and directly associated with FEV₁. 

► In COPD patients presenting with severe worsening dyspnoea, associated atrial fibrillation is frequently documented, and it may be either a trigger or a consequence of an acute exacerbation episode.

► The presence of atrial fibrillation does not alter the treatment of COPD. Bronchodilators have been previously described as potentially pro-arrhythmic agents however, available evidence suggests an overall acceptable safety profile for long-acting beta₂-agonists, anticholinergic drugs (and inhaled corticosteroids). Nevertheless, caution is advised when using short-acting beta₂-agonists and theophylline, which may precipitate AF and make control of the ventricular response rate difficult.

Peripheral vascular disease
► Peripheral artery disease (PAD) is an atherosclerotic process that refers to the occlusion of the arteries in the lower limbs; PAD is commonly associated with atherosclerotic heart disease and may have significant implications for functional activity as well as quality of life in patients with COPD.

► In a large cohort of patients with COPD of all degrees of severity, 8.8% were diagnosed with PAD that was higher than the prevalence in non-COPD controls (1.8%).

► COPD patients with PAD reported a worse functional capacity and worse health status compared to those without PAD. Clinicians should consider PAD in patients with COPD to those at risk for vascular events and to fully understand their functional impairments.

Hypertension
► Hypertension is likely to be the most frequently occurring comorbidity in COPD and may have implications for prognosis. Diastolic dysfunction as a result of optimally treated hypertension may be associated with exercise intolerance and mimic symptoms associated with an acute exacerbation thereby provoking hospitalization in COPD. These data stress the importance of optimal blood pressure control in COPD patients with underlying hypertension.

► Hypertension should be treated according to usual guidelines. There is no evidence that hypertension should be treated differently in the presence of COPD. The role of treatment with selective beta-blockers is less prominent in recent hypertension guidelines.

► COPD should be treated as usual as there is no direct evidence that COPD should be treated differently in the presence of hypertension.

Osteoporosis
► Osteoporosis is a major comorbidity\textsuperscript{2,9} which is often under-diagnosed\textsuperscript{42} and associated with poor health status and prognosis.

► Osteoporosis is often associated with emphysema,\textsuperscript{11} decreased body mass index\textsuperscript{44} and low fat-free mass.\textsuperscript{45} Low bone mineral density and fractures are commonly in COPD patients even after adjustment for steroid use, age, pack-years of smoking, current smoking, and exacerbations.\textsuperscript{46-47}

► Osteoporosis should be treated according to usual guidelines.

► COPD should be treated as usual despite the presence of osteoporosis. An association between inhaled corticosteroids and fractures has been found in pharmaco-epidemiological studies; however, these studies have not fully taken severity of COPD or exacerbations and their treatment into account.

► Systemic corticosteroids significantly increase the risk of osteoporosis and repeated courses for COPD exacerbations should be avoided if possible

**Anxiety and depression**

► Anxiety and depression are important comorbidities in COPD\textsuperscript{48-51} and both are associated with a poor prognosis,\textsuperscript{50,52} younger age, female gender, smoking, lower FEV\textsubscript{1}, cough, higher SGRQ score, and a history of cardiovascular disease.\textsuperscript{48,51,53}

► There is no evidence that anxiety and depression should be treated differently in the presence of COPD.

► COPD should be treated as usual. The potential impact of pulmonary rehabilitation should be stressed as studies have found that physical exercise has a beneficial effect on depression in general.\textsuperscript{54,55}

► COPD is very common in patients with other psychiatric illnesses, often under-diagnosed and treated.\textsuperscript{56,57}

**COPD and lung cancer**

► There is ample evidence of an association between COPD and lung cancer.\textsuperscript{4,9,58-60} The association between emphysema and lung cancer is stronger than between airflow limitation and lung cancer.\textsuperscript{51,61} The greatest risk is observed in subjects with both findings. Increased age and greater smoking history further increases risk.\textsuperscript{64}

► As for COPD, the best prevention for lung cancer is smoking cessation.\textsuperscript{55,66}

► Two studies of low-dose chest computed tomography (LDCT) screening have shown improved survival in subjects aged 55-74 years, current smokers or those who quit within the previous 15 years, with a smoking history of at least 30 pack-years.\textsuperscript{67,68} LDCT is now recommended in the US for
patients meeting these demographics. However, this is not a worldwide practice. The reasons are: concerns regarding avoidance of over-diagnosis; greater morbidity and mortality with needless diagnostic procedures for benign abnormalities; anxiety; and incomplete follow-up.

**Metabolic syndrome and diabetes**

► Studies have shown that metabolic syndrome and manifest diabetes are more frequent in COPD and the latter is likely to affect prognosis. ³

► The prevalence of metabolic syndrome has been estimated to be more than 30%. ⁶⁹

► Diabetes should be treated according to usual guidelines for diabetes. COPD should be treated as usual.

**Gastroesophageal reflux (GERD)**

► GERD is an independent risk factor for exacerbations and is associated with worse health status. ⁷⁰-⁷² The mechanisms responsible for increased risk of exacerbations are not yet fully established.

► Proton pump inhibitors are often used for treatment of GERD. One small, single-blind study suggested these agents decrease the risk of exacerbation, ⁷³ but their value in preventing these events remains controversial most effective treatment for this condition in COPD has yet to be established. ⁷⁴, ⁷⁵

**Bronchiectasis**

► With increasing use of computed tomography in the assessment of patients with COPD, the presence of previously unrecognized bronchiectasis is being identified. ⁷⁶

► Whether this diagnosis based on radiological criteria has the same impact as a clinical diagnosis of bronchiectasis remains unknown at present, although it is associated with longer exacerbations and increased mortality. ⁷⁷, ⁷⁸

► Bronchiectasis should be treated according to usual guidelines.

► Regarding COPD treatment, some patients may need more aggressive and prolonged antibiotic therapy. Inhaled corticosteroids may not be indicated in patients with bacterial colonization or recurrent lower respiratory tract infections.
Obstructive sleep apnea

► COPD has an estimated prevalence in U.S. adults of 13.9% and obstructive sleep apnea (OSA), a sleep disorder hallmarked by repeated episodes of upper airway closure, affects 9% to 26% of the U.S. adult population.

► The term “overlap syndrome” has been used to describe the association of both conditions in a single patient. Patients with overlap syndrome have a worse prognosis compared with COPD or OSA. During sleep, patients with both COPD and OSA suffer more frequent episodes of oxygen desaturation and have more total sleep time with hypoxemia and hypercapnia than OSA patients without COPD.

► The apneic events in patients with combined OSA and COPD have more profound hypoxemia and more cardiac arrhythmias. Additionally, patients with combined COPD and OSA are more likely to develop daytime pulmonary hypertension than patients with just OSA or COPD alone.

COPD as part of multimorbidity

► An increasing number of people in any aging population will suffer from multi-morbidity, defined as the presence of two or more chronic conditions, and COPD is present in the majority of multi-morbid patients.

► Multi-morbid patients have symptoms from multiple diseases and thus symptoms and signs are complex and most often attributable to several causes in the chronic state as well as during acute events.

► There is no evidence that COPD should be treated differently when part of multi-morbidity; however, it should be kept in mind that most evidence comes from trials in patients with COPD as the only significant disease.

► Treatments should be kept simple in the light of the unbearable polypharmacy that these patients are often exposed to.
REFERENCES


